A BILL 
To establish a fair price negotiation program, protect the 
Medicare program from excessive price increases, and 
establish an out-of-pocket maximum for Medicare part 
D enrollees, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
3
(a) SHORT TITLE.—This Act may be cited as the 
4
‘‘Elijah E. Cummings Lower Drug Costs Now Act’’. 
5
04:12 Apr 27, 2021
H3
2 
•HR 3 IH
(b) TABLE OF CONTENTS.—The table of contents is 
1
as follows: 
2
Sec. 1. Short title; table of contents. 
TITLE I—LOWERING PRICES THROUGH FAIR DRUG PRICE 
NEGOTIATION 
Sec. 101. Providing for lower prices for certain high-priced single source drugs. 
Sec. 102. Selected drug manufacturer excise tax imposed during noncompliance 
periods. 
Sec. 103. Fair Price Negotiation Implementation Fund. 
TITLE II—PRESCRIPTION DRUG INFLATION REBATES 
Sec. 201. Medicare part B rebate by manufacturers. 
Sec. 202. Medicare part D rebate by manufacturers. 
Sec. 203. Provision regarding inflation rebates for group health plans and 
group health insurance coverage. 
Sec. 204. Annual report on drug costs in group health plans and group health 
insurance coverage. 
Sec. 205. Collection of data. 
TITLE III—PART D IMPROVEMENTS AND MAXIMUM OUT-OF- 
Sec. 301. Medicare part D benefit redesign. 
Sec. 302. Allowing certain enrollees of prescription drug plans and MA–PD 
plans under Medicare program to spread out cost-sharing 
under certain circumstances. 
Sec. 303. Establishment of pharmacy quality measures under Medicare part D. 
TITLE IV—DRUG PRICE TRANSPARENCY 
Sec. 401. Drug price transparency. 
TITLE V—NIH, FDA, AND OVERDOSE EPIDEMIC FUNDING 
Subtitle A—Biomedical Innovation Expansion 
Sec. 501. NIH Innovation Initiatives. 
Sec. 502. NIH clinical trial. 
Sec. 503. Innovation Network. 
Subtitle B—Investing in Safety and Innovation 
Sec. 511. Food and Drug Administration. 
Sec. 512. Study on high-risk, high-reward drugs. 
Subtitle C—Overdose Epidemic Response 
Sec. 521. Overdose Epidemic Response Fund. 
Sec. 522. Substance Abuse and Mental Health Services Administration. 
Sec. 523. Centers for Disease Control and Prevention. 
Sec. 524. Food and Drug Administration. 
Sec. 525. National Institutes of Health. 
04:12 Apr 27, 2021
H3
3 
•HR 3 IH
Sec. 526. Health Resources and Services Administration. 
Sec. 527. Administration for Children and Families. 
TITLE 
I—LOWERING 
PRICES 
1
THROUGH FAIR DRUG PRICE 
2
NEGOTIATION 
3
SEC. 101. PROVIDING FOR LOWER PRICES FOR CERTAIN 
4
HIGH-PRICED SINGLE SOURCE DRUGS. 
5
(a) PROGRAM TO LOWER PRICES
FOR CERTAIN 
6
HIGH-PRICED SINGLE SOURCE DRUGS.—Title XI of the 
7
Social Security Act (42 U.S.C. 1301 et seq.) is amended 
8
by adding at the end the following new part: 
9
‘‘PART E—FAIR PRICE NEGOTIATION PROGRAM 
10
TO LOWER PRICES FOR CERTAIN HIGH- 
11
PRICED SINGLE SOURCE DRUGS 
12
‘‘SEC. 1191. ESTABLISHMENT OF PROGRAM. 
13
‘‘(a) IN GENERAL.—The Secretary shall establish a 
14
Fair Price Negotiation Program (in this part referred to 
15
as the ‘program’). Under the program, with respect to 
16
each price applicability period, the Secretary shall— 
17
‘‘(1) publish a list of selected drugs in accord-
18
ance with section 1192; 
19
‘‘(2) enter into agreements with manufacturers 
20
of selected drugs with respect to such period, in ac-
21
cordance with section 1193; 
22
04:12 Apr 27, 2021
H3
4 
•HR 3 IH
‘‘(3) negotiate and, if applicable, renegotiate 
1
maximum fair prices for such selected drugs, in ac-
2
cordance with section 1194; and 
3
‘‘(4) carry out the administrative duties de-
4
scribed in section 1196. 
5
‘‘(b) DEFINITIONS RELATING TO TIMING.—For pur-
6
poses of this part: 
7
‘‘(1) INITIAL PRICE APPLICABILITY YEAR.—The 
8
term ‘initial price applicability year’ means a plan 
9
year (beginning with plan year 2024) or, if agreed 
10
to in an agreement under section 1193 by the Sec-
11
retary and manufacturer involved, a period of more 
12
than one plan year (beginning on or after January 
13
1, 2024). 
14
‘‘(2) PRICE APPLICABILITY PERIOD.—The term 
15
‘price applicability period’ means, with respect to a 
16
drug, the period beginning with the initial price ap-
17
plicability year with respect to which such drug is a 
18
selected drug and ending with the last plan year 
19
during which the drug is a selected drug. 
20
‘‘(3) SELECTED
DRUG
PUBLICATION
DATE.— 
21
The term ‘selected drug publication date’ means, 
22
with respect to each initial price applicability year, 
23
April 15 of the plan year that begins 2 years prior 
24
to such year. 
25
04:12 Apr 27, 2021
H3
5 
•HR 3 IH
‘‘(4) VOLUNTARY NEGOTIATION PERIOD.—The 
1
term ‘voluntary negotiation period’ means, with re-
2
spect to an initial price applicability year with re-
3
spect to a selected drug, the period— 
4
‘‘(A) beginning on the sooner of— 
5
‘‘(i) the date on which the manufac-
6
turer of the drug and the Secretary enter 
7
into an agreement under section 1193 with 
8
respect to such drug; or 
9
‘‘(ii) June 15 following the selected 
10
drug publication date with respect to such 
11
selected drug; and 
12
‘‘(B) ending on March 31 of the year that 
13
begins one year prior to the initial price appli-
14
cability year. 
15
‘‘(c) OTHER DEFINITIONS.—For purposes of this 
16
part: 
17
‘‘(1) FAIR PRICE ELIGIBLE INDIVIDUAL.—The 
18
term ‘fair price eligible individual’ means, with re-
19
spect to a selected drug— 
20
‘‘(A) in the case such drug is furnished or 
21
dispensed to the individual at a pharmacy or by 
22
a mail order service— 
23
‘‘(i) an individual who is enrolled 
24
under a prescription drug plan under part 
25
04:12 Apr 27, 2021
H3
6 
•HR 3 IH
D of title XVIII or an MA–PD plan under 
1
part C of such title if coverage is provided 
2
under such plan for such selected drug; 
3
and 
4
‘‘(ii) an individual who is enrolled 
5
under a group health plan or health insur-
6
ance coverage offered in the group or indi-
7
vidual market (as such terms are defined 
8
in section 2791 of the Public Health Serv-
9
ice Act) with respect to which there is in 
10
effect an agreement with the Secretary 
11
under section 1197 with respect to such se-
12
lected drug as so furnished or dispensed; 
13
and 
14
‘‘(B) in the case such drug is furnished or 
15
administered to the individual by a hospital, 
16
physician, or other provider of services or sup-
17
plier— 
18
‘‘(i) an individual who is entitled to 
19
benefits under part A of title XVIII or en-
20
rolled under part B of such title if such se-
21
lected drug is covered under the respective 
22
part; and 
23
‘‘(ii) an individual who is enrolled 
24
under a group health plan or health insur-
25
04:12 Apr 27, 2021
H3
7 
•HR 3 IH
ance coverage offered in the group or indi-
1
vidual market (as such terms are defined 
2
in section 2791 of the Public Health Serv-
3
ice Act) with respect to which there is in 
4
effect an agreement with the Secretary 
5
under section 1197 with respect to such se-
6
lected drug as so furnished or adminis-
7
tered. 
8
‘‘(2) MAXIMUM FAIR PRICE.—The term ‘max-
9
imum fair price’ means, with respect to a plan year 
10
during a price applicability period and with respect 
11
to a selected drug (as defined in section 1192(c)) 
12
with respect to such period, the price published pur-
13
suant to section 1195 in the Federal Register for 
14
such drug and year. 
15
‘‘(3) AVERAGE INTERNATIONAL MARKET PRICE 
16
DEFINED.— 
17
‘‘(A) IN
GENERAL.—The terms ‘average 
18
international market price’ and ‘AIM price’ 
19
mean, with respect to a drug, the average price 
20
(which shall be the net average price, if prac-
21
ticable, and volume-weighted, if practicable) for 
22
a unit (as defined in paragraph (4)) of the drug 
23
for sales of such drug (calculated across dif-
24
ferent dosage forms and strengths of the drug 
25
04:12 Apr 27, 2021
H3
8 
•HR 3 IH
and not based on the specific formulation or 
1
package size or package type), as computed (as 
2
of the date of publication of such drug as a se-
3
lected drug under section 1192(a)) in all coun-
4
tries described in clause (ii) of subparagraph 
5
(B) that are applicable countries (as described 
6
in clause (i) of such subparagraph) with respect 
7
to such drug. 
8
‘‘(B) APPLICABLE COUNTRIES.— 
9
‘‘(i) IN
GENERAL.—For purposes of 
10
subparagraph (A), a country described in 
11
clause (ii) is an applicable country de-
12
scribed in this clause with respect to a 
13
drug if there is available an average price 
14
for any unit for the drug for sales of such 
15
drug in such country. 
16
‘‘(ii) COUNTRIES
DESCRIBED.—For 
17
purposes of this paragraph, the following 
18
are countries described in this clause: 
19
‘‘(I) Australia. 
20
‘‘(II) Canada. 
21
‘‘(III) France. 
22
‘‘(IV) Germany. 
23
‘‘(V) Japan. 
24
‘‘(VI) The United Kingdom. 
25
04:12 Apr 27, 2021
H3
9 
•HR 3 IH
‘‘(4) UNIT.—The term ‘unit’ means, with re-
1
spect to a drug, the lowest identifiable quantity 
2
(such as a capsule or tablet, milligram of molecules, 
3
or grams) of the drug that is dispensed. 
4
‘‘SEC. 1192. SELECTION OF NEGOTIATION-ELIGIBLE DRUGS 
5
AS SELECTED DRUGS. 
6
‘‘(a) IN GENERAL.—Not later than the selected drug 
7
publication date with respect to an initial price applica-
8
bility year, subject to subsection (h), the Secretary shall 
9
select and publish in the Federal Register a list of— 
10
‘‘(1)(A) with respect to an initial price applica-
11
bility year during 2024, at least 25 negotiation-eligi-
12
ble drugs described in subparagraphs (A) and (B), 
13
but not subparagraph (C), of subsection (d)(1) (or, 
14
with respect to an initial price applicability year dur-
15
ing such period beginning after 2024, the maximum 
16
number (if such number is less than 25) of such ne-
17
gotiation-eligible drugs for the year) with respect to 
18
such year; and 
19
‘‘(B) with respect to an initial price applica-
20
bility year during 2025 or a subsequent year, at 
21
least 50 negotiation-eligible drugs described in sub-
22
paragraphs (A) and (B), but not subparagraph (C), 
23
of subsection (d)(1) (or, with respect to an initial 
24
price applicability year during such period, the max-
25
04:12 Apr 27, 2021
H3
10 
•HR 3 IH
imum number (if such number is less than 50) of 
1
such negotiation-eligible drugs for the year) with re-
2
spect to such year; 
3
‘‘(2) all negotiation-eligible drugs described in 
4
subparagraph (C) of such subsection with respect to 
5
such year; and 
6
‘‘(3) all new-entrant negotiation-eligible drugs 
7
(as defined in subsection (g)(1)) with respect to such 
8
year. 
9
Each drug published on the list pursuant to the previous 
10
sentence shall be subject to the negotiation process under 
11
section 1194 for the voluntary negotiation period with re-
12
spect to such initial price applicability year (and the re-
13
negotiation process under such section as applicable for 
14
any subsequent year during the applicable price applica-
15
bility period). In applying this subsection, any negotiation- 
16
eligible drug that is selected under this subsection for an 
17
initial price applicability year shall not count toward the 
18
required minimum amount of drugs to be selected under 
19
paragraph (1) for any subsequent year, including such a 
20
drug so selected that is subject to renegotiation under sec-
21
tion 1194. 
22
‘‘(b) SELECTION OF DRUGS.—In carrying out sub-
23
section (a)(1) the Secretary shall select for inclusion on 
24
the published list described in subsection (a) with respect 
25
04:12 Apr 27, 2021
H3
11 
•HR 3 IH
to a price applicability period, the negotiation-eligible 
1
drugs that the Secretary projects will result in the greatest 
2
savings to the Federal Government or fair price eligible 
3
individuals during the price applicability period. In making 
4
this projection of savings for drugs for which there is an 
5
AIM price for a price applicability period, the savings shall 
6
be projected across different dosage forms and strengths 
7
of the drugs and not based on the specific formulation or 
8
package size or package type of the drugs, taking into con-
9
sideration both the volume of drugs for which payment 
10
is made, to the extent such data is available, and the 
11
amount by which the net price for the drugs exceeds the 
12
AIM price for the drugs. 
13
‘‘(c) SELECTED DRUG.—For purposes of this part, 
14
each drug included on the list published under subsection 
15
(a) with respect to an initial price applicability year shall 
16
be referred to as a ‘selected drug’ with respect to such 
17
year and each subsequent plan year beginning before the 
18
first plan year beginning after the date on which the Sec-
19
retary determines two or more drug products— 
20
‘‘(1) are approved or licensed (as applicable)— 
21
‘‘(A) under section 505(j) of the Federal 
22
Food, Drug, and Cosmetic Act using such drug 
23
as the listed drug; or 
24
04:12 Apr 27, 2021
H3
12 
•HR 3 IH
‘‘(B) under section 351(k) of the Public 
1
Health Service Act using such drug as the ref-
2
erence product; and 
3
‘‘(2) continue to be marketed. 
4
‘‘(d) NEGOTIATION-ELIGIBLE DRUG.— 
5
‘‘(1) IN GENERAL.—For purposes of this part, 
6
the term ‘negotiation-eligible drug’ means, with re-
7
spect to the selected drug publication date with re-
8
spect to an initial price applicability year, a quali-
9
fying single source drug, as defined in subsection 
10
(e), that meets any of the following criteria: 
11
‘‘(A) COVERED PART D DRUGS.—The drug 
12
is among the 125 covered part D drugs (as de-
13
fined in section 1860D–2(e)) for which there 
14
was an estimated greatest net spending under 
15
parts C and D of title XVIII, as determined by 
16
the Secretary, during the most recent plan year 
17
prior to such drug publication date for which 
18
data are available. 
19
‘‘(B) OTHER DRUGS.—The drug is among 
20
the 125 drugs for which there was an estimated 
21
greatest net spending in the United States (in-
22
cluding the 50 States, the District of Columbia, 
23
and the territories of the United States), as de-
24
termined by the Secretary, during the most re-
25
04:12 Apr 27, 2021
H3
13 
•HR 3 IH
cent plan year prior to such drug publication 
1
date for which data are available. 
2
‘‘(C) INSULIN.—The drug is a qualifying 
3
single source drug described in subsection 
4
(e)(3). 
5
‘‘(2) CLARIFICATION.—In determining whether 
6
a qualifying single source drug satisfies any of the 
7
criteria described in paragraph (1), the Secretary 
8
shall, to the extent practicable, use data that is ag-
9
gregated across dosage forms and strengths of the 
10
drug and not based on the specific formulation or 
11
package size or package type of the drug. 
12
‘‘(3) PUBLICATION.—Not later than the se-
13
lected drug publication date with respect to an ini-
14
tial price applicability year, the Secretary shall pub-
15
lish in the Federal Register a list of negotiation-eli-
16
gible drugs with respect to such selected drug publi-
17
cation date. 
18
‘‘(e) QUALIFYING SINGLE SOURCE DRUG.—For pur-
19
poses of this part, the term ‘qualifying single source drug’ 
20
means any of the following: 
21
‘‘(1) DRUG PRODUCTS.—A drug that— 
22
‘‘(A) is approved under section 505(c) of 
23
the Federal Food, Drug, and Cosmetic Act and 
24
04:12 Apr 27, 2021
H3
14 
•HR 3 IH
continues to be marketed pursuant to such ap-
1
proval; and 
2
‘‘(B) is not the listed drug for any drug 
3
that is approved and continues to be marketed 
4
under section 505(j) of such Act. 
5
‘‘(2) BIOLOGICAL
PRODUCTS.—A biological 
6
product that— 
7
‘‘(A) is licensed under section 351(a) of 
8
the Public Health Service Act, including any 
9
product that has been deemed to be licensed 
10
under section 351 of such Act pursuant to sec-
11
tion 7002(e)(4) of the Biologics Price Competi-
12
tion and Innovation Act of 2009, and continues 
13
to be marketed under section 351 of such Act; 
14
and 
15
‘‘(B) is not the reference product for any 
16
biological product that is licensed and continues 
17
to be marketed under section 351(k) of such 
18
Act. 
19
‘‘(3) 
INSULIN
PRODUCT.—Notwithstanding 
20
paragraphs (1) and (2), any insulin product that is 
21
approved under subsection (c) or (j) of section 505 
22
of the Federal Food, Drug, and Cosmetic Act or li-
23
censed under subsection (a) or (k) of section 351 of 
24
the Public Health Service Act and continues to be 
25
04:12 Apr 27, 2021
H3
15 
•HR 3 IH
marketed under such section 505 or 351, including 
1
any insulin product that has been deemed to be li-
2
censed under section 351(a) of the Public Health 
3
Service Act pursuant to section 7002(e)(4) of the 
4
Biologics Price Competition and Innovation Act of 
5
2009 and continues to be marketed pursuant to such 
6
licensure. 
7
For purposes of applying paragraphs (1) and (2), a drug 
8
or biological product that is marketed by the same sponsor 
9
or manufacturer (or an affiliate thereof or a cross-licensed 
10
producer or distributor) as the listed drug or reference 
11
product described in such respective paragraph shall not 
12
be taken into consideration. 
13
‘‘(f) INFORMATION
ON
INTERNATIONAL
DRUG 
14
PRICES.—For purposes of determining which negotiation- 
15
eligible drugs to select under subsection (a) and, in the 
16
case of such drugs that are selected drugs, to determine 
17
the maximum fair price for such a drug and whether such 
18
maximum fair price should be renegotiated under section 
19
1194, the Secretary shall use data relating to the AIM 
20
price with respect to such drug as available or provided 
21
to the Secretary and shall on an ongoing basis request 
22
from manufacturers of selected drugs information on the 
23
AIM price of such a drug. 
24
04:12 Apr 27, 2021
H3
16 
•HR 3 IH
‘‘(g) 
NEW-ENTRANT
NEGOTIATION-ELIGIBLE 
1
DRUGS.— 
2
‘‘(1) IN GENERAL.—For purposes of this part, 
3
the term ‘new-entrant negotiation-eligible drug’ 
4
means, with respect to the selected drug publication 
5
date with respect to an initial price applicability 
6
year, a qualifying single source drug— 
7
‘‘(A) that is first approved or licensed, as 
8
described in paragraph (1), (2), or (3) of sub-
9
section (e), as applicable, during the year pre-
10
ceding such selected drug publication date; and 
11
‘‘(B) that the Secretary determines under 
12
paragraph (2) is likely to be included as a nego-
13
tiation-eligible drug with respect to the subse-
14
quent selected drug publication date. 
15
‘‘(2) DETERMINATION.—In the case of a quali-
16
fying single source drug that meets the criteria de-
17
scribed in subparagraph (A) of paragraph (1), with 
18
respect to an initial price applicability year, if the 
19
wholesale acquisition cost at which such drug is first 
20
marketed in the United States is equal to or greater 
21
than the median household income (as determined 
22
according to the most recent data collected by the 
23
United States Census Bureau), the Secretary shall 
24
determine before the selected drug publication date 
25
04:12 Apr 27, 2021
H3
17 
•HR 3 IH
with respect to the initial price applicability year, if 
1
the drug is likely to be included as a negotiation-eli-
2
gible drug with respect to the subsequent selected 
3
drug publication date, based on the projected spend-
4
ing under title XVIII or in the United States on 
5
such drug. For purposes of this paragraph the term 
6
‘United States’ includes the 50 States, the District 
7
of Columbia, and the territories of the United 
8
States. 
9
‘‘(h) CONFLICT OF INTEREST.— 
10
‘‘(1) IN GENERAL.—In the case the Inspector 
11
General of the Department of Health and Human 
12
Services determines the Secretary has a conflict, 
13
with respect to a matter described in paragraph (2), 
14
the individual described in paragraph (3) shall carry 
15
out the duties of the Secretary under this part, with 
16
respect to a negotiation-eligible drug, that would 
17
otherwise be such a conflict. 
18
‘‘(2) MATTER DESCRIBED.—A matter described 
19
in this paragraph is— 
20
‘‘(A) a financial interest (as described in 
21
section 2635.402 of title 5, Code of Federal 
22
Regulations, as in effect on the date of the en-
23
actment of this section, (except for an interest 
24
described in subsection (b)(2)(iv) of such sec-
25
04:12 Apr 27, 2021
H3
18 
•HR 3 IH
tion)) on the date of the selected drug publica-
1
tion date, with respect the price applicability 
2
year (as applicable); 
3
‘‘(B) a personal or business relationship 
4
(as described in section 2635.502 of such title) 
5
on the date of the selected drug publication 
6
date, with respect the price applicability year; 
7
‘‘(C) employment by a manufacturer of a 
8
negotiation-eligible drug during the preceding 
9
10-year period beginning on the date of the se-
10
lected drug publication date, with respect to 
11
each price applicability year; and 
12
‘‘(D) any other matter the General Counsel 
13
determines appropriate. 
14
‘‘(3) INDIVIDUAL
DESCRIBED.—An individual 
15
described in this paragraph is— 
16
‘‘(A) the highest-ranking officer or em-
17
ployee of the Department of Health and 
18
Human Services (as determined by the organi-
19
zational chart of the Department) that does not 
20
have a conflict under this subsection; and 
21
‘‘(B) is nominated by the President and 
22
confirmed by the Senate with respect to the po-
23
sition. 
24
04:12 Apr 27, 2021
H3
19 
•HR 3 IH
‘‘SEC. 1193. MANUFACTURER AGREEMENTS. 
1
‘‘(a) 
IN
GENERAL.—For 
purposes 
of 
section 
2
1191(a)(2), the Secretary shall enter into agreements with 
3
manufacturers of selected drugs with respect to a price 
4
applicability period, by not later than June 15 following 
5
the selected drug publication date with respect to such se-
6
lected drug, under which— 
7
‘‘(1) during the voluntary negotiation period for 
8
the initial price applicability year for the selected 
9
drug, the Secretary and manufacturer, in accordance 
10
with section 1194, negotiate to determine (and, by 
11
not later than the last date of such period and in ac-
12
cordance with subsection (c), agree to) a maximum 
13
fair price for such selected drug of the manufacturer 
14
in order to provide access to such price— 
15
‘‘(A) to fair price eligible individuals who 
16
with respect to such drug are described in sub-
17
paragraph (A) of section 1191(c)(1) and are 
18
furnished or dispensed such drug during, sub-
19
ject to subparagraph (2), the price applicability 
20
period; and 
21
‘‘(B) to hospitals, physicians, and other 
22
providers of services and suppliers with respect 
23
to fair price eligible individuals who with re-
24
spect to such drug are described in subpara-
25
graph (B) of such section and are furnished or 
26
04:12 Apr 27, 2021
H3
20 
•HR 3 IH
administered such drug during, subject to sub-
1
paragraph (2), the price applicability period; 
2
‘‘(2) the Secretary and the manufacturer shall, 
3
in accordance with a process and during a period 
4
specified by the Secretary pursuant to rulemaking, 
5
renegotiate (and, by not later than the last date of 
6
such period and in accordance with subsection (c), 
7
agree to) the maximum fair price for such drug if 
8
the Secretary determines that there is a material 
9
change in any of the factors described in section 
10
1194(d) relating to the drug, including changes in 
11
the AIM price for such drug, in order to provide ac-
12
cess to such maximum fair price (as so renegoti-
13
ated)— 
14
‘‘(A) to fair price eligible individuals who 
15
with respect to such drug are described in sub-
16
paragraph (A) of section 1191(c)(1) and are 
17
furnished or dispensed such drug during any 
18
year during the price applicability period (be-
19
ginning after such renegotiation) with respect 
20
to such selected drug; and 
21
‘‘(B) to hospitals, physicians, and other 
22
providers of services and suppliers with respect 
23
to fair price eligible individuals who with re-
24
spect to such drug are described in subpara-
25
04:12 Apr 27, 2021
H3
21 
•HR 3 IH
graph (B) of such section and are furnished or 
1
administered such drug during any year de-
2
scribed in subparagraph (A); 
3
‘‘(3) the maximum fair price (including as re-
4
negotiated pursuant to paragraph (2)), with respect 
5
to such a selected drug, shall be provided to fair 
6
price eligible individuals, who with respect to such 
7
drug are described in subparagraph (A) of section 
8
1191(c)(1), at the pharmacy or by a mail order serv-
9
ice at the point-of-sale of such drug; 
10
‘‘(4) the manufacturer, subject to subsection 
11
(d), submits to the Secretary, in a form and manner 
12
specified by the Secretary— 
13
‘‘(A) for the voluntary negotiation period 
14
for the price applicability period (and, if appli-
15
cable, before any period of renegotiation speci-
16
fied pursuant to paragraph (2)) with respect to 
17
such drug all information that the Secretary re-
18
quires to carry out the negotiation (or renegoti-
19
ation process) under this part, including infor-
20
mation described in section 1192(f) and section 
21
1194(d)(1); and 
22
‘‘(B) on an ongoing basis, information on 
23
changes in prices for such drug that would af-
24
fect the AIM price for such drug or otherwise 
25
04:12 Apr 27, 2021
H3
22 
•HR 3 IH
provide a basis for renegotiation of the max-
1
imum fair price for such drug pursuant to 
2
paragraph (2); 
3
‘‘(5) the manufacturer agrees that in the case 
4
the selected drug of a manufacturer is a drug de-
5
scribed in subsection (c), the manufacturer will, in 
6
accordance with such subsection, make any payment 
7
required under such subsection with respect to such 
8
drug; and 
9
‘‘(6) the manufacturer complies with require-
10
ments imposed by the Secretary for purposes of ad-
11
ministering the program, including with respect to 
12
the duties described in section 1196. 
13
‘‘(b) AGREEMENT IN EFFECT UNTIL DRUG IS NO 
14
LONGER A SELECTED DRUG.—An agreement entered into 
15
under this section shall be effective, with respect to a drug, 
16
until such drug is no longer considered a selected drug 
17
under section 1192(c). 
18
‘‘(c) SPECIAL RULE FOR CERTAIN SELECTED DRUGS 
19
WITHOUT AIM PRICE.— 
20
‘‘(1) IN GENERAL.—In the case of a selected 
21
drug for which there is no AIM price available with 
22
respect to the initial price applicability year for such 
23
drug and for which an AIM price becomes available 
24
beginning with respect to a subsequent plan year 
25
04:12 Apr 27, 2021
H3
23 
•HR 3 IH
during the price applicability period for such drug, 
1
if the Secretary determines that the amount de-
2
scribed in paragraph (2)(A) for a unit of such drug 
3
is greater than the amount described in paragraph 
4
(2)(B) for a unit of such drug, then by not later 
5
than one year after the date of such determination, 
6
the manufacturer of such selected drug shall pay to 
7
the Treasury an amount equal to the product of— 
8
‘‘(A) the difference between such amount 
9
described in paragraph (2)(A) for a unit of 
10
such drug and such amount described in para-
11
graph (2)(B) for a unit of such drug; and 
12
‘‘(B) the number of units of such drug sold 
13
in the United States, including the 50 States, 
14
the District of Columbia, and the territories of 
15
the United States, during the period described 
16
in paragraph (2)(B). 
17
‘‘(2) AMOUNTS DESCRIBED.— 
18
‘‘(A) WEIGHTED AVERAGE PRICE BEFORE 
19
AIM PRICE AVAILABLE.—For purposes of para-
20
graph (1), the amount described in this sub-
21
paragraph for a selected drug described in such 
22
paragraph, is the amount equal to the weighted 
23
average manufacturer price (as defined in sec-
24
tion 1927(k)(1)) for such dosage strength and 
25
04:12 Apr 27, 2021
H3
24 
•HR 3 IH
form for the drug during the period beginning 
1
with the first plan year for which the drug is 
2
included on the list of negotiation-eligible drugs 
3
published under section 1192(d) and ending 
4
with the last plan year during the price applica-
5
bility period for such drug with respect to which 
6
there is no AIM price available for such drug. 
7
‘‘(B) AMOUNT
MULTIPLIER
AFTER
AIM 
8
PRICE AVAILABLE.—For purposes of paragraph 
9
(1), the amount described in this subparagraph 
10
for a selected drug described in such paragraph, 
11
is the amount equal to 200 percent of the AIM 
12
price for such drug with respect to the first 
13
plan year during the price applicability period 
14
for such drug with respect to which there is an 
15
AIM price available for such drug. 
16
‘‘(d) CONFIDENTIALITY
OF INFORMATION.—Infor-
17
mation submitted to the Secretary under this part by a 
18
manufacturer of a selected drug that is proprietary infor-
19
mation of such manufacturer (as determined by the Sec-
20
retary) may be used only by the Secretary or disclosed 
21
to and used by the Comptroller General of the United 
22
States or the Medicare Payment Advisory Commission for 
23
purposes of carrying out this part. 
24
‘‘(e) REGULATIONS.— 
25
04:12 Apr 27, 2021
H3
25 
•HR 3 IH
‘‘(1) IN GENERAL.—The Secretary shall, pursu-
1
ant to rulemaking, specify, in accordance with para-
2
graph (2), the information that must be submitted 
3
under subsection (a)(4). 
4
‘‘(2) INFORMATION
SPECIFIED.—Information 
5
described in paragraph (1), with respect to a se-
6
lected drug, shall include information on sales of the 
7
drug (by the manufacturer of the drug or by another 
8
entity under license or other agreement with the 
9
manufacturer, with respect to the sales of such drug, 
10
regardless of the name under which the drug is sold) 
11
in any foreign country that is part of the AIM price. 
12
The Secretary shall verify, to the extent practicable, 
13
such sales from appropriate officials of the govern-
14
ment of the foreign country involved. 
15
‘‘(f) COMPLIANCE WITH REQUIREMENTS FOR AD-
16
MINISTRATION OF PROGRAM.—Each manufacturer with 
17
an agreement in effect under this section shall comply with 
18
requirements imposed by the Secretary or a third party 
19
with a contract under section 1196(c)(1), as applicable, 
20
for purposes of administering the program. 
21
‘‘SEC. 1194. NEGOTIATION AND RENEGOTIATION PROCESS. 
22
‘‘(a) IN GENERAL.—For purposes of this part, under 
23
an agreement under section 1193 between the Secretary 
24
and a manufacturer of a selected drug, with respect to 
25
04:12 Apr 27, 2021
H3
26 
•HR 3 IH
the period for which such agreement is in effect and in 
1
accordance with subsections (b) and (c), the Secretary and 
2
the manufacturer— 
3
‘‘(1) shall during the voluntary negotiation pe-
4
riod with respect to the initial price applicability 
5
year for such drug, in accordance with this section, 
6
negotiate a maximum fair price for such drug for 
7
the purpose described in section 1193(a)(1); and 
8
‘‘(2) 
as 
applicable 
pursuant 
to 
section 
9
1193(a)(2) and in accordance with the process speci-
10
fied pursuant to such section, renegotiate such max-
11
imum fair price for such drug for the purpose de-
12
scribed in such section. 
13
‘‘(b) NEGOTIATING
METHODOLOGY
AND
OBJEC-
14
TIVE.— 
15
‘‘(1) IN GENERAL.—The Secretary shall develop 
16
and use a consistent methodology for negotiations 
17
under subsection (a) that, in accordance with para-
18
graph (2) and subject to paragraph (3), achieves the 
19
lowest maximum fair price for each selected drug 
20
while appropriately rewarding innovation. 
21
‘‘(2) PRIORITIZING
FACTORS.—In considering 
22
the factors described in subsection (d) in negotiating 
23
(and, as applicable, renegotiating) the maximum fair 
24
price for a selected drug, the Secretary shall, to the 
25
04:12 Apr 27, 2021
H3
27 
•HR 3 IH
extent practicable, consider all of the available fac-
1
tors listed but shall prioritize the following factors: 
2
‘‘(A) 
RESEARCH
AND
DEVELOPMENT 
3
COSTS.—The factor described in paragraph 
4
(1)(A) of subsection (d). 
5
‘‘(B) MARKET
DATA.—The factor de-
6
scribed in paragraph (1)(B) of such subsection. 
7
‘‘(C) UNIT
COSTS
OF
PRODUCTION
AND 
8
DISTRIBUTION.—The factor described in para-
9
graph (1)(C) of such subsection. 
10
‘‘(D) COMPARISON
TO
EXISTING
THERA-
11
PEUTIC ALTERNATIVES.—The factor described 
12
in paragraph (2)(A) of such subsection. 
13
‘‘(3) REQUIREMENT.— 
14
‘‘(A) IN
GENERAL.—In negotiating the 
15
maximum fair price of a selected drug, with re-
16
spect to an initial price applicability year for 
17
the selected drug, and, as applicable, in renego-
18
tiating the maximum fair price for such drug, 
19
with respect to a subsequent year during the 
20
price applicability period for such drug, in the 
21
case that the manufacturer of the selected drug 
22
offers under the negotiation or renegotiation, as 
23
applicable, a price for such drug that is not 
24
more than the target price described in sub-
25
04:12 Apr 27, 2021
H3
28 
•HR 3 IH
paragraph (B) for such drug for the respective 
1
year, the Secretary shall agree under such ne-
2
gotiation or renegotiation, respectively, to such 
3
offered price as the maximum fair price. 
4
‘‘(B) TARGET PRICE.— 
5
‘‘(i) IN GENERAL.—Subject to clause 
6
(ii), the target price described in this sub-
7
paragraph for a selected drug with respect 
8
to a year, is the average price (which shall 
9
be the net average price, if practicable, and 
10
volume-weighted, if practicable) for a unit 
11
of such drug for sales of such drug, as 
12
computed (across different dosage forms 
13
and strengths of the drug and not based 
14
on the specific formulation or package size 
15
or package type of the drug) in the appli-
16
cable 
country 
described 
in 
section 
17
1191(c)(3)(B) with respect to such drug 
18
that, with respect to such year, has the 
19
lowest average price for such drug as com-
20
pared to the average prices (as so com-
21
puted) of such drug with respect to such 
22
year in the other applicable countries de-
23
scribed in such section with respect to such 
24
drug. 
25
04:12 Apr 27, 2021
H3
29 
•HR 3 IH
‘‘(ii) SELECTED DRUGS WITHOUT AIM 
1
PRICE.—In applying this paragraph in the 
2
case of negotiating the maximum fair price 
3
of a selected drug for which there is no 
4
AIM price available with respect to the ini-
5
tial price applicability year for such drug, 
6
or, as applicable, renegotiating the max-
7
imum fair price for such drug with respect 
8
to a subsequent year during the price ap-
9
plicability period for such drug before the 
10
first plan year for which there is an AIM 
11
price available for such drug, the target 
12
price described in this subparagraph for 
13
such drug and respective year is the 
14
amount that is 80 percent of the average 
15
manufacturer price (as defined in section 
16
1927(k)(1)) for such drug and year. 
17
‘‘(4) ANNUAL REPORT.—After the completion 
18
of each voluntary negotiation period, the Secretary 
19
shall submit to Congress a report on the maximum 
20
fair prices negotiated (or, as applicable, renegoti-
21
ated) for such period. Such report shall include in-
22
formation on how such prices so negotiated (or re-
23
negotiated) meet the requirements of this part, in-
24
cluding the requirements of this subsection. 
25
04:12 Apr 27, 2021
H3
30 
•HR 3 IH
‘‘(c) LIMITATION.— 
1
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
2
the maximum fair price negotiated (including as re-
3
negotiated) under this section for a selected drug, 
4
with respect to each plan year during a price appli-
5
cability period for such drug, shall not exceed 120 
6
percent of the AIM price applicable to such drug 
7
with respect to such year. 
8
‘‘(2) SELECTED DRUGS WITHOUT AIM PRICE.— 
9
In the case of a selected drug for which there is no 
10
AIM price available with respect to the initial price 
11
applicability year for such drug, for each plan year 
12
during the price applicability period before the first 
13
plan year for which there is an AIM price available 
14
for such drug, the maximum fair price negotiated 
15
(including as renegotiated) under this section for the 
16
selected drug shall not exceed the amount equal to 
17
85 percent of the average manufacturer price for the 
18
drug with respect to such year. 
19
‘‘(d) CONSIDERATIONS.—For purposes of negotiating 
20
and, as applicable, renegotiating (including for purposes 
21
of determining whether to renegotiate) the maximum fair 
22
price of a selected drug under this part with the manufac-
23
turer of the drug, the Secretary, consistent with sub-
24
section (b)(2), shall take into consideration the factors de-
25
04:12 Apr 27, 2021
H3
31 
•HR 3 IH
scribed in paragraphs (1), (2), (3), and (5), and may take 
1
into consideration the factor described in paragraph (4): 
2
‘‘(1) 
MANUFACTURER-SPECIFIC
INFORMA-
3
TION.—The following information, including as sub-
4
mitted by the manufacturer: 
5
‘‘(A) Research and development costs of 
6
the manufacturer for the drug and the extent to 
7
which the manufacturer has recouped research 
8
and development costs. 
9
‘‘(B) Market data for the drug, including 
10
the distribution of sales across different pro-
11
grams and purchasers and projected future rev-
12
enues for the drug. 
13
‘‘(C) Unit costs of production and distribu-
14
tion of the drug. 
15
‘‘(D) Prior Federal financial support for 
16
novel therapeutic discovery and development 
17
with respect to the drug. 
18
‘‘(E) Data on patents and on existing and 
19
pending exclusivity for the drug. 
20
‘‘(F) National sales data for the drug. 
21
‘‘(G) Information on clinical trials for the 
22
drug in the United States or in applicable coun-
23
tries described in section 1191(c)(3)(B). 
24
04:12 Apr 27, 2021
H3
32 
•HR 3 IH
‘‘(2) INFORMATION
ON
ALTERNATIVE
PROD-
1
UCTS.—The following information: 
2
‘‘(A) The extent to which the drug rep-
3
resents a therapeutic advance as compared to 
4
existing therapeutic alternatives and, to the ex-
5
tent such information is available, the costs of 
6
such existing therapeutic alternatives. 
7
‘‘(B) Information on approval by the Food 
8
and Drug Administration of alternative drug 
9
products. 
10
‘‘(C) Information on comparative effective-
11
ness analysis for such products, taking into 
12
consideration the effects of such products on 
13
specific populations, such as individuals with 
14
disabilities, the elderly, terminally ill, children, 
15
and other patient populations. 
16
In considering information described in subpara-
17
graph (C), the Secretary shall not use evidence or 
18
findings from comparative clinical effectiveness re-
19
search in a manner that treats extending the life of 
20
an elderly, disabled, or terminally ill individual as of 
21
lower value than extending the life of an individual 
22
who is younger, nondisabled, or not terminally ill. 
23
Nothing in the previous sentence shall affect the ap-
24
04:12 Apr 27, 2021
H3
33 
•HR 3 IH
plication or consideration of an AIM price for a se-
1
lected drug. 
2
‘‘(3) FOREIGN
SALES
INFORMATION.—To the 
3
extent available on a timely basis, including as pro-
4
vided by a manufacturer of the selected drug or oth-
5
erwise, information on sales of the selected drug in 
6
each 
of 
the 
countries 
described 
in 
section 
7
1191(c)(3)(B). 
8
‘‘(4) VA DRUG PRICING INFORMATION.—Infor-
9
mation disclosed to the Secretary pursuant to sub-
10
section (f). 
11
‘‘(5) ADDITIONAL INFORMATION.—Information 
12
submitted to the Secretary, in accordance with a 
13
process specified by the Secretary, by other parties 
14
that are affected by the establishment of a maximum 
15
fair price for the selected drug. 
16
‘‘(e) REQUEST FOR INFORMATION.—For purposes of 
17
negotiating and, as applicable, renegotiating (including for 
18
purposes of determining whether to renegotiate) the max-
19
imum fair price of a selected drug under this part with 
20
the manufacturer of the drug, with respect to a price ap-
21
plicability period, and other relevant data for purposes of 
22
this section— 
23
‘‘(1) the Secretary shall, not later than the se-
24
lected drug publication date with respect to the ini-
25
04:12 Apr 27, 2021
H3
34 
•HR 3 IH
tial price applicability year of such period, request 
1
drug pricing information from the manufacturer of 
2
such selected drug, including information described 
3
in subsection (d)(1); and 
4
‘‘(2) by not later than October 1 following the 
5
selected drug publication date, the manufacturer of 
6
such selected drug shall submit to the Secretary 
7
such requested information in such form and man-
8
ner as the Secretary may require. 
9
The Secretary shall request, from the manufacturer or 
10
others, such additional information as may be needed to 
11
carry out the negotiation and renegotiation process under 
12
this section. 
13
‘‘(f) DISCLOSURE OF INFORMATION.—For purposes 
14
of this part, the Secretary of Veterans Affairs may disclose 
15
to the Secretary of Health and Human Services the price 
16
of any negotiation-eligible drug that is purchased pursuant 
17
to section 8126 of title 38, United States Code. 
18
‘‘SEC. 1195. PUBLICATION OF MAXIMUM FAIR PRICES. 
19
‘‘(a) IN GENERAL.—With respect to an initial price 
20
applicability year and selected drug with respect to such 
21
year, not later than April 1 of the plan year prior to such 
22
initial price applicability year, the Secretary shall publish 
23
in the Federal Register the maximum fair price for such 
24
04:12 Apr 27, 2021
H3
35 
•HR 3 IH
drug negotiated under this part with the manufacturer of 
1
such drug. 
2
‘‘(b) UPDATES.— 
3
‘‘(1) 
SUBSEQUENT
YEAR
MAXIMUM
FAIR 
4
PRICES.—For a selected drug, for each plan year 
5
subsequent to the initial price applicability year for 
6
such drug with respect to which an agreement for 
7
such drug is in effect under section 1193, the Sec-
8
retary shall publish in the Federal Register— 
9
‘‘(A) subject to subparagraph (B), the 
10
amount equal to the maximum fair price pub-
11
lished for such drug for the previous year, in-
12
creased by the annual percentage increase in 
13
the consumer price index for all urban con-
14
sumers (all items; U.S. city average) as of Sep-
15
tember of such previous year; or 
16
‘‘(B) in the case the maximum fair price 
17
for such drug was renegotiated, for the first 
18
year for which such price as so renegotiated ap-
19
plies, such renegotiated maximum fair price. 
20
‘‘(2) PRICES NEGOTIATED AFTER DEADLINE.— 
21
In the case of a selected drug with respect to an ini-
22
tial price applicability year for which the maximum 
23
fair price is determined under this part after the 
24
date of publication under this section, the Secretary 
25
04:12 Apr 27, 2021
H3
36 
•HR 3 IH
shall publish such maximum fair price in the Fed-
1
eral Register by not later than 30 days after the 
2
date such maximum price is so determined. 
3
‘‘SEC. 1196. ADMINISTRATIVE DUTIES; COORDINATION PRO-
4
VISIONS. 
5
‘‘(a) ADMINISTRATIVE DUTIES.— 
6
‘‘(1) IN
GENERAL.—For purposes of section 
7
1191, the administrative duties described in this sec-
8
tion are the following: 
9
‘‘(A) The establishment of procedures (in-
10
cluding through agreements with manufacturers 
11
under this part, contracts with prescription 
12
drug plans under part D of title XVIII and 
13
MA–PD plans under part C of such title, and 
14
agreements under section 1197 with group 
15
health plans and health insurance issuers of 
16
health insurance coverage offered in the indi-
17
vidual or group market) under which the max-
18
imum fair price for a selected drug is provided 
19
to fair price eligible individuals, who with re-
20
spect to such drug are described in subpara-
21
graph (A) of section 1191(c)(1), at pharmacies 
22
or by mail order service at the point-of-sale of 
23
the drug for the applicable price period for such 
24
drug and providing that such maximum fair 
25
04:12 Apr 27, 2021
H3
37 
•HR 3 IH
price is used for determining cost-sharing under 
1
such plans or coverage for the selected drug. 
2
‘‘(B) The establishment of procedures (in-
3
cluding through agreements with manufacturers 
4
under this part and contracts with hospitals, 
5
physicians, and other providers of services and 
6
suppliers and agreements under section 1197 
7
with group health plans and health insurance 
8
issuers of health insurance coverage offered in 
9
the individual or group market) under which, in 
10
the case of a selected drug furnished or admin-
11
istered by such a hospital, physician, or other 
12
provider of services or supplier to fair price eli-
13
gible individuals (who with respect to such drug 
14
are described in subparagraph (B) of section 
15
1191(c)(1)), the maximum fair price for the se-
16
lected drug is provided to such hospitals, physi-
17
cians, and other providers of services and sup-
18
pliers (as applicable) with respect to such indi-
19
viduals and providing that such maximum fair 
20
price is used for determining cost-sharing under 
21
the respective part, plan, or coverage for the se-
22
lected drug. 
23
‘‘(C) The establishment of procedures (in-
24
cluding through agreements and contracts de-
25
04:12 Apr 27, 2021
H3
38 
•HR 3 IH
scribed in subparagraphs (A) and (B)) to en-
1
sure that, not later than 90 days after the dis-
2
pensing of a selected drug to a fair price eligi-
3
ble individual by a pharmacy or mail order serv-
4
ice, the pharmacy or mail order service is reim-
5
bursed for an amount equal to the difference 
6
between— 
7
‘‘(i) the lesser of— 
8
‘‘(I) the wholesale acquisition 
9
cost of the drug; 
10
‘‘(II) the national average drug 
11
acquisition cost of the drug; and 
12
‘‘(III) any other similar deter-
13
mination of pharmacy acquisition 
14
costs of the drug, as determined by 
15
the Secretary; and 
16
‘‘(ii) the maximum fair price for the 
17
drug. 
18
‘‘(D) The establishment of procedures to 
19
ensure that the maximum fair price for a se-
20
lected drug is applied before— 
21
‘‘(i) any coverage or financial assist-
22
ance under other health benefit plans or 
23
programs that provide coverage or finan-
24
cial assistance for the purchase or provi-
25
04:12 Apr 27, 2021
H3
39 
•HR 3 IH
sion of prescription drug coverage on be-
1
half of fair price eligible individuals as the 
2
Secretary may specify; and 
3
‘‘(ii) any other discounts. 
4
‘‘(E) The establishment of procedures to 
5
enter into appropriate agreements and protocols 
6
for the ongoing computation of AIM prices for 
7
selected drugs, including, to the extent possible, 
8
to compute the AIM price for selected drugs 
9
and including by providing that the manufac-
10
turer of such a selected drug should provide in-
11
formation for such computation not later than 
12
3 months after the first date of the voluntary 
13
negotiation period for such selected drug. 
14
‘‘(F) The establishment of procedures to 
15
compute and apply the maximum fair price 
16
across different strengths and dosage forms of 
17
a selected drug and not based on the specific 
18
formulation or package size or package type of 
19
the drug. 
20
‘‘(G) The establishment of procedures to 
21
negotiate and apply the maximum fair price in 
22
a manner that does not include any dispensing 
23
or similar fee. 
24
04:12 Apr 27, 2021
H3
40 
•HR 3 IH
‘‘(H) The establishment of procedures to 
1
carry out the provisions of this part, as applica-
2
ble, with respect to— 
3
‘‘(i) fair price eligible individuals who 
4
are enrolled under a prescription drug plan 
5
under part D of title XVIII or an MA–PD 
6
plan under part C of such title; 
7
‘‘(ii) fair price eligible individuals who 
8
are enrolled under a group health plan or 
9
health insurance coverage offered by a 
10
health insurance issuer in the individual or 
11
group market with respect to which there 
12
is an agreement in effect under section 
13
1197; and 
14
‘‘(iii) fair price eligible individuals who 
15
are entitled to benefits under part A of 
16
title XVIII or enrolled under part B of 
17
such title. 
18
‘‘(I) The establishment of a negotiation 
19
process and renegotiation process in accordance 
20
with section 1194, including a process for ac-
21
quiring information described in subsection (d) 
22
of such section and determining amounts de-
23
scribed in subsection (b) of such section. 
24
04:12 Apr 27, 2021
H3
41 
•HR 3 IH
‘‘(J) The provision of a reasonable dispute 
1
resolution mechanism to resolve disagreements 
2
between manufacturers, fair price eligible indi-
3
viduals, and the third party with a contract 
4
under subsection (c)(1). 
5
‘‘(2) MONITORING COMPLIANCE.— 
6
‘‘(A) IN
GENERAL.—The Secretary shall 
7
monitor compliance by a manufacturer with the 
8
terms of an agreement under section 1193, in-
9
cluding by establishing a mechanism through 
10
which violations of such terms may be reported. 
11
‘‘(B) NOTIFICATION.—If a third party 
12
with a contract under subsection (c)(1) deter-
13
mines that the manufacturer is not in compli-
14
ance with such agreement, the third party shall 
15
notify the Secretary of such noncompliance for 
16
appropriate enforcement under section 4192 of 
17
the Internal Revenue Code of 1986 or section 
18
1198, as applicable. 
19
‘‘(b) COLLECTION OF DATA.— 
20
‘‘(1) FROM
PRESCRIPTION
DRUG
PLANS
AND 
21
MA–PD PLANS.—The Secretary may collect appro-
22
priate data from prescription drug plans under part 
23
D of title XVIII and MA–PD plans under part C of 
24
such title in a timeframe that allows for maximum 
25
04:12 Apr 27, 2021
H3
42 
•HR 3 IH
fair prices to be provided under this part for selected 
1
drugs. 
2
‘‘(2) FROM
HEALTH
PLANS.—The Secretary 
3
may collect appropriate data from group health 
4
plans or health insurance issuers offering group or 
5
individual health insurance coverage in a timeframe 
6
that allows for maximum fair prices to be provided 
7
under this part for selected drugs. 
8
‘‘(3) COORDINATION OF DATA COLLECTION.— 
9
To the extent feasible, as determined by the Sec-
10
retary, the Secretary shall ensure that data collected 
11
pursuant to this subsection is coordinated with, and 
12
not duplicative of, other Federal data collection ef-
13
forts. 
14
‘‘(c) CONTRACT WITH THIRD PARTIES.— 
15
‘‘(1) IN GENERAL.—The Secretary may enter 
16
into a contract with 1 or more third parties to ad-
17
minister the requirements established by the Sec-
18
retary in order to carry out this part. At a min-
19
imum, the contract with a third party under the pre-
20
ceding sentence shall require that the third party— 
21
‘‘(A) receive and transmit information be-
22
tween the Secretary, manufacturers, and other 
23
individuals or entities the Secretary determines 
24
appropriate; 
25
04:12 Apr 27, 2021
H3
43 
•HR 3 IH
‘‘(B) receive, distribute, or facilitate the 
1
distribution of funds of manufacturers to ap-
2
propriate individuals or entities in order to 
3
meet the obligations of manufacturers under 
4
agreements under this part; 
5
‘‘(C) provide adequate and timely informa-
6
tion to manufacturers, consistent with the 
7
agreement with the manufacturer under this 
8
part, as necessary for the manufacturer to ful-
9
fill its obligations under this part; and 
10
‘‘(D) permit manufacturers to conduct 
11
periodic audits, directly or through contracts, of 
12
the data and information used by the third 
13
party to determine discounts for applicable 
14
drugs of the manufacturer under the program. 
15
‘‘(2) 
PERFORMANCE
REQUIREMENTS.—The 
16
Secretary shall establish performance requirements 
17
for a third party with a contract under paragraph 
18
(1) and safeguards to protect the independence and 
19
integrity of the activities carried out by the third 
20
party under the program under this part. 
21
‘‘SEC. 
1197. 
VOLUNTARY 
PARTICIPATION 
BY 
OTHER 
22
HEALTH PLANS. 
23
‘‘(a) AGREEMENT TO PARTICIPATE UNDER PRO-
24
GRAM.— 
25
04:12 Apr 27, 2021
H3
44 
•HR 3 IH
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
1
under the program under this part the Secretary 
2
shall be treated as having in effect an agreement 
3
with a group health plan or health insurance issuer 
4
offering group or individual health insurance cov-
5
erage (as such terms are defined in section 2791 of 
6
the Public Health Service Act), with respect to a 
7
price applicability period and a selected drug with 
8
respect to such period— 
9
‘‘(A) with respect to such selected drug 
10
furnished or dispensed at a pharmacy or by 
11
mail order service if coverage is provided under 
12
such plan or coverage during such period for 
13
such selected drug as so furnished or dispensed; 
14
and 
15
‘‘(B) with respect to such selected drug 
16
furnished or administered by a hospital, physi-
17
cian, or other provider of services or supplier if 
18
coverage is provided under such plan or cov-
19
erage during such period for such selected drug 
20
as so furnished or administered. 
21
‘‘(2) OPTING OUT OF AGREEMENT.—The Sec-
22
retary shall not be treated as having in effect an 
23
agreement under the program under this part with 
24
a group health plan or health insurance issuer offer-
25
04:12 Apr 27, 2021
H3
45 
•HR 3 IH
ing group or individual health insurance coverage 
1
with respect to a price applicability period and a se-
2
lected drug with respect to such period if such a 
3
plan or issuer affirmatively elects, through a process 
4
specified by the Secretary, not to participate under 
5
the program with respect to such period and drug. 
6
‘‘(b) PUBLICATION OF ELECTION.—With respect to 
7
each price applicability period and each selected drug with 
8
respect to such period, the Secretary and the Secretary 
9
of Labor and the Secretary of the Treasury, as applicable, 
10
shall make public a list of each group health plan and each 
11
health insurance issuer offering group or individual health 
12
insurance coverage, with respect to which coverage is pro-
13
vided under such plan or coverage for such drug, that has 
14
elected under subsection (a) not to participate under the 
15
program with respect to such period and drug. 
16
‘‘SEC. 1198. CIVIL MONETARY PENALTY. 
17
‘‘(a) VIOLATIONS RELATING TO OFFERING OF MAX-
18
IMUM FAIR PRICE.—Any manufacturer of a selected drug 
19
that has entered into an agreement under section 1193, 
20
with respect to a plan year during the price applicability 
21
period for such drug, that does not provide access to a 
22
price that is not more than the maximum fair price (or 
23
a lesser price) for such drug for such year— 
24
04:12 Apr 27, 2021
H3
46 
•HR 3 IH
‘‘(1) to a fair price eligible individual who with 
1
respect to such drug is described in subparagraph 
2
(A) of section 1191(c)(1) and who is furnished or 
3
dispensed such drug during such year; or 
4
‘‘(2) to a hospital, physician, or other provider 
5
of services or supplier with respect to fair price eligi-
6
ble individuals who with respect to such drug is de-
7
scribed in subparagraph (B) of such section and is 
8
furnished or administered such drug by such hos-
9
pital, physician, or provider or supplier during such 
10
year; 
11
shall be subject to a civil monetary penalty equal to ten 
12
times the amount equal to the difference between the price 
13
for such drug made available for such year by such manu-
14
facturer with respect to such individual or hospital, physi-
15
cian, provider, or supplier and the maximum fair price for 
16
such drug for such year. 
17
‘‘(b) VIOLATIONS OF CERTAIN TERMS OF AGREE-
18
MENT.—Any manufacturer of a selected drug that has en-
19
tered into an agreement under section 1193, with respect 
20
to a plan year during the price applicability period for 
21
such drug, that is in violation of a requirement imposed 
22
pursuant to section 1193(a)(6) shall be subject to a civil 
23
monetary penalty of not more than $1,000,000 for each 
24
such violation. 
25
04:12 Apr 27, 2021
H3
47 
•HR 3 IH
‘‘(c) APPLICATION.—The provisions of section 1128A 
1
(other than subsections (a) and (b)) shall apply to a civil 
2
monetary penalty under this section in the same manner 
3
as such provisions apply to a penalty or proceeding under 
4
section 1128A(a). 
5
‘‘SEC. 1199. MISCELLANEOUS PROVISIONS. 
6
‘‘(a) PAPERWORK REDUCTION ACT.—Chapter 35 of 
7
title 44, United States Code, shall not apply to data col-
8
lected under this part. 
9
‘‘(b) NATIONAL ACADEMY OF MEDICINE STUDY.— 
10
Not later than December 31, 2027, the National Academy 
11
of Medicine shall conduct a study, and submit to Congress 
12
a report, on recommendations for improvements to the 
13
program under this part, including the determination of 
14
the limits applied under section 1194(c). 
15
‘‘(c) MEDPAC STUDY.—Not later than December 31, 
16
2027, the Medicare Payment Advisory Commission shall 
17
conduct a study, and submit to Congress a report, on the 
18
program under this part with respect to the Medicare pro-
19
gram under title XVIII, including with respect to the ef-
20
fect of the program on individuals entitled to benefits or 
21
enrolled under such title. 
22
‘‘(d) LIMITATION ON JUDICIAL REVIEW.—The fol-
23
lowing shall not be subject to judicial review: 
24
04:12 Apr 27, 2021
H3
48 
•HR 3 IH
‘‘(1) The selection of drugs for publication 
1
under section 1192(a). 
2
‘‘(2) The determination of whether a drug is a 
3
negotiation-eligible drug under section 1192(d). 
4
‘‘(3) The determination of the maximum fair 
5
price of a selected drug under section 1194. 
6
‘‘(4) The determination of units of a drug for 
7
purposes of section 1191(c)(3). 
8
‘‘(e) COORDINATION.—In carrying out this part with 
9
respect to group health plans or health insurance coverage 
10
offered in the group market that are subject to oversight 
11
by the Secretary of Labor or the Secretary of the Treas-
12
ury, the Secretary of Health and Human Services shall 
13
coordinate with such respective Secretary. 
14
‘‘(f) DATA SHARING.—The Secretary shall share with 
15
the Secretary of the Treasury such information as is nec-
16
essary to determine the tax imposed by section 4192 of 
17
the Internal Revenue Code of 1986. 
18
‘‘(g) GAO STUDY.—Not later than December 31, 
19
2027, the Comptroller General of the United States shall 
20
conduct a study of, and submit to Congress a report on, 
21
the implementation of the Fair Price Negotiation Program 
22
under this part.’’. 
23
(b) APPLICATION OF MAXIMUM FAIR PRICES AND 
24
CONFORMING AMENDMENTS.— 
25
04:12 Apr 27, 2021
H3
49 
•HR 3 IH
(1) UNDER MEDICARE.— 
1
(A) APPLICATION
TO
PAYMENTS
UNDER 
2
PART B.—Section 1847A(b)(1)(B) of the Social 
3
Security Act (42 U.S.C. 1395w–3a(b)(1)(B)) is 
4
amended by inserting ‘‘or in the case of such a 
5
drug or biological that is a selected drug (as de-
6
fined in section 1192(c)), with respect to a 
7
price applicability period (as defined in section 
8
1191(b)(2)), 106 percent of the maximum fair 
9
price (as defined in section 1191(c)(2)) applica-
10
ble for such drug and a plan year during such 
11
period’’ after ‘‘paragraph (4)’’. 
12
(B) EXCEPTION TO PART D NON-INTER-
13
FERENCE.—Section 1860D–11(i) of the Social 
14
Security Act (42 U.S.C. 1395w–111(i)) is 
15
amended by inserting ‘‘, except as provided 
16
under part E of title XI’’ after ‘‘the Secretary’’. 
17
(C) APPLICATION AS NEGOTIATED PRICE 
18
UNDER PART D.—Section 1860D–2(d)(1) of the 
19
Social 
Security 
Act 
(42 
U.S.C. 
1395w– 
20
102(d)(1)) is amended— 
21
(i) in subparagraph (B), by inserting 
22
‘‘, subject to subparagraph (D),’’ after 
23
‘‘negotiated prices’’; and 
24
04:12 Apr 27, 2021
H3
50 
•HR 3 IH
(ii) by adding at the end the following 
1
new subparagraph: 
2
‘‘(D) APPLICATION
OF
MAXIMUM
FAIR 
3
PRICE FOR SELECTED DRUGS.—In applying this 
4
section, in the case of a covered part D drug 
5
that is a selected drug (as defined in section 
6
1192(c)), with respect to a price applicability 
7
period (as defined in section 1191(b)(2)), the 
8
negotiated prices used for payment (as de-
9
scribed in this subsection) shall be the max-
10
imum 
fair 
price 
(as 
defined 
in 
section 
11
1191(c)(2)) for such drug and for each plan 
12
year during such period.’’. 
13
(D) INFORMATION
FROM
PRESCRIPTION 
14
DRUG PLANS AND MA–PD PLANS REQUIRED.— 
15
(i) PRESCRIPTION DRUG PLANS.—Sec-
16
tion 1860D–12(b) of the Social Security 
17
Act (42 U.S.C. 1395w–112(b)) is amended 
18
by adding at the end the following new 
19
paragraph: 
20
‘‘(8) PROVISION OF INFORMATION RELATED TO 
21
MAXIMUM FAIR PRICES.—Each contract entered into 
22
with a PDP sponsor under this part with respect to 
23
a prescription drug plan offered by such sponsor 
24
shall require the sponsor to provide information to 
25
04:12 Apr 27, 2021
H3
51 
•HR 3 IH
the Secretary as requested by the Secretary in ac-
1
cordance with section 1196(b).’’. 
2
(ii) 
MA–PD 
PLANS.—Section 
3
1857(f)(3) of the Social Security Act (42 
4
U.S.C. 1395w–27(f)(3)) is amended by 
5
adding at the end the following new sub-
6
paragraph: 
7
‘‘(E) PROVISION
OF
INFORMATION
RE-
8
LATED
TO
MAXIMUM
FAIR
PRICES.—Section 
9
1860D–12(b)(8).’’. 
10
(2) UNDER
GROUP
HEALTH
PLANS
AND 
11
HEALTH INSURANCE COVERAGE.— 
12
(A) PHSA.—Part D of title XXVII of the 
13
Public Health Service Act (42 U.S.C. 300gg– 
14
111 et seq.) is amended by adding at the end 
15
the following new section: 
16
‘‘SEC. 2799A–11. FAIR PRICE NEGOTIATION PROGRAM AND 
17
APPLICATION OF MAXIMUM FAIR PRICES. 
18
‘‘(a) IN GENERAL.—In the case of a group health 
19
plan or health insurance issuer offering group or indi-
20
vidual health insurance coverage that is treated under sec-
21
tion 1197 of the Social Security Act as having in effect 
22
an agreement with the Secretary under the Fair Price Ne-
23
gotiation Program under part E of title XI of such Act, 
24
with respect to a price applicability period (as defined in 
25
04:12 Apr 27, 2021
H3
52 
•HR 3 IH
section 1191(b) of such Act) and a selected drug (as de-
1
fined in section 1192(c) of such Act) with respect to such 
2
period with respect to which coverage is provided under 
3
such plan or coverage— 
4
‘‘(1) the provisions of such part shall apply— 
5
‘‘(A) if coverage of such selected drug is 
6
provided under such plan or coverage if the 
7
drug is furnished or dispensed at a pharmacy 
8
or by a mail order service, to the plans or cov-
9
erage offered by such plan or issuer, and to the 
10
individuals enrolled under such plans or cov-
11
erage, during such period, with respect to such 
12
selected drug, in the same manner as such pro-
13
visions apply to prescription drug plans and 
14
MA–PD plans, and to individuals enrolled 
15
under such prescription drug plans and MA– 
16
PD plans during such period; and 
17
‘‘(B) if coverage of such selected drug is 
18
provided under such plan or coverage if the 
19
drug is furnished or administered by a hospital, 
20
physician, or other provider of services or sup-
21
plier, to the plans or coverage offered by such 
22
plan or issuers, to the individuals enrolled 
23
under such plans or coverage, and to hospitals, 
24
physicians, and other providers of services and 
25
04:12 Apr 27, 2021
H3
53 
•HR 3 IH
suppliers during such period, with respect to 
1
such drug in the same manner as such provi-
2
sions apply to the Secretary, to individuals enti-
3
tled to benefits under part A of title XVIII or 
4
enrolled under part B of such title, and to hos-
5
pitals, physicians, and other providers and sup-
6
pliers participating under title XVIII during 
7
such period; 
8
‘‘(2) the plan or issuer shall apply any cost- 
9
sharing responsibilities under such plan or coverage, 
10
with respect to such selected drug, by substituting 
11
an amount not more than the maximum fair price 
12
negotiated under such part E of title XI for such 
13
drug in lieu of the drug price upon which the cost- 
14
sharing would have otherwise applied, and such cost- 
15
sharing responsibilities with respect to such selected 
16
drug may not exceed such maximum fair price; and 
17
‘‘(3) the Secretary shall apply the provisions of 
18
such part E to such plan, issuer, and coverage, such 
19
individuals so enrolled in such plans and coverage, 
20
and such hospitals, physicians, and other providers 
21
and suppliers participating in such plans and cov-
22
erage. 
23
‘‘(b) NOTIFICATION REGARDING NONPARTICIPATION 
24
IN FAIR PRICE NEGOTIATION PROGRAM.—A group health 
25
04:12 Apr 27, 2021
H3
54 
•HR 3 IH
plan or a health insurance issuer offering group or indi-
1
vidual health insurance coverage shall publicly disclose in 
2
a manner and in accordance with a process specified by 
3
the Secretary any election made under section 1197 of the 
4
Social Security Act by the plan or issuer to not participate 
5
in the Fair Price Negotiation Program under part E of 
6
title XI of such Act with respect to a selected drug (as 
7
defined in section 1192(c) of such Act) for which coverage 
8
is provided under such plan or coverage before the begin-
9
ning of the plan year for which such election was made.’’. 
10
(B) ERISA.— 
11
(i) IN GENERAL.—Subpart B of part 
12
7 of subtitle B of title I of the Employee 
13
Retirement Income Security Act of 1974 
14
(29 U.S.C. 1181 et seq.) is amended by 
15
adding at the end the following new sec-
16
tion: 
17
‘‘SEC. 726. FAIR PRICE NEGOTIATION PROGRAM AND APPLI-
18
CATION OF MAXIMUM FAIR PRICES. 
19
‘‘(a) IN GENERAL.—In the case of a group health 
20
plan or health insurance issuer offering group health in-
21
surance coverage that is treated under section 1197 of the 
22
Social Security Act as having in effect an agreement with 
23
the Secretary under the Fair Price Negotiation Program 
24
under part E of title XI of such Act, with respect to a 
25
04:12 Apr 27, 2021
H3
55 
•HR 3 IH
price applicability period (as defined in section 1191(b) 
1
of such Act) and a selected drug (as defined in section 
2
1192(c) of such Act) with respect to such period with re-
3
spect to which coverage is provided under such plan or 
4
coverage— 
5
‘‘(1) the provisions of such part shall apply, as 
6
applicable— 
7
‘‘(A) if coverage of such selected drug is 
8
provided under such plan or coverage if the 
9
drug is furnished or dispensed at a pharmacy 
10
or by a mail order service, to the plans or cov-
11
erage offered by such plan or issuer, and to the 
12
individuals enrolled under such plans or cov-
13
erage, during such period, with respect to such 
14
selected drug, in the same manner as such pro-
15
visions apply to prescription drug plans and 
16
MA–PD plans, and to individuals enrolled 
17
under such prescription drug plans and MA– 
18
PD plans during such period; and 
19
‘‘(B) if coverage of such selected drug is 
20
provided under such plan or coverage if the 
21
drug is furnished or administered by a hospital, 
22
physician, or other provider of services or sup-
23
plier, to the plans or coverage offered by such 
24
plan or issuers, to the individuals enrolled 
25
04:12 Apr 27, 2021
H3
56 
•HR 3 IH
under such plans or coverage, and to hospitals, 
1
physicians, and other providers of services and 
2
suppliers during such period, with respect to 
3
such drug in the same manner as such provi-
4
sions apply to the Secretary, to individuals enti-
5
tled to benefits under part A of title XVIII or 
6
enrolled under part B of such title, and to hos-
7
pitals, physicians, and other providers and sup-
8
pliers participating under title XVIII during 
9
such period; 
10
‘‘(2) the plan or issuer shall apply any cost- 
11
sharing responsibilities under such plan or coverage, 
12
with respect to such selected drug, by substituting 
13
an amount not more than the maximum fair price 
14
negotiated under such part E of title XI for such 
15
drug in lieu of the drug price upon which the cost- 
16
sharing would have otherwise applied, and such cost- 
17
sharing responsibilities with respect to such selected 
18
drug may not exceed such maximum fair price; and 
19
‘‘(3) the Secretary shall apply the provisions of 
20
such part E to such plan, issuer, and coverage, and 
21
such individuals so enrolled in such plans. 
22
‘‘(b) NOTIFICATION REGARDING NONPARTICIPATION 
23
IN FAIR PRICE NEGOTIATION PROGRAM.—A group health 
24
plan or a health insurance issuer offering group health in-
25
04:12 Apr 27, 2021
H3
57 
•HR 3 IH
surance coverage shall publicly disclose in a manner and 
1
in accordance with a process specified by the Secretary 
2
any election made under section 1197 of the Social Secu-
3
rity Act by the plan or issuer to not participate in the 
4
Fair Price Negotiation Program under part E of title XI 
5
of such Act with respect to a selected drug (as defined 
6
in section 1192(c) of such Act) for which coverage is pro-
7
vided under such plan or coverage before the beginning 
8
of the plan year for which such election was made.’’. 
9
(ii) APPLICATION
TO
RETIREE
AND 
10
CERTAIN SMALL GROUP HEALTH PLANS.— 
11
Section 732(a) of the Employee Retire-
12
ment Income Security Act of 1974 (29 
13
U.S.C. 1191a(a)) is amended by striking 
14
‘‘section 711’’ and inserting ‘‘sections 711 
15
and 726’’. 
16
(iii) 
CLERICAL
AMENDMENT.—The 
17
table of sections for subpart B of part 7 of 
18
subtitle B of title I of the Employee Re-
19
tirement Income Security Act of 1974 is 
20
amended by adding at the end the fol-
21
lowing: 
22
‘‘Sec. 726. Fair Price Negotiation Program and application of maximum fair 
prices.’’. 
(C) IRC.— 
23
04:12 Apr 27, 2021
H3
58 
•HR 3 IH
(i) IN
GENERAL.—Subchapter B of 
1
chapter 100 of the Internal Revenue Code 
2
of 1986 is amended by adding at the end 
3
the following new section: 
4
‘‘SEC. 9826. FAIR PRICE NEGOTIATION PROGRAM AND AP-
5
PLICATION OF MAXIMUM FAIR PRICES. 
6
‘‘(a) IN GENERAL.—In the case of a group health 
7
plan that is treated under section 1197 of the Social Secu-
8
rity Act as having in effect an agreement with the Sec-
9
retary under the Fair Price Negotiation Program under 
10
part E of title XI of such Act, with respect to a price 
11
applicability period (as defined in section 1191(b) of such 
12
Act) and a selected drug (as defined in section 1192(c) 
13
of such Act) with respect to such period with respect to 
14
which coverage is provided under such plan— 
15
‘‘(1) the provisions of such part shall apply, as 
16
applicable— 
17
‘‘(A) if coverage of such selected drug is 
18
provided under such plan if the drug is fur-
19
nished or dispensed at a pharmacy or by a mail 
20
order service, to the plan, and to the individuals 
21
enrolled under such plan during such period, 
22
with respect to such selected drug, in the same 
23
manner as such provisions apply to prescription 
24
drug plans and MA–PD plans, and to individ-
25
04:12 Apr 27, 2021
H3
59 
•HR 3 IH
uals enrolled under such prescription drug 
1
plans and MA–PD plans during such period; 
2
and 
3
‘‘(B) if coverage of such selected drug is 
4
provided under such plan if the drug is fur-
5
nished or administered by a hospital, physician, 
6
or other provider of services or supplier, to the 
7
plan, to the individuals enrolled under such 
8
plan, and to hospitals, physicians, and other 
9
providers of services and suppliers during such 
10
period, with respect to such drug in the same 
11
manner as such provisions apply to the Sec-
12
retary, to individuals entitled to benefits under 
13
part A of title XVIII or enrolled under part B 
14
of such title, and to hospitals, physicians, and 
15
other providers and suppliers participating 
16
under title XVIII during such period; 
17
‘‘(2) the plan shall apply any cost-sharing re-
18
sponsibilities under such plan, with respect to such 
19
selected drug, by substituting an amount not more 
20
than the maximum fair price negotiated under such 
21
part E of title XI for such drug in lieu of the drug 
22
price upon which the cost-sharing would have other-
23
wise applied, and such cost-sharing responsibilities 
24
04:12 Apr 27, 2021
H3
60 
•HR 3 IH
with respect to such selected drug may not exceed 
1
such maximum fair price; and 
2
‘‘(3) the Secretary shall apply the provisions of 
3
such part E to such plan and such individuals so en-
4
rolled in such plan. 
5
‘‘(b) NOTIFICATION REGARDING NONPARTICIPATION 
6
IN FAIR PRICE NEGOTIATION PROGRAM.—A group health 
7
plan shall publicly disclose in a manner and in accordance 
8
with a process specified by the Secretary any election 
9
made under section 1197 of the Social Security Act by 
10
the plan to not participate in the Fair Price Negotiation 
11
Program under part E of title XI of such Act with respect 
12
to a selected drug (as defined in section 1192(c) of such 
13
Act) for which coverage is provided under such plan before 
14
the beginning of the plan year for which such election was 
15
made.’’. 
16
(ii) APPLICATION
TO
RETIREE
AND 
17
CERTAIN SMALL GROUP HEALTH PLANS.— 
18
Section 9831(a)(2) of the Internal Revenue 
19
Code of 1986 is amended by inserting 
20
‘‘other than with respect to section 9826,’’ 
21
before ‘‘any group health plan’’. 
22
(iii) 
CLERICAL
AMENDMENT.—The 
23
table of sections for subchapter B of chap-
24
04:12 Apr 27, 2021
H3
61 
•HR 3 IH
ter 100 of such Code is amended by add-
1
ing at the end the following new item: 
2
‘‘Sec. 9826. Fair Price Negotiation Program and application of maximum fair 
prices.’’. 
(3) FAIR PRICE NEGOTIATION PROGRAM PRICES 
3
INCLUDED IN BEST PRICE AND AMP.—Section 1927 
4
of the Social Security Act (42 U.S.C. 1396r–8) is 
5
amended— 
6
(A) in subsection (c)(1)(C)(ii)— 
7
(i) in subclause (III), by striking at 
8
the end ‘‘; and’’; 
9
(ii) in subclause (IV), by striking at 
10
the end the period and inserting ‘‘; and’’; 
11
and 
12
(iii) by adding at the end the fol-
13
lowing new subclause: 
14
‘‘(V) in the case of a rebate pe-
15
riod and a covered outpatient drug 
16
that is a selected drug (as defined in 
17
section 1192(c)) during such rebate 
18
period, shall be inclusive of the price 
19
for such drug made available from the 
20
manufacturer during the rebate period 
21
by reason of application of part E of 
22
title XI to any wholesaler, retailer, 
23
provider, health maintenance organi-
24
04:12 Apr 27, 2021
H3
62 
•HR 3 IH
zation, nonprofit entity, or govern-
1
mental entity within the United 
2
States.’’; and 
3
(B) in subsection (k)(1)(B), by adding at 
4
the end the following new clause: 
5
‘‘(iii) 
CLARIFICATION.—Notwith-
6
standing clause (i), in the case of a rebate 
7
period and a covered outpatient drug that 
8
is a selected drug (as defined in section 
9
1192(c)) during such rebate period, any 
10
reduction in price paid during the rebate 
11
period to the manufacturer for the drug by 
12
a wholesaler or retail community pharmacy 
13
described in subparagraph (A) by reason of 
14
application of part E of title XI shall be 
15
included in the average manufacturer price 
16
for the covered outpatient drug.’’. 
17
(4) FEHBP.—Section 8902 of title 5, United 
18
States Code, is amended by adding at the end the 
19
following: 
20
‘‘(p) A contract may not be made or a plan approved 
21
under this chapter with any carrier that has affirmatively 
22
elected, pursuant to section 1197 of the Social Security 
23
Act, not to participate in the Fair Price Negotiation Pro-
24
gram established under section 1191 of such Act for any 
25
04:12 Apr 27, 2021
H3
63 
•HR 3 IH
selected drug (as that term is defined in section 1192(c) 
1
of such Act).’’. 
2
(5) OPTION OF SECRETARY OF VETERANS AF-
3
FAIRS TO PURCHASE COVERED DRUGS AT MAXIMUM 
4
FAIR
PRICES.—Section 8126 of title 38, United 
5
States Code, is amended— 
6
(A) in subsection (a)(2), by inserting ‘‘, 
7
subject to subsection (j),’’ after ‘‘may not ex-
8
ceed’’; 
9
(B) in subsection (d), in the matter pre-
10
ceding paragraph (1), by inserting ‘‘, subject to 
11
subsection (j)’’ after ‘‘for the procurement of 
12
the drug’’; and 
13
(C) by adding at the end the following new 
14
subsection: 
15
‘‘(j)(1) In the case of a covered drug that is a selected 
16
drug, for any year during the price applicability period for 
17
such drug, if the Secretary determines that the maximum 
18
fair price of such drug for such year is less than the price 
19
for such drug otherwise in effect pursuant to this section 
20
(including after application of any reduction under sub-
21
section (a)(2) and any discount under subsection (c)), at 
22
the option of the Secretary, in lieu of the maximum price 
23
(determined after application of the reduction under sub-
24
section (a)(2) and any discount under subsection (c), as 
25
04:12 Apr 27, 2021
H3
64 
•HR 3 IH
applicable) that would be permitted to be charged during 
1
such year for such drug pursuant to this section without 
2
application of this subsection, the maximum price per-
3
mitted to be charged during such year for such drug pur-
4
suant to this section shall be such maximum fair price for 
5
such drug and year. 
6
‘‘(2) For purposes of this subsection: 
7
‘‘(A) The term ‘maximum fair price’ means, 
8
with respect to a selected drug and year during the 
9
price applicability period for such drug, the max-
10
imum fair price (as defined in section 1191(c)(2) of 
11
the Social Security Act) for such drug and year. 
12
‘‘(B) The term ‘negotiation eligible drug’ has 
13
the meaning given such term in section 1192(d)(1) 
14
of the Social Security Act. 
15
‘‘(C) The term ‘price applicability period’ has, 
16
with respect to a selected drug, the meaning given 
17
such term in section 1191(b)(2) of such Act. 
18
‘‘(D) The term ‘selected drug’ means, with re-
19
spect to a year, a drug that is a selected drug under 
20
section 1192(c) of such Act for such year.’’. 
21
04:12 Apr 27, 2021
H3
65 
•HR 3 IH
SEC. 102. SELECTED DRUG MANUFACTURER EXCISE TAX 
1
IMPOSED DURING NONCOMPLIANCE PERI-
2
ODS. 
3
(a) IN GENERAL.—Subchapter E of chapter 32 of the 
4
Internal Revenue Code of 1986 is amended by adding at 
5
the end the following new section: 
6
‘‘SEC. 4192. SELECTED DRUGS DURING NONCOMPLIANCE 
7
PERIODS. 
8
‘‘(a) IN GENERAL.—There is hereby imposed on the 
9
sale by the manufacturer, producer, or importer of any 
10
selected drug during a day described in subsection (b) a 
11
tax in an amount such that the applicable percentage is 
12
equal to the ratio of— 
13
‘‘(1) such tax, divided by 
14
‘‘(2) the sum of such tax and the price for 
15
which so sold. 
16
‘‘(b) NONCOMPLIANCE PERIODS.—A day is described 
17
in this subsection with respect to a selected drug if it is 
18
a day during one of the following periods: 
19
‘‘(1) The period beginning on the June 16th 
20
immediately following the selected drug publication 
21
date and ending on the first date during which the 
22
manufacturer of the drug has in place an agreement 
23
described in subsection (a) of section 1193 of the 
24
Social Security Act with respect to such drug. 
25
04:12 Apr 27, 2021
H3
66 
•HR 3 IH
‘‘(2) The period beginning on the April 1st im-
1
mediately following the June 16th described in para-
2
graph (1) and ending on the first date during which 
3
the manufacturer of the drug has agreed to a max-
4
imum fair price under such agreement. 
5
‘‘(3) In the case of a selected drug with respect 
6
to which the Secretary of Health and Human Serv-
7
ices has specified a renegotiation period under such 
8
agreement, the period beginning on the first date 
9
after the last date of such renegotiation period and 
10
ending on the first date during which the manufac-
11
turer of the drug has agreed to a renegotiated max-
12
imum fair price under such agreement. 
13
‘‘(4) With respect to information that is re-
14
quired to be submitted to the Secretary of Health 
15
and Human Services under such agreement, the pe-
16
riod beginning on the date on which such Secretary 
17
certifies that such information is overdue and ending 
18
on the date that such information is so submitted. 
19
‘‘(5) In the case of a selected drug with respect 
20
to which a payment is due under subsection (c) of 
21
such section 1193, the period beginning on the date 
22
on which the Secretary of Health and Human Serv-
23
ices certifies that such payment is overdue and end-
24
ing on the date that such payment is made in full. 
25
04:12 Apr 27, 2021
H3
67 
•HR 3 IH
‘‘(c) APPLICABLE PERCENTAGE.—For purposes of 
1
this section, the term ‘applicable percentage’ means— 
2
‘‘(1) in the case of sales of a selected drug dur-
3
ing the first 90 days described in subsection (b) with 
4
respect to such drug, 65 percent, 
5
‘‘(2) in the case of sales of such drug during 
6
the 91st day through the 180th day described in 
7
subsection (b) with respect to such drug, 75 percent, 
8
‘‘(3) in the case of sales of such drug during 
9
the 181st day through the 270th day described in 
10
subsection (b) with respect to such drug, 85 percent, 
11
and 
12
‘‘(4) in the case of sales of such drug during 
13
any subsequent day, 95 percent. 
14
‘‘(d) SELECTED DRUG.—For purposes of this sec-
15
tion— 
16
‘‘(1) IN GENERAL.—The term ‘selected drug’ 
17
means any selected drug (within the meaning of sec-
18
tion 1192 of the Social Security Act) which is manu-
19
factured or produced in the United States or entered 
20
into the United States for consumption, use, or 
21
warehousing. 
22
‘‘(2) UNITED
STATES.—The term ‘United 
23
States’ has the meaning given such term by section 
24
4612(a)(4). 
25
04:12 Apr 27, 2021
H3
68 
•HR 3 IH
‘‘(3) COORDINATION WITH RULES FOR POSSES-
1
SIONS OF THE UNITED STATES.—Rules similar to 
2
the rules of paragraphs (2) and (4) of section 
3
4132(c) shall apply for purposes of this section. 
4
‘‘(e) OTHER DEFINITIONS.—For purposes of this 
5
section, the terms ‘selected drug publication date’ and 
6
‘maximum fair price’ have the meaning given such terms 
7
in section 1191 of the Social Security Act. 
8
‘‘(f) ANTI-ABUSE RULE.—In the case of a sale which 
9
was timed for the purpose of avoiding the tax imposed by 
10
this section, the Secretary may treat such sale as occur-
11
ring during a day described in subsection (b).’’. 
12
(b) NO DEDUCTION FOR EXCISE TAX PAYMENTS.— 
13
Section 275 of the Internal Revenue Code of 1986 is 
14
amended by adding ‘‘or by section 4192’’ before the period 
15
at the end of subsection (a)(6). 
16
(c) CONFORMING AMENDMENTS.— 
17
(1) Section 4221(a) of the Internal Revenue 
18
Code of 1986 is amended by inserting ‘‘or 4192’’ 
19
after ‘‘section 4191’’. 
20
(2) Section 6416(b)(2) of such Code is amend-
21
ed by inserting ‘‘or 4192’’ after ‘‘section 4191’’. 
22
(d) CLERICAL AMENDMENTS.— 
23
(1) The heading of subchapter E of chapter 32 
24
of the Internal Revenue Code of 1986 is amended by 
25
04:12 Apr 27, 2021
H3
69 
•HR 3 IH
striking 
‘‘Medical 
Devices’’ 
and 
inserting 
1
‘‘Other Medical Products’’. 
2
(2) The table of subchapters for chapter 32 of 
3
such Code is amended by striking the item relating 
4
to subchapter E and inserting the following new 
5
item: 
6
‘‘SUBCHAPTER E. OTHER MEDICAL PRODUCTS’’. 
(3) The table of sections for subchapter E of 
7
chapter 32 of such Code is amended by adding at 
8
the end the following new item: 
9
‘‘Sec. 4192. Selected drugs during noncompliance periods.’’. 
(e) EFFECTIVE DATE.—The amendments made by 
10
this section shall apply to sales after the date of the enact-
11
ment of this Act. 
12
SEC. 103. FAIR PRICE NEGOTIATION IMPLEMENTATION 
13
FUND. 
14
(a) IN GENERAL.—There is hereby established a Fair 
15
Price Negotiation Implementation Fund (referred to in 
16
this section as the ‘‘Fund’’). The Secretary of Health and 
17
Human Services may obligate and expend amounts in the 
18
Fund to carry out this title and titles II and III (and the 
19
amendments made by such titles). 
20
(b) FUNDING.—There is authorized to be appro-
21
priated, and there is hereby appropriated, out of any mon-
22
ies in the Treasury not otherwise appropriated, to the 
23
04:12 Apr 27, 2021
H3
70 
•HR 3 IH
Fund $3,000,000,000, to remain available until expended, 
1
of which— 
2
(1) $600,000,000 shall become available on the 
3
date of the enactment of this Act; 
4
(2) $600,000,000 shall become available on Oc-
5
tober 1, 2022; 
6
(3) $600,000,000 shall become available on Oc-
7
tober 1, 2023; 
8
(4) $600,000,000 shall become available on Oc-
9
tober 1, 2024; and 
10
(5) $600,000,000 shall become available on Oc-
11
tober 1, 2025. 
12
(c) SUPPLEMENT NOT SUPPLANT.—Any amounts 
13
appropriated pursuant to this section shall be in addition 
14
to any other amounts otherwise appropriated pursuant to 
15
any other provision of law. 
16
TITLE II—PRESCRIPTION DRUG 
17
INFLATION REBATES 
18
SEC. 201. MEDICARE PART B REBATE BY MANUFACTURERS. 
19
(a) IN GENERAL.—Section 1834 of the Social Secu-
20
rity Act (42 U.S.C. 1395m) is amended by adding at the 
21
end the following new subsection: 
22
‘‘(z) REBATE
BY MANUFACTURERS
FOR SINGLE 
23
SOURCE DRUGS WITH PRICES INCREASING FASTER 
24
THAN INFLATION.— 
25
04:12 Apr 27, 2021
H3
71 
•HR 3 IH
‘‘(1) REQUIREMENTS.— 
1
‘‘(A) SECRETARIAL PROVISION OF INFOR-
2
MATION.—Not later than 6 months after the 
3
end of each calendar quarter beginning on or 
4
after July 1, 2023, the Secretary shall, for each 
5
part B rebatable drug, report to each manufac-
6
turer of such part B rebatable drug the fol-
7
lowing for such calendar quarter: 
8
‘‘(i) Information on the total number 
9
of units of the billing and payment code 
10
described in subparagraph (A)(i) of para-
11
graph (3) with respect to such drug and 
12
calendar quarter. 
13
‘‘(ii) Information on the amount (if 
14
any) of the excess average sales price in-
15
crease described in subparagraph (A)(ii) of 
16
such paragraph for such drug and calendar 
17
quarter. 
18
‘‘(iii) The rebate amount specified 
19
under such paragraph for such part B 
20
rebatable drug and calendar quarter. 
21
‘‘(B) MANUFACTURER
REQUIREMENT.— 
22
For each calendar quarter beginning on or after 
23
July 1, 2023, the manufacturer of a part B 
24
rebatable drug shall, for such drug, not later 
25
04:12 Apr 27, 2021
H3
72 
•HR 3 IH
than 30 days after the date of receipt from the 
1
Secretary of the information described in sub-
2
paragraph (A) for such calendar quarter, pro-
3
vide to the Secretary a rebate that is equal to 
4
the amount specified in paragraph (3) for such 
5
drug for such calendar quarter. 
6
‘‘(2) PART B REBATABLE DRUG DEFINED.— 
7
‘‘(A) IN GENERAL.—In this subsection, the 
8
term ‘part B rebatable drug’ means a single 
9
source drug or biological (as defined in sub-
10
paragraph (D) of section 1847A(c)(6)), includ-
11
ing a biosimilar biological product (as defined 
12
in subparagraph (H) of such section), paid for 
13
under this part, except such term shall not in-
14
clude such a drug or biological— 
15
‘‘(i) if the average total allowed 
16
charges for a year per individual that uses 
17
such a drug or biological, as determined by 
18
the Secretary, are less than, subject to 
19
subparagraph (B), $100; or 
20
‘‘(ii) that is a vaccine described in 
21
subparagraph (A) or (B) of section 
22
1861(s)(10). 
23
‘‘(B) INCREASE.—The dollar amount ap-
24
plied under subparagraph (A)(i)— 
25
04:12 Apr 27, 2021
H3
73 
•HR 3 IH
‘‘(i) for 2024, shall be the dollar 
1
amount specified under such subparagraph 
2
for 2023, increased by the percentage in-
3
crease in the consumer price index for all 
4
urban consumers (United States city aver-
5
age) for the 12-month period ending with 
6
June of the previous year; and 
7
‘‘(ii) for a subsequent year, shall be 
8
the dollar amount specified in this clause 
9
(or clause (i)) for the previous year, in-
10
creased by the percentage increase in the 
11
consumer price index for all urban con-
12
sumers (United States city average) for 
13
the 12-month period ending with June of 
14
the previous year. 
15
Any dollar amount specified under this sub-
16
paragraph that is not a multiple of $10 shall be 
17
rounded to the nearest multiple of $10. 
18
‘‘(3) REBATE AMOUNT.— 
19
‘‘(A) IN GENERAL.—For purposes of para-
20
graph (1), the amount specified in this para-
21
graph for a part B rebatable drug assigned to 
22
a billing and payment code for a calendar quar-
23
ter is, subject to paragraph (4), the amount 
24
equal to the product of— 
25
04:12 Apr 27, 2021
H3
74 
•HR 3 IH
‘‘(i) subject to subparagraphs (B) and 
1
(G), the total number of units of the bill-
2
ing and payment code for such part B 
3
rebatable drug furnished under this part 
4
during the calendar quarter; and 
5
‘‘(ii) the amount (if any) by which— 
6
‘‘(I) the payment amount under 
7
subparagraph (B) or (C) of section 
8
1847A(b)(1), as applicable, for such 
9
part B rebatable drug during the cal-
10
endar quarter; exceeds 
11
‘‘(II) the inflation-adjusted pay-
12
ment amount determined under sub-
13
paragraph (C) for such part B 
14
rebatable drug during the calendar 
15
quarter. 
16
‘‘(B) EXCLUDED UNITS.—For purposes of 
17
subparagraph (A)(i), the total number of units 
18
of the billing and payment code for each part 
19
B rebatable drug furnished during a calendar 
20
quarter shall not include— 
21
‘‘(i) units packaged into the payment 
22
for a procedure or service under section 
23
1833(t) or under section 1833(i) (instead 
24
04:12 Apr 27, 2021
H3
75 
•HR 3 IH
of separately payable under such respective 
1
section); 
2
‘‘(ii) units included under the single 
3
payment system for renal dialysis services 
4
under section 1881(b)(14); or 
5
‘‘(iii) units of a part B rebatable drug 
6
of a manufacturer furnished to an indi-
7
vidual, if such manufacturer, with respect 
8
to the furnishing of such units of such 
9
drug, provides for discounts under section 
10
340B of the Public Health Service Act or 
11
for rebates under section 1927. 
12
‘‘(C) DETERMINATION OF INFLATION-AD-
13
JUSTED PAYMENT AMOUNT.—The inflation-ad-
14
justed payment amount determined under this 
15
subparagraph for a part B rebatable drug for 
16
a calendar quarter is— 
17
‘‘(i) the payment amount for the bill-
18
ing and payment code for such drug in the 
19
payment amount benchmark quarter (as 
20
defined in subparagraph (D)); increased by 
21
‘‘(ii) the percentage by which the re-
22
bate period CPI–U (as defined in subpara-
23
graph (F)) for the calendar quarter ex-
24
04:12 Apr 27, 2021
H3
76 
•HR 3 IH
ceeds the benchmark period CPI–U (as de-
1
fined in subparagraph (E)). 
2
‘‘(D) 
PAYMENT
AMOUNT
BENCHMARK 
3
QUARTER.—The term ‘payment amount bench-
4
mark quarter’ means the calendar quarter be-
5
ginning January 1, 2016. 
6
‘‘(E) BENCHMARK
PERIOD
CPI–U.—The 
7
term ‘benchmark period CPI–U’ means the con-
8
sumer price index for all urban consumers 
9
(United States city average) for July 2015. 
10
‘‘(F) REBATE PERIOD CPI–U.—The term 
11
‘rebate period CPI–U’ means, with respect to a 
12
calendar quarter described in subparagraph 
13
(C), the greater of the benchmark period CPI– 
14
U and the consumer price index for all urban 
15
consumers (United States city average) for the 
16
first month of the calendar quarter that is two 
17
calendar quarters prior to such described cal-
18
endar quarter. 
19
‘‘(G) COUNTING UNITS.— 
20
‘‘(i) CUT-OFF
PERIOD
TO
COUNT 
21
UNITS.—For purposes of subparagraph 
22
(A)(i), subject to clause (ii), to count the 
23
total number of billing units for a part B 
24
rebatable drug for a quarter, the Secretary 
25
04:12 Apr 27, 2021
H3
77 
•HR 3 IH
may use a cut-off period in order to ex-
1
clude from such total number of billing 
2
units for such quarter claims for services 
3
furnished during such quarter that were 
4
not processed at an appropriate time prior 
5
to the end of the cut-off period. 
6
‘‘(ii) COUNTING
UNITS
FOR
CLAIMS 
7
PROCESSED
AFTER
CUT-OFF
PERIOD.—If 
8
the Secretary uses a cut-off period pursu-
9
ant to clause (i), in the case of units of a 
10
part B rebatable drug furnished during a 
11
quarter but pursuant to application of such 
12
cut-off period excluded for purposes of sub-
13
paragraph (A)(i) from the total number of 
14
billing units for the drug for such quarter, 
15
the Secretary shall count such units of 
16
such drug so furnished in the total number 
17
of billing units for such drug for a subse-
18
quent quarter, as the Secretary determines 
19
appropriate. 
20
‘‘(4) SPECIAL TREATMENT OF CERTAIN DRUGS 
21
AND EXEMPTION.— 
22
‘‘(A) SUBSEQUENTLY APPROVED DRUGS.— 
23
Subject to subparagraph (B), in the case of a 
24
part B rebatable drug first approved or licensed 
25
04:12 Apr 27, 2021
H3
78 
•HR 3 IH
by the Food and Drug Administration after 
1
July 1, 2015, clause (i) of paragraph (3)(C) 
2
shall be applied as if the term ‘payment amount 
3
benchmark quarter’ were defined under para-
4
graph (3)(D) as the third full calendar quarter 
5
after the day on which the drug was first mar-
6
keted and clause (ii) of paragraph (3)(C) shall 
7
be applied as if the term ‘benchmark period 
8
CPI–U’ were defined under paragraph (3)(E) 
9
as if the reference to ‘July 2015’ under such 
10
paragraph were a reference to ‘the first month 
11
of the first full calendar quarter after the day 
12
on which the drug was first marketed’. 
13
‘‘(B) TIMELINE
FOR
PROVISION
OF
RE-
14
BATES
FOR
SUBSEQUENTLY
APPROVED 
15
DRUGS.—In the case of a part B rebatable drug 
16
first approved or licensed by the Food and 
17
Drug Administration after July 1, 2015, para-
18
graph (1)(B) shall be applied as if the reference 
19
to ‘July 1, 2023’ under such paragraph were a 
20
reference to the later of the 6th full calendar 
21
quarter after the day on which the drug was 
22
first marketed or July 1, 2023. 
23
‘‘(C) EXEMPTION FOR SHORTAGES.—The 
24
Secretary may reduce or waive the rebate 
25
04:12 Apr 27, 2021
H3
79 
•HR 3 IH
amount under paragraph (1)(B) with respect to 
1
a part B rebatable drug that is described as 
2
currently in shortage on the shortage list in ef-
3
fect under section 506E of the Federal Food, 
4
Drug, and Cosmetic Act or in the case of other 
5
exigent circumstances, as determined by the 
6
Secretary. 
7
‘‘(D) SELECTED DRUGS.—In the case of a 
8
part B rebatable drug that is a selected drug 
9
(as defined in section 1192(c)) for a price appli-
10
cability 
period 
(as 
defined 
in 
section 
11
1191(b)(2))— 
12
‘‘(i) for calendar quarters during such 
13
period for which a maximum fair price (as 
14
defined in section 1191(c)(2)) for such 
15
drug has been determined and is applied 
16
under part E of title XI, the rebate 
17
amount under paragraph (1)(B) shall be 
18
waived; and 
19
‘‘(ii) in the case such drug is deter-
20
mined (pursuant to such section 1192(c)) 
21
to no longer be a selected drug, for each 
22
applicable year beginning after the price 
23
applicability period with respect to such 
24
drug, clause (i) of paragraph (3)(C) shall 
25
04:12 Apr 27, 2021
H3
80 
•HR 3 IH
be applied as if the term ‘payment amount 
1
benchmark quarter’ were defined under 
2
paragraph (3)(D) as the calendar quarter 
3
beginning January 1 of the last year be-
4
ginning during such price applicability pe-
5
riod with respect to such selected drug and 
6
clause (ii) of paragraph (3)(C) shall be ap-
7
plied as if the term ‘benchmark period 
8
CPI–U’ were defined under paragraph 
9
(3)(E) as if the reference to ‘July 2015’ 
10
under such paragraph were a reference to 
11
the July of the year preceding such last 
12
year. 
13
‘‘(5) APPLICATION TO BENEFICIARY COINSUR-
14
ANCE.—In the case of a part B rebatable drug, if 
15
the payment amount for a quarter exceeds the infla-
16
tion adjusted payment for such quarter— 
17
‘‘(A) in computing the amount of any coin-
18
surance applicable under this title to an indi-
19
vidual with respect to such drug, the computa-
20
tion of such coinsurance shall be based on the 
21
inflation-adjusted payment amount determined 
22
under paragraph (3)(C) for such part B 
23
rebatable drug; and 
24
04:12 Apr 27, 2021
H3
81 
•HR 3 IH
‘‘(B) the amount of such coinsurance is 
1
equal to 20 percent of such inflation-adjusted 
2
payment amount so determined. 
3
‘‘(6) REBATE DEPOSITS.—Amounts paid as re-
4
bates under paragraph (1)(B) shall be deposited into 
5
the Federal Supplementary Medical Insurance Trust 
6
Fund established under section 1841. 
7
‘‘(7) CIVIL MONEY PENALTY.—If a manufac-
8
turer of a part B rebatable drug has failed to com-
9
ply with the requirements under paragraph (1)(B) 
10
for such drug for a calendar quarter, the manufac-
11
turer shall be subject to, in accordance with a proc-
12
ess established by the Secretary pursuant to regula-
13
tions, a civil money penalty in an amount equal to 
14
at least 125 percent of the amount specified in para-
15
graph (3) for such drug for such calendar quarter. 
16
The provisions of section 1128A (other than sub-
17
sections (a) (with respect to amounts of penalties or 
18
additional assessments) and (b)) shall apply to a 
19
civil money penalty under this paragraph in the 
20
same manner as such provisions apply to a penalty 
21
or proceeding under section 1128A(a). 
22
‘‘(8) STUDY AND REPORT.— 
23
04:12 Apr 27, 2021
H3
82 
•HR 3 IH
‘‘(A) STUDY.—The Secretary shall conduct 
1
a study of the feasibility of and operational 
2
issues involved with the following: 
3
‘‘(i) Including multiple source drugs 
4
(as defined in section 1847A(c)(6)(C)) in 
5
the rebate system under this subsection. 
6
‘‘(ii) Including drugs and biologicals 
7
paid for under MA plans under part C in 
8
the rebate system under this subsection. 
9
‘‘(iii) Including drugs excluded under 
10
paragraph (2)(A) and units of the billing 
11
and payment code of the drugs excluded 
12
under paragraph (3)(B) in the rebate sys-
13
tem under this subsection. 
14
‘‘(B) REPORT.—Not later than 3 years 
15
after the date of the enactment of this sub-
16
section, the Secretary shall submit to Congress 
17
a report on the study conducted under subpara-
18
graph (A). 
19
‘‘(9) APPLICATION
TO
MULTIPLE
SOURCE 
20
DRUGS.—The Secretary may, based on the report 
21
submitted under paragraph (8) and pursuant to 
22
rulemaking, apply the provisions of this subsection 
23
to multiple source drugs (as defined in section 
24
1847A(c)(6)(C)), including, for purposes of deter-
25
04:12 Apr 27, 2021
H3
83 
•HR 3 IH
mining the rebate amount under paragraph (3), by 
1
calculating 
manufacturer-specific 
average 
sales 
2
prices for the benchmark period and the rebate pe-
3
riod.’’. 
4
(b) AMOUNTS PAYABLE; COST-SHARING.—Section 
5
1833 of the Social Security Act (42 U.S.C. 1395l) is 
6
amended— 
7
(1) in subsection (a)— 
8
(A) in paragraph (1)— 
9
(i) in subparagraph (S), by striking 
10
‘‘with respect to’’ and inserting ‘‘subject to 
11
subparagraph (DD), with respect to’’; 
12
(ii) by striking ‘‘and (DD)’’ and in-
13
serting ‘‘(EE)’’; and 
14
(iii) by inserting before the semicolon 
15
at the end the following: ‘‘, and (EE) with 
16
respect to a part B rebatable drug (as de-
17
fined in paragraph (2) of section 1834(z)) 
18
for which the payment amount for a cal-
19
endar 
quarter 
under 
paragraph 
20
(3)(A)(ii)(I) of such section for such quar-
21
ter exceeds the inflation-adjusted payment 
22
under paragraph (3)(A)(ii)(II) of such sec-
23
tion for such quarter, the amounts paid 
24
shall be the difference between (i) the pay-
25
04:12 Apr 27, 2021
H3
84 
•HR 3 IH
ment 
amount 
under 
paragraph 
1
(3)(A)(ii)(I) of such section for such drug, 
2
and (ii) 20 percent of the inflation-ad-
3
justed payment amount under paragraph 
4
(3)(A)(ii)(II) of such section for such 
5
drug’’; and 
6
(B) by adding at the end of the flush left 
7
matter following paragraph (9), the following: 
8
‘‘For purposes of applying paragraph (1)(EE), sub-
9
sections (i)(9) and (t)(8)(F), and section 1834(z)(5), the 
10
Secretary shall make such estimates and use such data 
11
as the Secretary determines appropriate, and notwith-
12
standing any other provision of law, may do so by program 
13
instruction or otherwise.’’; 
14
(2) in subsection (i), by adding at the end the 
15
following new paragraph: 
16
‘‘(9) In the case of a part B rebatable drug (as de-
17
fined in paragraph (2) of section 1834(z)) for which pay-
18
ment under this subsection is not packaged into a payment 
19
for a covered OPD service (as defined in subsection 
20
(t)(1)(B)) (or group of services) furnished on or after July 
21
1, 2023, under the system under this subsection, in lieu 
22
of calculation of coinsurance and the amount of payment 
23
otherwise applicable under this subsection, the provisions 
24
of section 1834(z)(5), paragraph (1)(EE) of subsection 
25
04:12 Apr 27, 2021
H3
85 
•HR 3 IH
(a), and the flush left matter following paragraph (9) of 
1
subsection (a), shall, as determined appropriate by the 
2
Secretary, apply under this subsection in the same manner 
3
as such provisions of section 1834(z)(5) and subsection 
4
(a) apply under such section and subsection.’’; and 
5
(3) in subsection (t)(8), by adding at the end 
6
the following new subparagraph: 
7
‘‘(F) PART B REBATABLE DRUGS.—In the 
8
case of a part B rebatable drug (as defined in 
9
paragraph (2) of section 1834(z)) for which 
10
payment under this part is not packaged into a 
11
payment for a service furnished on or after July 
12
1, 2023, under the system under this sub-
13
section, in lieu of calculation of coinsurance and 
14
the amount of payment otherwise applicable 
15
under this subsection, the provisions of section 
16
1834(z)(5), paragraph (1)(EE) of subsection 
17
(a), and the flush left matter following para-
18
graph (9) of subsection (a), shall, as determined 
19
appropriate by the Secretary, apply under this 
20
subsection in the same manner as such provi-
21
sions of section 1834(z)(5) and subsection (a) 
22
apply under such section and subsection.’’. 
23
(c) CONFORMING AMENDMENTS.— 
24
04:12 Apr 27, 2021
H3
86 
•HR 3 IH
(1) TO
PART
B
ASP
CALCULATION.—Section 
1
1847A(c)(3) of the Social Security Act (42 U.S.C. 
2
1395w–3a(c)(3)) is amended by inserting ‘‘or section 
3
1834(z)’’ after ‘‘section 1927’’. 
4
(2) EXCLUDING PARTS B DRUG INFLATION RE-
5
BATE
FROM
BEST
PRICE.—Section 
6
1927(c)(1)(C)(ii)(I) of the Social Security Act (42 
7
U.S.C. 1396r–8(c)(1)(C)(ii)(I)) is amended by in-
8
serting ‘‘or section 1834(z)’’ after ‘‘this section’’. 
9
(3) COORDINATION WITH MEDICAID REBATE IN-
10
FORMATION DISCLOSURE.—Section 1927(b)(3)(D)(i) 
11
of the Social Security Act (42 U.S.C. 1396r– 
12
8(b)(3)(D)(i)) is amended by striking ‘‘or to carry 
13
out section 1847B’’ and inserting ‘‘to carry out sec-
14
tion 1847B or section 1834(z)’’. 
15
SEC. 202. MEDICARE PART D REBATE BY MANUFACTURERS. 
16
(a) IN GENERAL.—Part D of title XVIII of the Social 
17
Security Act is amended by inserting after section 1860D– 
18
14A (42 U.S.C. 1395w–114a) the following new section: 
19
‘‘SEC. 1860D–14B. MANUFACTURER REBATE FOR CERTAIN 
20
DRUGS WITH PRICES INCREASING FASTER 
21
THAN INFLATION. 
22
‘‘(a) IN GENERAL.— 
23
‘‘(1) IN GENERAL.—Subject to the provisions of 
24
this section, in order for coverage to be available 
25
04:12 Apr 27, 2021
H3
87 
•HR 3 IH
under this part for a part D rebatable drug (as de-
1
fined in subsection (h)(1)) of a manufacturer (as de-
2
fined in section 1927(k)(5)) dispensed during an ap-
3
plicable year, the manufacturer must have entered 
4
into and have in effect an agreement described in 
5
subsection (b). 
6
‘‘(2) AUTHORIZING COVERAGE FOR DRUGS NOT 
7
COVERED
UNDER
AGREEMENTS.—Paragraph (1) 
8
shall not apply to the dispensing of a covered part 
9
D drug if— 
10
‘‘(A) the Secretary has made a determina-
11
tion that the availability of the drug is essential 
12
to the health of beneficiaries under this part; or 
13
‘‘(B) the Secretary determines that in the 
14
period beginning on January 1, 2023, and end-
15
ing on December 31, 2023, there were extenu-
16
ating circumstances. 
17
‘‘(3) APPLICABLE YEAR.—For purposes of this 
18
section the term ‘applicable year’ means a year be-
19
ginning with 2023. 
20
‘‘(b) AGREEMENTS.— 
21
‘‘(1) TERMS OF AGREEMENT.—An agreement 
22
described in this subsection, with respect to a manu-
23
facturer of a part D rebatable drug, is an agreement 
24
under which the following shall apply: 
25
04:12 Apr 27, 2021
H3
88 
•HR 3 IH
‘‘(A) SECRETARIAL PROVISION OF INFOR-
1
MATION.—Not later than 9 months after the 
2
end of each applicable year with respect to 
3
which the agreement is in effect, the Secretary, 
4
for each part D rebatable drug of the manufac-
5
turer, shall report to the manufacturer the fol-
6
lowing for such year: 
7
‘‘(i) Information on the total number 
8
of units (as defined in subsection (h)(2)) 
9
for each dosage form and strength with re-
10
spect to such part D rebatable drug and 
11
year. 
12
‘‘(ii) Information on the amount (if 
13
any) of the excess average manufacturer 
14
price increase described in subsection 
15
(c)(1)(B) for each dosage form and 
16
strength with respect to such drug and 
17
year. 
18
‘‘(iii) The rebate amount specified 
19
under subsection (c) for each dosage form 
20
and strength with respect to such drug and 
21
year. 
22
‘‘(B) MANUFACTURER
REQUIREMENTS.— 
23
For each applicable year with respect to which 
24
the agreement is in effect, the manufacturer of 
25
04:12 Apr 27, 2021
H3
89 
•HR 3 IH
the part D rebatable drug, for each dosage 
1
form and strength with respect to such drug, 
2
not later than 30 days after the date of receipt 
3
from the Secretary of the information described 
4
in subparagraph (A) for such year, shall pro-
5
vide to the Secretary a rebate that is equal to 
6
the amount specified in subsection (c) for such 
7
dosage form and strength with respect to such 
8
drug for such year. 
9
‘‘(2) LENGTH OF AGREEMENT.— 
10
‘‘(A) IN GENERAL.—An agreement under 
11
this section, with respect to a part D rebatable 
12
drug, shall be effective for an initial period of 
13
not less than one year and shall be automati-
14
cally renewed for a period of not less than one 
15
year unless terminated under subparagraph 
16
(B). 
17
‘‘(B) TERMINATION.— 
18
‘‘(i) BY SECRETARY.—The Secretary 
19
may provide for termination of an agree-
20
ment under this section for violation of the 
21
requirements of the agreement or other 
22
good cause shown. Such termination shall 
23
not be effective earlier than 30 days after 
24
the date of notice of such termination. The 
25
04:12 Apr 27, 2021
H3
90 
•HR 3 IH
Secretary shall provide, upon request, a 
1
manufacturer with a hearing concerning 
2
such a termination, but such hearing shall 
3
not delay the effective date of the termi-
4
nation. 
5
‘‘(ii) BY A MANUFACTURER.—A man-
6
ufacturer may terminate an agreement 
7
under this section for any reason. Any 
8
such termination shall be effective, with re-
9
spect to a plan year— 
10
‘‘(I) if the termination occurs be-
11
fore January 30 of the plan year, as 
12
of the day after the end of the plan 
13
year; and 
14
‘‘(II) if the termination occurs on 
15
or after January 30 of the plan year, 
16
as of the day after the end of the suc-
17
ceeding plan year. 
18
‘‘(C) EFFECTIVENESS OF TERMINATION.— 
19
Any termination under this paragraph shall not 
20
affect rebates due under the agreement under 
21
this section before the effective date of its ter-
22
mination. 
23
‘‘(D) DELAY
BEFORE
REENTRY.—In the 
24
case of any agreement under this section with 
25
04:12 Apr 27, 2021
H3
91 
•HR 3 IH
a manufacturer that is terminated in a plan 
1
year, the Secretary may not enter into another 
2
such agreement with the manufacturer (or a 
3
successor manufacturer) before the subsequent 
4
plan year, unless the Secretary finds good cause 
5
for an earlier reinstatement of such an agree-
6
ment. 
7
‘‘(c) REBATE AMOUNT.— 
8
‘‘(1) IN GENERAL.—For purposes of this sec-
9
tion, the amount specified in this subsection for a 
10
dosage form and strength with respect to a part D 
11
rebatable drug and applicable year is, subject to sub-
12
paragraphs (B) and (C) of paragraph (5), the 
13
amount equal to the product of— 
14
‘‘(A) the total number of units of such dos-
15
age form and strength with respect to such part 
16
D rebatable drug and year; and 
17
‘‘(B) the amount (if any) by which— 
18
‘‘(i) the annual manufacturer price 
19
(as determined in paragraph (2)) paid for 
20
such dosage form and strength with re-
21
spect to such part D rebatable drug for the 
22
year; exceeds 
23
‘‘(ii) the inflation-adjusted payment 
24
amount determined under paragraph (3) 
25
04:12 Apr 27, 2021
H3
92 
•HR 3 IH
for such dosage form and strength with re-
1
spect to such part D rebatable drug for the 
2
year. 
3
‘‘(2) DETERMINATION OF ANNUAL MANUFAC-
4
TURER PRICE.—The annual manufacturer price de-
5
termined under this paragraph for a dosage form 
6
and strength, with respect to a part D rebatable 
7
drug and an applicable year, is the sum of the prod-
8
ucts of— 
9
‘‘(A) the average manufacturer price (as 
10
defined in subsection (h)(6)) of such dosage 
11
form and strength, as calculated for a unit of 
12
such drug, with respect to each of the calendar 
13
quarters of such year; and 
14
‘‘(B) the ratio of— 
15
‘‘(i) the total number of units of such 
16
dosage form and strength dispensed during 
17
each such calendar quarter of such year; to 
18
‘‘(ii) the total number of units of such 
19
dosage form and strength dispensed during 
20
such year. 
21
‘‘(3) DETERMINATION OF INFLATION-ADJUSTED 
22
PAYMENT AMOUNT.—The inflation-adjusted payment 
23
amount determined under this paragraph for a dos-
24
age form and strength with respect to a part D 
25
04:12 Apr 27, 2021
H3
93 
•HR 3 IH
rebatable drug for an applicable year, subject to sub-
1
paragraphs (A) and (D) of paragraph (5), is— 
2
‘‘(A) the benchmark year manufacturer 
3
price determined under paragraph (4) for such 
4
dosage form and strength with respect to such 
5
drug and an applicable year; increased by 
6
‘‘(B) the percentage by which the applica-
7
ble year CPI–U (as defined in subsection 
8
(h)(5)) for the applicable year exceeds the 
9
benchmark period CPI–U (as defined in sub-
10
section (h)(4)). 
11
‘‘(4) DETERMINATION
OF
BENCHMARK
YEAR 
12
MANUFACTURER PRICE.—The benchmark year man-
13
ufacturer price determined under this paragraph for 
14
a dosage form and strength, with respect to a part 
15
D rebatable drug and an applicable year, is the sum 
16
of the products of— 
17
‘‘(A) the average manufacturer price (as 
18
defined in subsection (h)(6)) of such dosage 
19
form and strength, as calculated for a unit of 
20
such drug, with respect to each of the calendar 
21
quarters of the payment amount benchmark 
22
year (as defined in subsection (h)(3)); and 
23
‘‘(B) the ratio of— 
24
04:12 Apr 27, 2021
H3
94 
•HR 3 IH
‘‘(i) the total number of units of such 
1
dosage form and strength dispensed during 
2
each such calendar quarter of such pay-
3
ment amount benchmark year; to 
4
‘‘(ii) the total number of units of such 
5
dosage form and strength dispensed during 
6
such payment amount benchmark year. 
7
‘‘(5) SPECIAL TREATMENT OF CERTAIN DRUGS 
8
AND EXEMPTION.— 
9
‘‘(A) SUBSEQUENTLY APPROVED DRUGS.— 
10
In the case of a part D rebatable drug first ap-
11
proved or licensed by the Food and Drug Ad-
12
ministration after January 1, 2016, subpara-
13
graphs (A) and (B) of paragraph (4) shall be 
14
applied as if the term ‘payment amount bench-
15
mark year’ were defined under subsection 
16
(h)(3) as the first calendar year beginning after 
17
the day on which the drug was first marketed 
18
by any manufacturer and subparagraph (B) of 
19
paragraph (3) shall be applied as if the term 
20
‘benchmark period CPI–U’ were defined under 
21
subsection (h)(4) as if the reference to ‘January 
22
2016’ under such subsection were a reference to 
23
‘January of the first year beginning after the 
24
04:12 Apr 27, 2021
H3
95 
•HR 3 IH
date on which the drug was first marketed by 
1
any manufacturer’. 
2
‘‘(B) EXEMPTION FOR SHORTAGES.—The 
3
Secretary may reduce or waive the rebate under 
4
paragraph (1) with respect to a part D 
5
rebatable drug that is described as currently in 
6
shortage on the shortage list in effect under 
7
section 506E of the Federal Food, Drug, and 
8
Cosmetic Act or in the case of other exigent cir-
9
cumstances, as determined by the Secretary. 
10
‘‘(C) TREATMENT
OF
NEW
FORMULA-
11
TIONS.— 
12
‘‘(i) IN GENERAL.—In the case of a 
13
part D rebatable drug that is a line exten-
14
sion of a part D rebatable drug that is an 
15
oral solid dosage form, the Secretary shall 
16
establish a formula for determining the 
17
amount specified in this subsection with 
18
respect to such part D rebatable drug and 
19
an applicable year with consideration of 
20
the original part D rebatable drug. 
21
‘‘(ii) LINE EXTENSION DEFINED.—In 
22
this subparagraph, the term ‘line exten-
23
sion’ means, with respect to a part D 
24
rebatable drug, a new formulation of the 
25
04:12 Apr 27, 2021
H3
96 
•HR 3 IH
drug (as determined by the Secretary), 
1
such as an extended release formulation, 
2
but does not include an abuse-deterrent 
3
formulation of the drug (as determined by 
4
the Secretary), regardless of whether such 
5
abuse-deterrent formulation is an extended 
6
release formulation. 
7
‘‘(D) SELECTED DRUGS.—In the case of a 
8
part D rebatable drug that is a selected drug 
9
(as defined in section 1192(c)) for a price appli-
10
cability 
period 
(as 
defined 
in 
section 
11
1191(b)(2))— 
12
‘‘(i) for plan years during such period 
13
for which a maximum fair price (as defined 
14
in section 1191(c)(2)) for such drug has 
15
been determined and is applied under part 
16
E of title XI, the rebate under subsection 
17
(b)(1)(B) shall be waived; and 
18
‘‘(ii) in the case such drug is deter-
19
mined (pursuant to such section 1192(c)) 
20
to no longer be a selected drug, for each 
21
applicable year beginning after the price 
22
applicability period with respect to such 
23
drug, subparagraphs (A) and (B) of para-
24
graph (4) shall be applied as if the term 
25
04:12 Apr 27, 2021
H3
97 
•HR 3 IH
‘payment amount benchmark year’ were 
1
defined under subsection (h)(3) as the last 
2
year beginning during such price applica-
3
bility period with respect to such selected 
4
drug and subparagraph (B) of paragraph 
5
(3) shall be applied as if the term ‘bench-
6
mark period CPI–U’ were defined under 
7
subsection (h)(4) as if the reference to 
8
‘January 2016’ under such subsection were 
9
a reference to January of the last year be-
10
ginning during such price applicability pe-
11
riod with respect to such drug. 
12
‘‘(d) REBATE DEPOSITS.—Amounts paid as rebates 
13
under subsection (c) shall be deposited into the Medicare 
14
Prescription Drug Account in the Federal Supplementary 
15
Medical Insurance Trust Fund established under section 
16
1841. 
17
‘‘(e) INFORMATION.—For purposes of carrying out 
18
this section, the Secretary shall use information submitted 
19
by manufacturers under section 1927(b)(3). 
20
‘‘(f) CIVIL MONEY PENALTY.—In the case of a man-
21
ufacturer of a part D rebatable drug with an agreement 
22
in effect under this section who has failed to comply with 
23
the terms of the agreement under subsection (b)(1)(B) 
24
with respect to such drug for an applicable year, the Sec-
25
04:12 Apr 27, 2021
H3
98 
•HR 3 IH
retary may impose a civil money penalty on such manufac-
1
turer in an amount equal to 125 percent of the amount 
2
specified in subsection (c) for such drug for such year. 
3
The provisions of section 1128A (other than subsections 
4
(a) (with respect to amounts of penalties or additional as-
5
sessments) and (b)) shall apply to a civil money penalty 
6
under this subsection in the same manner as such provi-
7
sions apply to a penalty or proceeding under section 
8
1128A(a). 
9
‘‘(g) JUDICIAL REVIEW.—There shall be no judicial 
10
review of the following: 
11
‘‘(1) The determination of units under this sec-
12
tion. 
13
‘‘(2) The determination of whether a drug is a 
14
part D rebatable drug under this section. 
15
‘‘(3) The calculation of the rebate amount 
16
under this section. 
17
‘‘(h) DEFINITIONS.—In this section: 
18
‘‘(1) PART D REBATABLE DRUG DEFINED.— 
19
‘‘(A) IN
GENERAL.—The term ‘part D 
20
rebatable drug’ means a drug or biological that 
21
would (without application of this section) be a 
22
covered part D drug, except such term shall, 
23
with respect to an applicable year, not include 
24
such a drug or biological if the average annual 
25
04:12 Apr 27, 2021
H3
99 
•HR 3 IH
total cost under this part for such year per in-
1
dividual who uses such a drug or biological, as 
2
determined by the Secretary, is less than, sub-
3
ject to subparagraph (B), $100, as determined 
4
by the Secretary using the most recent data 
5
available or, if data is not available, as esti-
6
mated by the Secretary. 
7
‘‘(B) INCREASE.—The dollar amount ap-
8
plied under subparagraph (A)— 
9
‘‘(i) for 2024, shall be the dollar 
10
amount specified under such subparagraph 
11
for 2023, increased by the percentage in-
12
crease in the consumer price index for all 
13
urban consumers (United States city aver-
14
age) for the 12-month period beginning 
15
with January of 2023; and 
16
‘‘(ii) for a subsequent year, shall be 
17
the dollar amount specified in this sub-
18
paragraph for the previous year, increased 
19
by the percentage increase in the consumer 
20
price index for all urban consumers 
21
(United States city average) for the 12- 
22
month period beginning with January of 
23
the previous year. 
24
04:12 Apr 27, 2021
H3
100 
•HR 3 IH
Any dollar amount specified under this sub-
1
paragraph that is not a multiple of $10 shall be 
2
rounded to the nearest multiple of $10. 
3
‘‘(2) UNIT DEFINED.—The term ‘unit’ means, 
4
with respect to a part D rebatable drug, the lowest 
5
identifiable quantity (such as a capsule or tablet, 
6
milligram of molecules, or grams) of the part D 
7
rebatable drug that is dispensed to individuals under 
8
this part. 
9
‘‘(3) PAYMENT AMOUNT BENCHMARK YEAR.— 
10
The term ‘payment amount benchmark year’ means 
11
the year beginning January 1, 2016. 
12
‘‘(4) BENCHMARK
PERIOD
CPI–U.—The term 
13
‘benchmark period CPI–U’ means the consumer 
14
price index for all urban consumers (United States 
15
city average) for January 2016. 
16
‘‘(5) APPLICABLE YEAR CPI–U.—The term ‘ap-
17
plicable year CPI–U’ means, with respect to an ap-
18
plicable year, the consumer price index for all urban 
19
consumers (United States city average) for January 
20
of such year. 
21
‘‘(6) AVERAGE
MANUFACTURER
PRICE.—The 
22
term ‘average manufacturer price’ has the meaning, 
23
with respect to a part D rebatable drug of a manu-
24
facturer, given such term in section 1927(k)(1), with 
25
04:12 Apr 27, 2021
H3
101 
•HR 3 IH
respect to a covered outpatient drug of a manufac-
1
turer for a rebate period under section 1927.’’. 
2
(b) CONFORMING AMENDMENTS.— 
3
(1) TO
PART
B
ASP
CALCULATION.—Section 
4
1847A(c)(3) of the Social Security Act (42 U.S.C. 
5
1395w–3a(c)(3)), as amended by section 201(c)(1), 
6
is further amended by striking ‘‘section 1927 or sec-
7
tion 1834(z)’’ and inserting ‘‘section 1927, section 
8
1834(z), or section 1860D–14B’’. 
9
(2) EXCLUDING PART D DRUG INFLATION RE-
10
BATE
FROM
BEST
PRICE.—Section 
11
1927(c)(1)(C)(ii)(I) of the Social Security Act (42 
12
U.S.C. 1396r–8(c)(1)(C)(ii)(I)), as amended by sec-
13
tion 201(c)(2), is further amended by striking ‘‘or 
14
section 1834(z)’’ and inserting ‘‘, section 1834(z), or 
15
section 1860D–14B’’. 
16
(3) COORDINATION WITH MEDICAID REBATE IN-
17
FORMATION DISCLOSURE.—Section 1927(b)(3)(D)(i) 
18
of the Social Security Act (42 U.S.C. 1396r– 
19
8(b)(3)(D)(i)), as amended by section 201(c)(3), is 
20
further amended by striking ‘‘or section 1834(z)’’ 
21
and inserting ‘‘, section 1834(z), or section 1860D– 
22
14B’’. 
23
04:12 Apr 27, 2021
H3
102 
•HR 3 IH
SEC. 203. PROVISION REGARDING INFLATION REBATES 
1
FOR GROUP HEALTH PLANS AND GROUP 
2
HEALTH INSURANCE COVERAGE. 
3
(a) IN GENERAL.—Not later than December 31, 
4
2023, the Secretary of Labor, in consultation with the 
5
Secretary of Health and Human Services and the Sec-
6
retary of the Treasury, shall submit to Congress a report 
7
on— 
8
(1) potential models for an agreement process 
9
with manufacturers of prescription drugs under 
10
which such manufacturers provide for inflation re-
11
bates with respect to such drugs that are furnished 
12
or dispensed to participants and beneficiaries of 
13
group health plans and health insurance coverage of-
14
fered in the group market in a manner similar to 
15
how manufacturers provide for rebates under section 
16
1834(z) of the Social Security Act, as added by sec-
17
tion 201, and section 1860D–14B of such Act, as 
18
added by section 202, with respect to prescription 
19
drugs that are furnished or dispensed under part B 
20
of title XVIII of such Act and part D of such title, 
21
respectively; and 
22
(2) potential models for enforcement mecha-
23
nisms with respect to such an agreement process 
24
that ensure that such inflation rebates are propor-
25
tionally distributed, with respect to costs, to group 
26
04:12 Apr 27, 2021
H3
103 
•HR 3 IH
health plans and health insurance issuers offering 
1
health insurance coverage in the group market, to 
2
participants and beneficiaries of such plans and cov-
3
erage, or to both. 
4
(b) REGULATIONS.—Not later than December 31, 
5
2024, the Secretary of Labor shall, in consultation with 
6
the Secretary of Health and Human Services and the Sec-
7
retary of the Treasury, promulgate regulations to imple-
8
ment a model described in subsection (a)(1) and a model 
9
described in subsection (a)(2), if the Secretary determines 
10
that— 
11
(1) the prices of a sufficient number (as deter-
12
mined by the Secretary) of drugs described in sub-
13
section (a)(1) have increased over a period of time 
14
(as determined by the Secretary) at a percentage 
15
that exceeds the percentage by which the consumer 
16
price index for all urban consumers (United States 
17
city average) has increased over such period; and 
18
(2) such model described in subsection (a)(1) 
19
and such model described in subsection (a)(2) are 
20
feasible. 
21
04:12 Apr 27, 2021
H3
104 
•HR 3 IH
SEC. 204. ANNUAL REPORT ON DRUG COSTS IN GROUP 
1
HEALTH PLANS AND GROUP HEALTH INSUR-
2
ANCE COVERAGE. 
3
(a) INITIAL REPORT.—Not later than December 31, 
4
2023, the Secretary of Labor shall, in consultation with 
5
the Secretary of Health and Human Services and the Sec-
6
retary of the Treasury, submit to Congress a report, with 
7
respect to a period (as determined by the Secretary of 
8
Labor), on— 
9
(1) whether the prices of prescription drugs 
10
that are furnished or dispensed to participants and 
11
beneficiaries of group health plans and health insur-
12
ance coverage offered in the group market during 
13
such period have increased at a percentage that ex-
14
ceeds the percentage by which the consumer price 
15
index for all urban consumers (United States city 
16
average) increased for such period; and 
17
(2) whether there are mechanisms by which 
18
manufacturers of prescription drugs have attempted 
19
to recover rebate payments required of such manu-
20
facturers under section 1834(z) of the Social Secu-
21
rity Act, as added by section 201, and section 
22
1860D–14B of such Act, as added by section 202, 
23
with respect to prescription drugs that are furnished 
24
or dispensed under part B of title XVIII of such Act 
25
and part D of such title, respectively, through in-
26
04:12 Apr 27, 2021
H3
105 
•HR 3 IH
creased prices charged with respect to drugs that are 
1
furnished or dispensed to participants and bene-
2
ficiaries of group health plans and health insurance 
3
coverage offered in the group market during such 
4
period. 
5
(b) ANNUAL REPORT.—Not later than December 31 
6
of each year following 2023, the Secretary of Labor shall, 
7
in consultation with the Secretary of Health and Human 
8
Services and the Secretary of the Treasury, submit to 
9
Congress a report updating the information and analysis 
10
included in the report required under subsection (a), re-
11
flecting, in part, new price and cost information and data 
12
for the 12-month period after the period on which the 
13
prior year’s report was based. 
14
SEC. 205. COLLECTION OF DATA. 
15
(a) MANUFACTURERS OF PRESCRIPTION DRUGS.— 
16
Manufacturers of prescription drugs shall submit to the 
17
Secretary of Health and Human Services, the Secretary 
18
of Labor, and the Secretary of the Treasury appropriate 
19
data as necessary for the Secretaries to obtain information 
20
needed to provide the reports under sections 203 and 204. 
21
(b) GROUP HEALTH PLANS AND HEALTH INSUR-
22
ANCE ISSUERS OFFERING HEALTH INSURANCE COV-
23
ERAGE IN THE GROUP MARKET.—Group health plans and 
24
health insurance issuers offering health insurance cov-
25
04:12 Apr 27, 2021
H3
106 
•HR 3 IH
erage in the group market shall submit to the Secretary 
1
of Health and Human Services, the Secretary of Labor, 
2
and the Secretary of the Treasury appropriate data as 
3
necessary for the Secretaries to obtain information needed 
4
to provide the reports under sections 203 and 204. 
5
TITLE 
III—PART 
D 
IMPROVE-
6
MENTS AND MAXIMUM OUT- 
7
OF-POCKET CAP FOR MEDI-
8
CARE BENEFICIARIES 
9
SEC. 301. MEDICARE PART D BENEFIT REDESIGN. 
10
(a) 
BENEFIT
STRUCTURE
REDESIGN.—Section 
11
1860D–2(b) of the Social Security Act (42 U.S.C. 1395w– 
12
102(b)) is amended— 
13
(1) in paragraph (2)— 
14
(A) in subparagraph (A), in the matter 
15
preceding clause (i), by inserting ‘‘for a year 
16
preceding 2024 and for costs above the annual 
17
deductible specified in paragraph (1) and up to 
18
the annual out-of-pocket threshold specified in 
19
paragraph (4)(B) for 2024 and each subsequent 
20
year’’ after ‘‘paragraph (3)’’; 
21
(B) in subparagraph (C)— 
22
(i) in clause (i), in the matter pre-
23
ceding subclause (I), by inserting ‘‘for a 
24
04:12 Apr 27, 2021
H3
107 
•HR 3 IH
year preceding 2024,’’ after ‘‘paragraph 
1
(4),’’; and 
2
(ii) in clause (ii)(III), by striking 
3
‘‘and each subsequent year’’ and inserting 
4
‘‘through 2023’’; and 
5
(C) in subparagraph (D)— 
6
(i) in clause (i)— 
7
(I) in the matter preceding sub-
8
clause (I), by inserting ‘‘for a year 
9
preceding 2024,’’ after ‘‘paragraph 
10
(4),’’; and 
11
(II) in subclause (I)(bb), by 
12
striking ‘‘a year after 2018’’ and in-
13
serting ‘‘each of years 2018 through 
14
2023’’; and 
15
(ii) in clause (ii)(V), by striking 
16
‘‘2019 and each subsequent year’’ and in-
17
serting ‘‘each of years 2019 through 
18
2023’’; 
19
(2) in paragraph (3)(A)— 
20
(A) in the matter preceding clause (i), by 
21
inserting ‘‘for a year preceding 2024,’’ after 
22
‘‘and (4),’’; and 
23
04:12 Apr 27, 2021
H3
108 
•HR 3 IH
(B) in clause (ii), by striking ‘‘for a subse-
1
quent year’’ and inserting ‘‘for each of years 
2
2007 through 2023’’; and 
3
(3) in paragraph (4)— 
4
(A) in subparagraph (A)— 
5
(i) in clause (i)— 
6
(I) by redesignating subclauses 
7
(I) and (II) as items (aa) and (bb), 
8
respectively, and moving the margin 
9
of each such redesignated item 2 ems 
10
to the right; 
11
(II) in the matter preceding item 
12
(aa), as redesignated by subclause (I), 
13
by striking ‘‘is equal to the greater 
14
of—’’ and inserting ‘‘is equal to— 
15
‘‘(I) for a year preceding 2024, 
16
the greater of—’’; 
17
(III) by striking the period at the 
18
end of item (bb), as redesignated by 
19
subclause (I), and inserting ‘‘; and’’; 
20
and 
21
(IV) by adding at the end the fol-
22
lowing: 
23
‘‘(II) for 2024 and each suc-
24
ceeding year, $0.’’; and 
25
04:12 Apr 27, 2021
H3
109 
•HR 3 IH
(ii) in clause (ii), by striking ‘‘clause 
1
(i)(I)’’ and inserting ‘‘clause (i)(I)(aa)’’; 
2
(B) in subparagraph (B)— 
3
(i) in clause (i)— 
4
(I) in subclause (V), by striking 
5
‘‘or’’ at the end; 
6
(II) in subclause (VI)— 
7
(aa) by striking ‘‘for a sub-
8
sequent year’’ and inserting ‘‘for 
9
each of years 2021 through 
10
2023’’; and 
11
(bb) by striking the period 
12
at the end and inserting a semi-
13
colon; and 
14
(III) by adding at the end the 
15
following new subclauses: 
16
‘‘(VII) for 2024, is equal to 
17
$2,000; or 
18
‘‘(VIII) for a subsequent year, is 
19
equal to the amount specified in this 
20
subparagraph for the previous year, 
21
increased by the annual percentage in-
22
crease described in paragraph (6) for 
23
the year involved.’’; and 
24
04:12 Apr 27, 2021
H3
110 
•HR 3 IH
(ii) in clause (ii), by striking ‘‘clause 
1
(i)(II)’’ and inserting ‘‘clause (i)’’; 
2
(C) in subparagraph (C)(i), by striking 
3
‘‘and for amounts’’ and inserting ‘‘and, for a 
4
year preceding 2024, for amounts’’; and 
5
(D) in subparagraph (E), by striking ‘‘In 
6
applying’’ and inserting ‘‘For each of years 
7
2011 through 2023, in applying’’. 
8
(b) 
DECREASING
REINSURANCE
PAYMENT 
9
AMOUNT.—Section 1860D–15(b)(1) of the Social Security 
10
Act (42 U.S.C. 1395w–115(b)(1)) is amended by inserting 
11
after ‘‘80 percent’’ the following: ‘‘(or, with respect to a 
12
coverage year after 2023, 20 percent)’’. 
13
(c) MANUFACTURER DISCOUNT PROGRAM.— 
14
(1) IN GENERAL.—Part D of title XVIII of the 
15
Social Security Act (42 U.S.C. 1395w–101 et seq.), 
16
as amended by section 202, is further amended by 
17
inserting after section 1860D–14B the following new 
18
section: 
19
‘‘SEC. 1860D–14C. MANUFACTURER DISCOUNT PROGRAM. 
20
‘‘(a) ESTABLISHMENT.—The Secretary shall estab-
21
lish a manufacturer discount program (in this section re-
22
ferred to as the ‘program’). Under the program, the Sec-
23
retary shall enter into agreements described in subsection 
24
(b) with manufacturers and provide for the performance 
25
04:12 Apr 27, 2021
H3
111 
•HR 3 IH
of the duties described in subsection (c). The Secretary 
1
shall establish a model agreement for use under the pro-
2
gram by not later than January 1, 2023, in consultation 
3
with manufacturers, and allow for comment on such model 
4
agreement. 
5
‘‘(b) TERMS OF AGREEMENT.— 
6
‘‘(1) IN GENERAL.— 
7
‘‘(A) AGREEMENT.—An agreement under 
8
this section shall require the manufacturer to 
9
provide applicable beneficiaries access to dis-
10
counted prices for applicable drugs of the man-
11
ufacturer that are dispensed on or after Janu-
12
ary 1, 2024. 
13
‘‘(B) PROVISION OF DISCOUNTED PRICES 
14
AT THE POINT-OF-SALE.—The discounted prices 
15
described in subparagraph (A) shall be provided 
16
to the applicable beneficiary at the pharmacy or 
17
by the mail order service at the point-of-sale of 
18
an applicable drug. 
19
‘‘(C) TIMING OF AGREEMENT.— 
20
‘‘(i) SPECIAL
RULE
FOR
2024.—In 
21
order for an agreement with a manufac-
22
turer to be in effect under this section with 
23
respect to the period beginning on January 
24
1, 2024, and ending on December 31, 
25
04:12 Apr 27, 2021
H3
112 
•HR 3 IH
2024, the manufacturer shall enter into 
1
such agreement not later than 30 days 
2
after the date of the establishment of a 
3
model agreement under subsection (a). 
4
‘‘(ii) 
2025 
AND
SUBSEQUENT 
5
YEARS.—In order for an agreement with a 
6
manufacturer to be in effect under this 
7
section with respect to plan year 2025 or 
8
a subsequent plan year, the manufacturer 
9
shall enter into such agreement (or such 
10
agreement shall be renewed under para-
11
graph (4)(A)) not later than January 30 of 
12
the preceding year. 
13
‘‘(2) PROVISION OF APPROPRIATE DATA.—Each 
14
manufacturer with an agreement in effect under this 
15
section shall collect and have available appropriate 
16
data, as determined by the Secretary, to ensure that 
17
it can demonstrate to the Secretary compliance with 
18
the requirements under the program. 
19
‘‘(3) COMPLIANCE
WITH
REQUIREMENTS
FOR 
20
ADMINISTRATION
OF
PROGRAM.—Each manufac-
21
turer with an agreement in effect under this section 
22
shall comply with requirements imposed by the Sec-
23
retary or a third party with a contract under sub-
24
section (d)(3), as applicable, for purposes of admin-
25
04:12 Apr 27, 2021
H3
113 
•HR 3 IH
istering the program, including any determination 
1
under subparagraph (A) of subsection (c)(1) or pro-
2
cedures established under such subsection (c)(1). 
3
‘‘(4) LENGTH OF AGREEMENT.— 
4
‘‘(A) IN GENERAL.—An agreement under 
5
this section shall be effective for an initial pe-
6
riod of not less than 12 months and shall be 
7
automatically renewed for a period of not less 
8
than 1 year unless terminated under subpara-
9
graph (B). 
10
‘‘(B) TERMINATION.— 
11
‘‘(i) BY THE SECRETARY.—The Sec-
12
retary may provide for termination of an 
13
agreement under this section for a knowing 
14
and willful violation of the requirements of 
15
the agreement or other good cause shown. 
16
Such termination shall not be effective ear-
17
lier than 30 days after the date of notice 
18
to the manufacturer of such termination. 
19
The Secretary shall provide, upon request, 
20
a manufacturer with a hearing concerning 
21
such a termination, and such hearing shall 
22
take place prior to the effective date of the 
23
termination with sufficient time for such 
24
04:12 Apr 27, 2021
H3
114 
•HR 3 IH
effective date to be repealed if the Sec-
1
retary determines appropriate. 
2
‘‘(ii) BY A MANUFACTURER.—A man-
3
ufacturer may terminate an agreement 
4
under this section for any reason. Any 
5
such termination shall be effective, with re-
6
spect to a plan year— 
7
‘‘(I) if the termination occurs be-
8
fore January 30 of a plan year, as of 
9
the day after the end of the plan year; 
10
and 
11
‘‘(II) if the termination occurs on 
12
or after January 30 of a plan year, as 
13
of the day after the end of the suc-
14
ceeding plan year. 
15
‘‘(iii) EFFECTIVENESS
OF
TERMI-
16
NATION.—Any termination under this sub-
17
paragraph shall not affect discounts for 
18
applicable drugs of the manufacturer that 
19
are due under the agreement before the ef-
20
fective date of its termination. 
21
‘‘(iv) NOTICE TO THIRD PARTY.—The 
22
Secretary shall provide notice of such ter-
23
mination to a third party with a contract 
24
under subsection (d)(3) within not less 
25
04:12 Apr 27, 2021
H3
115 
•HR 3 IH
than 30 days before the effective date of 
1
such termination. 
2
‘‘(c) DUTIES DESCRIBED.—The duties described in 
3
this subsection are the following: 
4
‘‘(1) ADMINISTRATION OF PROGRAM.—Admin-
5
istering the program, including— 
6
‘‘(A) the determination of the amount of 
7
the discounted price of an applicable drug of a 
8
manufacturer; 
9
‘‘(B) the establishment of procedures 
10
under which discounted prices are provided to 
11
applicable beneficiaries at pharmacies or by 
12
mail order service at the point-of-sale of an ap-
13
plicable drug; 
14
‘‘(C) the establishment of procedures to 
15
ensure that, not later than the applicable num-
16
ber of calendar days after the dispensing of an 
17
applicable drug by a pharmacy or mail order 
18
service, the pharmacy or mail order service is 
19
reimbursed for an amount equal to the dif-
20
ference between— 
21
‘‘(i) the negotiated price of the appli-
22
cable drug; and 
23
‘‘(ii) the discounted price of the appli-
24
cable drug; 
25
04:12 Apr 27, 2021
H3
116 
•HR 3 IH
‘‘(D) the establishment of procedures to 
1
ensure that the discounted price for an applica-
2
ble drug under this section is applied before any 
3
coverage or financial assistance under other 
4
health benefit plans or programs that provide 
5
coverage or financial assistance for the pur-
6
chase or provision of prescription drug coverage 
7
on behalf of applicable beneficiaries as the Sec-
8
retary may specify; and 
9
‘‘(E) providing a reasonable dispute resolu-
10
tion mechanism to resolve disagreements be-
11
tween manufacturers, applicable beneficiaries, 
12
and the third party with a contract under sub-
13
section (d)(3). 
14
‘‘(2) MONITORING COMPLIANCE.— 
15
‘‘(A) IN
GENERAL.—The Secretary shall 
16
monitor compliance by a manufacturer with the 
17
terms of an agreement under this section. 
18
‘‘(B) NOTIFICATION.—If a third party 
19
with a contract under subsection (d)(3) deter-
20
mines that the manufacturer is not in compli-
21
ance with such agreement, the third party shall 
22
notify the Secretary of such noncompliance for 
23
appropriate enforcement under subsection (e). 
24
04:12 Apr 27, 2021
H3
117 
•HR 3 IH
‘‘(3) COLLECTION OF DATA FROM PRESCRIP-
1
TION DRUG PLANS AND MA–PD PLANS.—The Sec-
2
retary may collect appropriate data from prescrip-
3
tion drug plans and MA–PD plans in a timeframe 
4
that allows for discounted prices to be provided for 
5
applicable drugs under this section. 
6
‘‘(d) ADMINISTRATION.— 
7
‘‘(1) IN GENERAL.—Subject to paragraph (2), 
8
the Secretary shall provide for the implementation of 
9
this section, including the performance of the duties 
10
described in subsection (c). 
11
‘‘(2) LIMITATION.—In providing for the imple-
12
mentation of this section, the Secretary shall not re-
13
ceive or distribute any funds of a manufacturer 
14
under the program. 
15
‘‘(3) CONTRACT
WITH
THIRD
PARTIES.—The 
16
Secretary shall enter into a contract with 1 or more 
17
third parties to administer the requirements estab-
18
lished by the Secretary in order to carry out this 
19
section. At a minimum, the contract with a third 
20
party under the preceding sentence shall require 
21
that the third party— 
22
‘‘(A) receive and transmit information be-
23
tween the Secretary, manufacturers, and other 
24
04:12 Apr 27, 2021
H3
118 
•HR 3 IH
individuals or entities the Secretary determines 
1
appropriate; 
2
‘‘(B) receive, distribute, or facilitate the 
3
distribution of funds of manufacturers to ap-
4
propriate individuals or entities in order to 
5
meet the obligations of manufacturers under 
6
agreements under this section; 
7
‘‘(C) provide adequate and timely informa-
8
tion to manufacturers, consistent with the 
9
agreement with the manufacturer under this 
10
section, as necessary for the manufacturer to 
11
fulfill its obligations under this section; and 
12
‘‘(D) permit manufacturers to conduct 
13
periodic audits, directly or through contracts, of 
14
the data and information used by the third 
15
party to determine discounts for applicable 
16
drugs of the manufacturer under the program. 
17
‘‘(4) 
PERFORMANCE
REQUIREMENTS.—The 
18
Secretary shall establish performance requirements 
19
for a third party with a contract under paragraph 
20
(3) and safeguards to protect the independence and 
21
integrity of the activities carried out by the third 
22
party under the program under this section. 
23
‘‘(5) IMPLEMENTATION.—Notwithstanding any 
24
other provision of law, the Secretary may implement 
25
04:12 Apr 27, 2021
H3
119 
•HR 3 IH
the program under this section by program instruc-
1
tion or otherwise. 
2
‘‘(6) ADMINISTRATION.—Chapter 35 of title 44, 
3
United States Code, shall not apply to the program 
4
under this section. 
5
‘‘(e) ENFORCEMENT.— 
6
‘‘(1) AUDITS.—Each manufacturer with an 
7
agreement in effect under this section shall be sub-
8
ject to periodic audit by the Secretary. 
9
‘‘(2) CIVIL MONEY PENALTY.— 
10
‘‘(A) IN
GENERAL.—The Secretary may 
11
impose a civil money penalty on a manufacturer 
12
that fails to provide applicable beneficiaries dis-
13
counts for applicable drugs of the manufacturer 
14
in accordance with such agreement for each 
15
such failure in an amount the Secretary deter-
16
mines is equal to the sum of— 
17
‘‘(i) the amount that the manufac-
18
turer would have paid with respect to such 
19
discounts under the agreement, which will 
20
then be used to pay the discounts which 
21
the manufacturer had failed to provide; 
22
and 
23
‘‘(ii) 25 percent of such amount. 
24
04:12 Apr 27, 2021
H3
120 
•HR 3 IH
‘‘(B) APPLICATION.—The provisions of 
1
section 1128A (other than subsections (a) and 
2
(b)) shall apply to a civil money penalty under 
3
this paragraph in the same manner as such 
4
provisions apply to a penalty or proceeding 
5
under section 1128A(a). 
6
‘‘(f) CLARIFICATION REGARDING AVAILABILITY OF 
7
OTHER COVERED PART D DRUGS.—Nothing in this sec-
8
tion shall prevent an applicable beneficiary from pur-
9
chasing a covered part D drug that is not an applicable 
10
drug (including a generic drug or a drug that is not on 
11
the formulary of the prescription drug plan or MA–PD 
12
plan that the applicable beneficiary is enrolled in). 
13
‘‘(g) DEFINITIONS.—In this section: 
14
‘‘(1) APPLICABLE
BENEFICIARY.—The term 
15
‘applicable beneficiary’ means an individual who, on 
16
the date of dispensing a covered part D drug— 
17
‘‘(A) is enrolled in a prescription drug plan 
18
or an MA–PD plan; 
19
‘‘(B) is not enrolled in a qualified retiree 
20
prescription drug plan; and 
21
‘‘(C) has incurred costs, as determined in 
22
accordance with section 1860D–2(b)(4)(C), for 
23
covered part D drugs in the year that exceed 
24
the annual deductible with respect to such indi-
25
04:12 Apr 27, 2021
H3
121 
•HR 3 IH
vidual for such year, as specified in section 
1
1860D–2(b)(1), section 1860D–14(a)(1)(B), or 
2
section 1860D–14(a)(2)(B), as applicable. 
3
‘‘(2) APPLICABLE DRUG.—The term ‘applicable 
4
drug’, with respect to an applicable beneficiary— 
5
‘‘(A) means a covered part D drug— 
6
‘‘(i) approved under a new drug appli-
7
cation under section 505(c) of the Federal 
8
Food, Drug, and Cosmetic Act or, in the 
9
case of a biologic product, licensed under 
10
section 351 of the Public Health Service 
11
Act; and 
12
‘‘(ii)(I) if the PDP sponsor of the pre-
13
scription drug plan or the MA organization 
14
offering the MA–PD plan uses a for-
15
mulary, which is on the formulary of the 
16
prescription drug plan or MA–PD plan 
17
that the applicable beneficiary is enrolled 
18
in; 
19
‘‘(II) if the PDP sponsor of the pre-
20
scription drug plan or the MA organization 
21
offering the MA–PD plan does not use a 
22
formulary, for which benefits are available 
23
under the prescription drug plan or MA– 
24
04:12 Apr 27, 2021
H3
122 
•HR 3 IH
PD plan that the applicable beneficiary is 
1
enrolled in; or 
2
‘‘(III) is provided through an excep-
3
tion or appeal; and 
4
‘‘(B) does not include a selected drug (as 
5
defined in section 1192(c)) during a price appli-
6
cability 
period 
(as 
defined 
in 
section 
7
1191(b)(2)) with respect to such drug. 
8
‘‘(3) APPLICABLE
NUMBER
OF
CALENDAR 
9
DAYS.—The term ‘applicable number of calendar 
10
days’ means— 
11
‘‘(A) with respect to claims for reimburse-
12
ment submitted electronically, 14 days; and 
13
‘‘(B) with respect to claims for reimburse-
14
ment submitted otherwise, 30 days. 
15
‘‘(4) DISCOUNTED PRICE.— 
16
‘‘(A) IN GENERAL.—The term ‘discounted 
17
price’ means, with respect to an applicable drug 
18
of a manufacturer dispensed during a year to 
19
an applicable beneficiary— 
20
‘‘(i) who has not incurred costs, as de-
21
termined 
in 
accordance 
with 
section 
22
1860D–2(b)(4)(C), for covered part D 
23
drugs in the year that are equal to or ex-
24
ceed the annual out-of-pocket threshold 
25
04:12 Apr 27, 2021
H3
123 
•HR 3 IH
specified in section 1860D–2(b)(4)(B)(i) 
1
for the year, 90 percent of the negotiated 
2
price of such drug; and 
3
‘‘(ii) who has incurred such costs, as 
4
so determined, in the year that are equal 
5
to or exceed such threshold for the year, 
6
70 percent of the negotiated price of such 
7
drug. 
8
‘‘(B) CLARIFICATION.—Nothing in this 
9
section shall be construed as affecting the re-
10
sponsibility of an applicable beneficiary for pay-
11
ment of a dispensing fee for an applicable drug. 
12
‘‘(C) 
SPECIAL
CASE
FOR
CERTAIN 
13
CLAIMS.— 
14
‘‘(i) 
CLAIMS
SPANNING
DEDUCT-
15
IBLE.—In the case where the entire 
16
amount of the negotiated price of an indi-
17
vidual claim for an applicable drug with re-
18
spect to an applicable beneficiary does not 
19
fall above the annual deductible specified 
20
in section 1860D–2(b)(1) for the year, the 
21
manufacturer of the applicable drug shall 
22
provide the discounted price under this 
23
section on only the portion of the nego-
24
04:12 Apr 27, 2021
H3
124 
•HR 3 IH
tiated price of the applicable drug that 
1
falls above such annual deductible. 
2
‘‘(ii) CLAIMS SPANNING OUT-OF-POCK-
3
ET THRESHOLD.—In the case where the 
4
entire amount of the negotiated price of an 
5
individual claim for an applicable drug 
6
with respect to an applicable beneficiary 
7
does not fall entirely below or entirely 
8
above the annual out-of-pocket threshold 
9
specified in section 1860D–2(b)(4)(B)(i) 
10
for the year, the manufacturer of the ap-
11
plicable drug shall provide the discounted 
12
price— 
13
‘‘(I) in accordance with subpara-
14
graph (A)(i) on the portion of the ne-
15
gotiated price of the applicable drug 
16
that falls below such threshold; and 
17
‘‘(II) in accordance with subpara-
18
graph (A)(ii) on the portion of such 
19
price of such drug that falls at or 
20
above such threshold. 
21
‘‘(5) MANUFACTURER.—The term ‘manufac-
22
turer’ means any entity which is engaged in the pro-
23
duction, preparation, propagation, compounding, 
24
conversion, or processing of prescription drug prod-
25
04:12 Apr 27, 2021
H3
125 
•HR 3 IH
ucts, either directly or indirectly by extraction from 
1
substances of natural origin, or independently by 
2
means of chemical synthesis, or by a combination of 
3
extraction and chemical synthesis. Such term does 
4
not include a wholesale distributor of drugs or a re-
5
tail pharmacy licensed under State law. 
6
‘‘(6) NEGOTIATED
PRICE.—The term ‘nego-
7
tiated price’ has the meaning given such term in sec-
8
tion 423.100 of title 42, Code of Federal Regula-
9
tions (or any successor regulation), except that, with 
10
respect to an applicable drug, such negotiated price 
11
shall not include any dispensing fee for the applica-
12
ble drug. 
13
‘‘(7) QUALIFIED RETIREE PRESCRIPTION DRUG 
14
PLAN.—The term ‘qualified retiree prescription drug 
15
plan’ has the meaning given such term in section 
16
1860D–22(a)(2).’’. 
17
(2) SUNSET OF MEDICARE COVERAGE GAP DIS-
18
COUNT PROGRAM.—Section 1860D–14A of the So-
19
cial Security Act (42 U.S.C. 1395–114a) is amend-
20
ed— 
21
(A) in subsection (a), in the first sentence, 
22
by striking ‘‘The Secretary’’ and inserting 
23
‘‘Subject to subsection (h), the Secretary’’; and 
24
04:12 Apr 27, 2021
H3
126 
•HR 3 IH
(B) by adding at the end the following new 
1
subsection: 
2
‘‘(h) SUNSET OF PROGRAM.— 
3
‘‘(1) IN
GENERAL.—The program shall not 
4
apply with respect to applicable drugs dispensed on 
5
or after January 1, 2024, and, subject to paragraph 
6
(2), agreements under this section shall be termi-
7
nated as of such date. 
8
‘‘(2) CONTINUED APPLICATION FOR APPLICA-
9
BLE
DRUGS
DISPENSED
PRIOR
TO
SUNSET.—The 
10
provisions of this section (including all responsibil-
11
ities and duties) shall continue to apply after Janu-
12
ary 1, 2024, with respect to applicable drugs dis-
13
pensed prior to such date.’’. 
14
(3) INCLUSION OF ACTUARIAL VALUE OF MANU-
15
FACTURER DISCOUNTS IN BIDS.—Section 1860D–11 
16
of the Social Security Act (42 U.S.C. 1395w–111) 
17
is amended— 
18
(A) in subsection (b)(2)(C)(iii)— 
19
(i) by striking ‘‘assumptions regarding 
20
the reinsurance’’ and inserting ‘‘assump-
21
tions regarding— 
22
‘‘(I) the reinsurance’’; and 
23
(ii) by adding at the end the fol-
24
lowing: 
25
04:12 Apr 27, 2021
H3
127 
•HR 3 IH
‘‘(II) for 2024 and each subse-
1
quent year, the manufacturer dis-
2
counts provided under section 1860D– 
3
14C subtracted from the actuarial 
4
value to produce such bid; and’’; and 
5
(B) in subsection (c)(1)(C)— 
6
(i) by striking ‘‘an actuarial valuation 
7
of the reinsurance’’ and inserting ‘‘an ac-
8
tuarial valuation of— 
9
‘‘(i) the reinsurance’’; 
10
(ii) in clause (i), as inserted by clause 
11
(i) of this subparagraph, by adding ‘‘and’’ 
12
at the end; and 
13
(iii) by adding at the end the fol-
14
lowing: 
15
‘‘(ii) for 2024 and each subsequent 
16
year, the manufacturer discounts provided 
17
under section 1860D–14C;’’. 
18
(d) CONFORMING AMENDMENTS.— 
19
(1) Section 1860D–2 of the Social Security Act 
20
(42 U.S.C. 1395w–102) is amended— 
21
(A) in subsection (a)(2)(A)(i)(I), by strik-
22
ing ‘‘, or an increase in the initial’’ and insert-
23
ing ‘‘or, for a year preceding 2024, an increase 
24
in the initial’’; 
25
04:12 Apr 27, 2021
H3
128 
•HR 3 IH
(B) in subsection (c)(1)(C)— 
1
(i) in the subparagraph heading, by 
2
striking ‘‘AT
INITIAL
COVERAGE
LIMIT’’; 
3
and 
4
(ii) by inserting ‘‘for a year preceding 
5
2024 or the annual out-of-pocket threshold 
6
specified in subsection (b)(4)(B) for the 
7
year for 2024 and each subsequent year’’ 
8
after ‘‘subsection (b)(3) for the year’’ each 
9
place it appears; and 
10
(C) in subsection (d)(1)(A), by striking ‘‘or 
11
an initial’’ and inserting ‘‘or, for a year pre-
12
ceding 2024, an initial’’. 
13
(2) Section 1860D–4(a)(4)(B)(i) of the Social 
14
Security Act (42 U.S.C. 1395w–104(a)(4)(B)(i)) is 
15
amended by striking ‘‘the initial’’ and inserting ‘‘for 
16
a year preceding 2024, the initial’’. 
17
(3) Section 1860D–14(a) of the Social Security 
18
Act (42 U.S.C. 1395w–114(a)) is amended— 
19
(A) in paragraph (1)— 
20
(i) in subparagraph (C), by striking 
21
‘‘The continuation’’ and inserting ‘‘For a 
22
year preceding 2024, the continuation’’; 
23
04:12 Apr 27, 2021
H3
129 
•HR 3 IH
(ii) in subparagraph (D)(iii), by strik-
1
ing ‘‘1860D–2(b)(4)(A)(i)(I)’’ and insert-
2
ing ‘‘1860D–2(b)(4)(A)(i)(I)(aa)’’; and 
3
(iii) in subparagraph (E), by striking 
4
‘‘The elimination’’ and inserting ‘‘For a 
5
year preceding 2024, the elimination’’; and 
6
(B) in paragraph (2)— 
7
(i) in subparagraph (C), by striking 
8
‘‘The continuation’’ and inserting ‘‘For a 
9
year preceding 2024, the continuation’’; 
10
and 
11
(ii) in subparagraph (E), by striking 
12
‘‘1860D–2(b)(4)(A)(i)(I)’’ and inserting 
13
‘‘1860D–2(b)(4)(A)(i)(I)(aa)’’. 
14
(4) Section 1860D–21(d)(7) of the Social Secu-
15
rity Act (42 U.S.C. 1395w–131(d)(7)) is amended 
16
by striking ‘‘section 1860D–2(b)(4)(B)(i)’’ and in-
17
serting ‘‘section 1860D–2(b)(4)(C)(i)’’. 
18
(5) Section 1860D–22(a)(2)(A) of the Social 
19
Security Act (42 U.S.C. 1395w–132(a)(2)(A)) is 
20
amended— 
21
(A) by striking ‘‘the value of any discount’’ 
22
and inserting the following: ‘‘the value of— 
23
‘‘(i) for years prior to 2024, any dis-
24
count’’; 
25
04:12 Apr 27, 2021
H3
130 
•HR 3 IH
(B) in clause (i), as inserted by subpara-
1
graph (A) of this paragraph, by striking the pe-
2
riod at the end and inserting ‘‘; and’’; and 
3
(C) by adding at the end the following new 
4
clause: 
5
‘‘(ii) for 2024 and each subsequent 
6
year, any discount provided pursuant to 
7
section 1860D–14C.’’. 
8
(6) Section 1860D–41(a)(6) of the Social Secu-
9
rity Act (42 U.S.C. 1395w–151(a)(6)) is amended— 
10
(A) by inserting ‘‘for a year before 2024’’ 
11
after ‘‘1860D–2(b)(3)’’; and 
12
(B) by inserting ‘‘for such year’’ before the 
13
period. 
14
(7) Section 1860D–43 of the Social Security 
15
Act (42 U.S.C. 1395w–153) is amended— 
16
(A) in subsection (a)— 
17
(i) by striking paragraph (1) and in-
18
serting the following: 
19
‘‘(1) participate in— 
20
‘‘(A) for 2011 through 2023, the Medicare 
21
coverage gap discount program under section 
22
1860D–14A; and 
23
04:12 Apr 27, 2021
H3
131 
•HR 3 IH
‘‘(B) for 2024 and each subsequent year, 
1
the manufacturer discount program under sec-
2
tion 1860D–14C;’’; 
3
(ii) by striking paragraph (2) and in-
4
serting the following: 
5
‘‘(2) have entered into and have in effect— 
6
‘‘(A) for 2011 through 2023, an agreement 
7
described in subsection (b) of section 1860D– 
8
14A with the Secretary; and 
9
‘‘(B) for 2024 and each subsequent year, 
10
an agreement described in subsection (b) of sec-
11
tion 1860D–14C with the Secretary; and’’; and 
12
(iii) by striking paragraph (3) and in-
13
serting the following: 
14
‘‘(3) have entered into and have in effect, under 
15
terms and conditions specified by the Secretary— 
16
‘‘(A) for 2011 through 2023, a contract 
17
with a third party that the Secretary has en-
18
tered into a contract with under subsection 
19
(d)(3) of section 1860D–14A; and 
20
‘‘(B) for 2024 and each subsequent year, 
21
a contract with a third party that the Secretary 
22
has entered into a contract with under sub-
23
section (d)(3) of section 1860D–14C.’’; and 
24
04:12 Apr 27, 2021
H3
132 
•HR 3 IH
(B) by striking subsection (b) and insert-
1
ing the following: 
2
‘‘(b) EFFECTIVE DATE.—Paragraphs (1)(A), (2)(A), 
3
and (3)(A) of subsection (a) shall apply to covered part 
4
D drugs dispensed under this part on or after January 
5
1, 2011, and before January 1, 2024, and paragraphs 
6
(1)(B), (2)(B), and (3)(B) of such subsection shall apply 
7
to covered part D drugs dispensed under this part on or 
8
after January 1, 2024.’’. 
9
(8) Section 1927 of the Social Security Act (42 
10
U.S.C. 1396r–8) is amended— 
11
(A) in subsection (c)(1)(C)(i)(VI), by in-
12
serting before the period at the end the fol-
13
lowing: ‘‘or under the manufacturer discount 
14
program under section 1860D–14C’’; and 
15
(B) in subsection (k)(1)(B)(i)(V), by in-
16
serting before the period at the end the fol-
17
lowing: ‘‘or under section 1860D–14C’’. 
18
(e) EFFECTIVE DATE.—The amendments made by 
19
this section shall apply with respect to plan year 2024 and 
20
subsequent plan years. 
21
04:12 Apr 27, 2021
H3
133 
•HR 3 IH
SEC. 302. ALLOWING CERTAIN ENROLLEES OF PRESCRIP-
1
TION DRUG PLANS AND MA–PD PLANS UNDER 
2
MEDICARE PROGRAM TO SPREAD OUT COST- 
3
SHARING UNDER CERTAIN CIRCUMSTANCES. 
4
Section 1860D–2(b)(2) of the Social Security Act (42 
5
U.S.C. 1395w–102(b)(2)), as amended by section 301, is 
6
further amended— 
7
(1) in subparagraph (A), by striking ‘‘Subject 
8
to subparagraphs (C) and (D)’’ and inserting ‘‘Sub-
9
ject to subparagraphs (C), (D), and (E)’’; and 
10
(2) by adding at the end the following new sub-
11
paragraph: 
12
‘‘(E) 
ENROLLEE
OPTION
REGARDING 
13
SPREADING
COST-SHARING.—The 
Secretary 
14
shall establish by regulation a process under 
15
which, with respect to plan year 2024 and sub-
16
sequent plan years, a prescription drug plan or 
17
an MA–PD plan shall, in the case of a part D 
18
eligible individual enrolled with such plan for 
19
such plan year who is not a subsidy eligible in-
20
dividual (as defined in section 1860D–14(a)(3)) 
21
and with respect to whom the plan projects that 
22
the dispensing of the first fill of a covered part 
23
D drug to such individual will result in the indi-
24
vidual incurring costs that are equal to or above 
25
the annual out-of-pocket threshold specified in 
26
04:12 Apr 27, 2021
H3
134 
•HR 3 IH
paragraph (4)(B) for such plan year, provide 
1
such individual with the option to make the co-
2
insurance payment required under subpara-
3
graph (A) (for the portion of such costs that 
4
are not above such annual out-of-pocket thresh-
5
old) in the form of periodic installments over 
6
the remainder of such plan year.’’. 
7
SEC. 303. ESTABLISHMENT OF PHARMACY QUALITY MEAS-
8
URES UNDER MEDICARE PART D. 
9
Section 1860D–4(c) of the Social Security Act (42 
10
U.S.C. 1395w–104(c)) is amended— 
11
(1) by redesignating the paragraph (6), as 
12
added by section 50354 of division E of the Bipar-
13
tisan Budget Act of 2018 (Public Law 115–123), as 
14
paragraph (7); and 
15
(2) by adding at the end the following new 
16
paragraph: 
17
‘‘(8) APPLICATION
OF
PHARMACY
QUALITY 
18
MEASURES.— 
19
‘‘(A) IN GENERAL.—A PDP sponsor that 
20
implements incentive payments to a pharmacy 
21
or price concessions paid by a pharmacy based 
22
on quality measures shall use measures estab-
23
lished or approved by the Secretary under sub-
24
04:12 Apr 27, 2021
H3
135 
•HR 3 IH
paragraph (B) with respect to payment for cov-
1
ered part D drugs dispensed by such pharmacy. 
2
‘‘(B) 
STANDARD
PHARMACY
QUALITY 
3
MEASURES.—The Secretary shall establish or 
4
approve standard quality measures from a con-
5
sensus and evidence-based organization for pay-
6
ments described in subparagraph (A). Such 
7
measures shall focus on patient health outcomes 
8
and be based on proven criteria measuring 
9
pharmacy performance. 
10
‘‘(C) EFFECTIVE DATE.—The requirement 
11
under subparagraph (A) shall take effect for 
12
plan years beginning on or after January 1, 
13
2024, or such earlier date specified by the Sec-
14
retary if the Secretary determines there are suf-
15
ficient measures established or approved under 
16
subparagraph (B) to meet the requirement 
17
under subparagraph (A).’’. 
18
TITLE IV—DRUG PRICE 
19
TRANSPARENCY 
20
SEC. 401. DRUG PRICE TRANSPARENCY. 
21
Part A of title XI of the Social Security Act is 
22
amended by adding at the end the following new sections: 
23
‘‘SEC. 1150D. REPORTING ON DRUG PRICES. 
24
‘‘(a) DEFINITIONS.—In this section: 
25
04:12 Apr 27, 2021
H3
136 
•HR 3 IH
‘‘(1) MANUFACTURER.—The term ‘manufac-
1
turer’ means the person— 
2
‘‘(A) that holds the application for a drug 
3
approved under section 505 of the Federal 
4
Food, Drug, and Cosmetic Act or licensed 
5
under section 351 of the Public Health Service 
6
Act; or 
7
‘‘(B) who is responsible for setting the 
8
wholesale acquisition cost for the drug. 
9
‘‘(2) QUALIFYING DRUG.—The term ‘qualifying 
10
drug’ means any drug that is approved under sub-
11
section (c) or (j) of section 505 of the Federal Food, 
12
Drug, and Cosmetic Act or licensed under subsection 
13
(a) or (k) of section 351 of the Public Health Serv-
14
ice Act— 
15
‘‘(A) that has a wholesale acquisition cost 
16
of $100 or more, adjusted for inflation occur-
17
ring after the date of enactment of this section, 
18
for a month’s supply or a typical course of 
19
treatment that lasts less than a month, and 
20
is— 
21
‘‘(i) subject to section 503(b)(1) of 
22
the Federal Food, Drug, and Cosmetic 
23
Act; and 
24
‘‘(ii) not a preventative vaccine; and 
25
04:12 Apr 27, 2021
H3
137 
•HR 3 IH
‘‘(B) for which, during the previous cal-
1
endar year, at least 1 dollar of the total amount 
2
of sales were for individuals enrolled under the 
3
Medicare program under title XVIII or under a 
4
State Medicaid plan under title XIX or under 
5
a waiver of such plan. 
6
‘‘(3) WHOLESALE
ACQUISITION
COST.—The 
7
term ‘wholesale acquisition cost’ has the meaning 
8
given that term in section 1847A(c)(6)(B). 
9
‘‘(b) REPORT.— 
10
‘‘(1) REPORT REQUIRED.—The manufacturer of 
11
a qualifying drug shall submit a report to the Sec-
12
retary if, with respect to the qualifying drug— 
13
‘‘(A) there is an increase in the price of 
14
the qualifying drug that results in an increase 
15
in the wholesale acquisition cost of that drug 
16
that is equal to— 
17
‘‘(i) 10 percent or more within a 12- 
18
month period beginning on or after Janu-
19
ary 1, 2021; or 
20
‘‘(ii) 25 percent or more within a 36- 
21
month period beginning on or after Janu-
22
ary 1, 2021; 
23
‘‘(B) the estimated price of the qualifying 
24
drug or spending per individual or per user of 
25
04:12 Apr 27, 2021
H3
138 
•HR 3 IH
such drug (as estimated by the Secretary) for 
1
the applicable year (or per course of treatment 
2
in such applicable year as determined by the 
3
Secretary) is at least $26,000 beginning on or 
4
after January 1, 2023; or 
5
‘‘(C) there was an increase in the price of 
6
the qualifying drug that resulted in an increase 
7
in the wholesale acquisition cost of that drug 
8
that is equal to— 
9
‘‘(i) 10 percent or more within a 12- 
10
month period that begins and ends during 
11
the 5-year period preceding January 1, 
12
2023; or 
13
‘‘(ii) 25 percent or more within a 36- 
14
month period that begins and ends during 
15
the 5-year period preceding January 1, 
16
2023. 
17
‘‘(2) REPORT
DEADLINE.—Each report de-
18
scribed in paragraph (1) shall be submitted to the 
19
Secretary— 
20
‘‘(A) in the case of a report with respect 
21
to an increase in the price of a qualifying drug 
22
that occurs during the period beginning on Jan-
23
uary 1, 2021, and ending on the day that is 60 
24
days after the date of the enactment of this sec-
25
04:12 Apr 27, 2021
H3
139 
•HR 3 IH
tion, not later than 90 days after such date of 
1
enactment; 
2
‘‘(B) in the case of a report with respect 
3
to an increase in the price of a qualifying drug 
4
that occurs after the period described in sub-
5
paragraph (A), not later than 30 days prior to 
6
the planned effective date of such price increase 
7
for such qualifying drug; 
8
‘‘(C) in the case of a report with respect 
9
to a qualifying drug that meets the criteria 
10
under paragraph (1)(B), not later than 30 days 
11
after such drug meets such criteria; and 
12
‘‘(D) in the case of a report with respect 
13
to an increase in the price of a qualifying drug 
14
that occurs during a 12-month or 36-month pe-
15
riod described in paragraph (1)(C), not later 
16
than April 1, 2023. 
17
‘‘(c) CONTENTS.—A report under subsection (b), con-
18
sistent with the standard for disclosures described in sec-
19
tion 213.3(d) of title 12, Code of Federal Regulations (as 
20
in effect on the date of enactment of this section), shall, 
21
at a minimum, include— 
22
‘‘(1) with respect to the qualifying drug— 
23
‘‘(A) the percentage by which the manufac-
24
turer will raise the wholesale acquisition cost of 
25
04:12 Apr 27, 2021
H3
140 
•HR 3 IH
the drug within the 12-month period or 36- 
1
month period as described in subsection 
2
(b)(1)(A)(i), 
(b)(1)(A)(ii), 
(b)(1)(C)(i), 
or 
3
(b)(1)(C)(ii), as applicable, and the effective 
4
date of such price increase or the cost associ-
5
ated with a qualifying drug if such drug meets 
6
the criteria under subsection (b)(1)(B) and the 
7
effective date at which such drug meets such 
8
criteria; 
9
‘‘(B) an explanation for, and description 
10
of, each price increase for such drug that will 
11
occur during the 12-month period or the 36- 
12
month 
period 
described 
in 
subsection 
13
(b)(1)(A)(i), 
(b)(1)(A)(ii), 
(b)(1)(C)(i), 
or 
14
(b)(1)(C)(ii), as applicable; 
15
‘‘(C) an explanation for, and description 
16
of, the cost associated with a qualifying drug if 
17
such drug meets the criteria under subsection 
18
(b)(1)(B), as applicable; 
19
‘‘(D) if known and different from the man-
20
ufacturer of the qualifying drug, the identity 
21
of— 
22
‘‘(i) the sponsor or sponsors of any in-
23
vestigational new drug applications under 
24
section 505(i) of the Federal Food, Drug, 
25
04:12 Apr 27, 2021
H3
141 
•HR 3 IH
and Cosmetic Act for clinical investigations 
1
with respect to such drug, for which the 
2
full reports are submitted as part of the 
3
application— 
4
‘‘(I) for approval of the drug 
5
under section 505 of such Act; or 
6
‘‘(II) for licensure of the drug 
7
under section 351 of the Public 
8
Health Service Act; and 
9
‘‘(ii) the sponsor of an application for 
10
the drug approved under such section 505 
11
of the Federal Food, Drug, and Cosmetic 
12
Act or licensed under section 351 of the 
13
Public Health Service Act; 
14
‘‘(E) a description of the history of the 
15
manufacturer’s price increases for the drug 
16
since the approval of the application for the 
17
drug under section 505 of the Federal Food, 
18
Drug, and Cosmetic Act or the issuance of the 
19
license for the drug under section 351 of the 
20
Public Health Service Act, or since the manu-
21
facturer acquired such approved application or 
22
license, if applicable; 
23
‘‘(F) the current wholesale acquisition cost 
24
of the drug; 
25
04:12 Apr 27, 2021
H3
142 
•HR 3 IH
‘‘(G) the total expenditures of the manu-
1
facturer on— 
2
‘‘(i) materials and manufacturing for 
3
such drug; 
4
‘‘(ii) acquiring patents and licensing 
5
for such drug; and 
6
‘‘(iii) purchasing or acquiring such 
7
drug from another manufacturer, if appli-
8
cable; 
9
‘‘(H) the percentage of total expenditures 
10
of the manufacturer on research and develop-
11
ment for such drug that was derived from Fed-
12
eral funds; 
13
‘‘(I) the total expenditures of the manufac-
14
turer on research and development for such 
15
drug that is necessary to demonstrate that it 
16
meets applicable statutory standards for ap-
17
proval under section 505 of the Federal Food, 
18
Drug, and Cosmetic Act or licensure under sec-
19
tion 351 of the Public Health Service Act, as 
20
applicable; 
21
‘‘(J) the total expenditures of the manufac-
22
turer on pursuing new or expanded indications 
23
or dosage changes for such drug under section 
24
505 of the Federal Food, Drug, and Cosmetic 
25
04:12 Apr 27, 2021
H3
143 
•HR 3 IH
Act or section 351 of the Public Health Service 
1
Act; 
2
‘‘(K) the total expenditures of the manu-
3
facturer on carrying out postmarket require-
4
ments related to such drug, including under 
5
section 505(o)(3) of the Federal Food, Drug, 
6
and Cosmetic Act; 
7
‘‘(L) the total revenue and the net profit 
8
generated from the qualifying drug for each cal-
9
endar year since the approval of the application 
10
for the drug under section 505 of the Federal 
11
Food, Drug, and Cosmetic Act or the issuance 
12
of the license for the drug under section 351 of 
13
the Public Health Service Act, or since the 
14
manufacturer acquired such approved applica-
15
tion or license; and 
16
‘‘(M) the total costs associated with mar-
17
keting and advertising for the qualifying drug; 
18
‘‘(2) with respect to the manufacturer— 
19
‘‘(A) the total revenue and the net profit 
20
of the manufacturer for each of the 12-month 
21
period described in subsection (b)(1)(A)(i) or 
22
(b)(1)(C)(i) or the 36-month period described in 
23
subsection (b)(1)(A)(ii) or (b)(1)(C)(ii), as ap-
24
plicable; 
25
04:12 Apr 27, 2021
H3
144 
•HR 3 IH
‘‘(B) all stock-based performance metrics 
1
used by the manufacturer to determine execu-
2
tive compensation for each of the 12-month pe-
3
riods described in subsection (b)(1)(A)(i) or 
4
(b)(1)(C)(i) or the 36-month periods described 
5
in subsection (b)(1)(A)(ii) or (b)(1)(C)(ii), as 
6
applicable; and 
7
‘‘(C) any additional information the manu-
8
facturer chooses to provide related to drug pric-
9
ing decisions, such as total expenditures on— 
10
‘‘(i) drug research and development; 
11
or 
12
‘‘(ii) clinical trials, including on drugs 
13
that failed to receive approval by the Food 
14
and Drug Administration; and 
15
‘‘(3) such other related information as the Sec-
16
retary considers appropriate and as specified by the 
17
Secretary. 
18
‘‘(d) INFORMATION PROVIDED.—The manufacturer 
19
of a qualifying drug that is required to submit a report 
20
under subsection (b), shall ensure that such report and 
21
any explanation for, and description of, each price increase 
22
described in subsection (c)(1) shall be truthful, not mis-
23
leading, and accurate. 
24
04:12 Apr 27, 2021
H3
145 
•HR 3 IH
‘‘(e) CIVIL MONETARY PENALTY.—Any manufac-
1
turer of a qualifying drug that fails to submit a report 
2
for the drug as required by this section, following notifica-
3
tion by the Secretary to the manufacturer that the manu-
4
facturer is not in compliance with this section, shall be 
5
subject to a civil monetary penalty of $75,000 for each 
6
day on which the violation continues. 
7
‘‘(f) FALSE INFORMATION.—Any manufacturer that 
8
submits a report for a drug as required by this section 
9
that knowingly provides false information in such report 
10
is subject to a civil monetary penalty in an amount not 
11
to exceed $100,000 for each item of false information. 
12
‘‘(g) PUBLIC POSTING.— 
13
‘‘(1) IN GENERAL.—Subject to paragraph (4), 
14
the Secretary shall post each report submitted under 
15
subsection (b) on the public website of the Depart-
16
ment of Health and Human Services the day the 
17
price increase of a qualifying drug is scheduled to go 
18
into effect. 
19
‘‘(2) FORMAT.—In developing the format in 
20
which reports will be publicly posted under para-
21
graph (1), the Secretary shall consult with stake-
22
holders, including beneficiary groups, and shall seek 
23
feedback from consumer advocates and readability 
24
experts on the format and presentation of the con-
25
04:12 Apr 27, 2021
H3
146 
•HR 3 IH
tent of such reports to ensure that such reports 
1
are— 
2
‘‘(A) user-friendly to the public; and 
3
‘‘(B) written in plain language that con-
4
sumers can readily understand. 
5
‘‘(3) LIST.—In addition to the reports sub-
6
mitted under subsection (b), the Secretary shall also 
7
post a list of each qualifying drug with respect to 
8
which the manufacturer was required to submit such 
9
a report in the preceding year and whether such 
10
manufacturer was required to submit such report 
11
based on a qualifying price increase or whether such 
12
drug meets the criteria under subsection (b)(1)(B). 
13
‘‘(4) PROTECTED
INFORMATION.—In carrying 
14
out this section, the Secretary shall enforce applica-
15
ble law concerning the protection of confidential 
16
commercial information and trade secrets. 
17
‘‘SEC. 1150E. ANNUAL REPORT TO CONGRESS. 
18
‘‘(a) IN GENERAL.—Subject to subsection (b), the 
19
Secretary shall submit to the Committees on Energy and 
20
Commerce and Ways and Means of the House of Rep-
21
resentatives and the Committees on Health, Education, 
22
Labor, and Pensions and Finance of the Senate, and post 
23
on the public website of the Department of Health and 
24
Human Services in a way that is user-friendly to the pub-
25
04:12 Apr 27, 2021
H3
147 
•HR 3 IH
lic and written in plain language that consumers can read-
1
ily understand, an annual report— 
2
‘‘(1) summarizing the information reported pur-
3
suant to section 1150D; 
4
‘‘(2) including copies of the reports and sup-
5
porting detailed economic analyses submitted pursu-
6
ant to such section; 
7
‘‘(3) detailing the costs and expenditures in-
8
curred by the Department of Health and Human 
9
Services in carrying out section 1150D; and 
10
‘‘(4) explaining how the Department of Health 
11
and Human Services is improving consumer and 
12
provider information about drug value and drug 
13
price transparency. 
14
‘‘(b) PROTECTED INFORMATION.—In carrying out 
15
this section, the Secretary shall enforce applicable law con-
16
cerning the protection of confidential commercial informa-
17
tion and trade secrets.’’. 
18
TITLE V—NIH, FDA, AND 
19
OVERDOSE EPIDEMIC FUNDING 
20
Subtitle A—Biomedical Innovation 
21
Expansion 
22
SEC. 501. NIH INNOVATION INITIATIVES. 
23
(a) NIH INNOVATION ACCOUNT.— 
24
04:12 Apr 27, 2021
H3
148 
•HR 3 IH
(1) IN GENERAL.—Section 1001(b) of the 21st 
1
Century Cures Act (Public Law 114–255) is amend-
2
ed by adding at the end the following: 
3
‘‘(5) SUPPLEMENTAL
FUNDING
AND
ADDI-
4
TIONAL ACTIVITIES.— 
5
‘‘(A) IN
GENERAL.—In addition to the 
6
funds made available under paragraph (2), 
7
there are authorized to be appropriated, and 
8
are hereby appropriated, to the Account, out of 
9
any monies in the Treasury not otherwise ap-
10
propriated, to be available until expended with-
11
out further appropriation, the following: 
12
‘‘(i) 
For 
fiscal 
year 
2022, 
13
$255,400,000. 
14
‘‘(ii) 
For 
fiscal 
year 
2023, 
15
$160,400,000. 
16
‘‘(iii) 
For 
fiscal 
year 
2024, 
17
$414,600,000. 
18
‘‘(iv) 
For 
fiscal 
year 
2025, 
19
$547,000,000. 
20
‘‘(v) 
For 
fiscal 
year 
2026, 
21
$948,000,000. 
22
‘‘(vi) 
For 
fiscal 
year 
2027, 
23
$842,400,000. 
24
04:12 Apr 27, 2021
H3
149 
•HR 3 IH
‘‘(vii) 
For 
fiscal 
year 
2028, 
1
$1,089,600,000. 
2
‘‘(viii) 
For 
fiscal 
year 
2029, 
3
$1,115,600,000. 
4
‘‘(ix) 
For 
fiscal 
year 
2030, 
5
$1,170,600,000. 
6
‘‘(x) 
For 
fiscal 
year 
2031, 
7
$956,400,000. 
8
‘‘(B) SUPPLEMENTAL FUNDING FOR CER-
9
TAIN PROJECTS.—Of the total amounts made 
10
available under subparagraph (A) for each of 
11
fiscal years 2022 through 2031, a total amount 
12
not to exceed the following shall be made avail-
13
able for the following categories of NIH Innova-
14
tion Projects: 
15
‘‘(i) For projects described in para-
16
graph (4)(A), an amount not to exceed a 
17
total of $2,070,600,000 as follows: 
18
‘‘(I) For each of fiscal years 
19
2022 and 2024, $50,000,000. 
20
‘‘(II) 
For 
fiscal 
year 
2025, 
21
$100,000,000. 
22
‘‘(III) For each of fiscal years 
23
2026 and 2027, $300,000,000. 
24
04:12 Apr 27, 2021
H3
150 
•HR 3 IH
‘‘(IV) For each of fiscal years 
1
2028 through 2030, $317,000,000. 
2
‘‘(V) 
For 
fiscal 
year 
2031, 
3
$319,600,000. 
4
‘‘(ii) For projects described in para-
5
graph (4)(B), an amount not to exceed a 
6
total of $2,041,900,000 as follows: 
7
‘‘(I) For each of fiscal years 
8
2022 and 2024, $50,000,000. 
9
‘‘(II) 
For 
fiscal 
year 
2025, 
10
$128,000,000. 
11
‘‘(III) For fiscal year 2026, 
12
$209,000,000. 
13
‘‘(IV) For fiscal year 2027, 
14
$100,000,000. 
15
‘‘(V) 
For 
fiscal 
year 
2028, 
16
$325,000,000. 
17
‘‘(VI) For fiscal year 2029, 
18
$350,000,000. 
19
‘‘(VII) For fiscal year 2030, 
20
$400,000,000. 
21
‘‘(VIII) For fiscal year 2031, 
22
$429,900,000. 
23
04:12 Apr 27, 2021
H3
151 
•HR 3 IH
‘‘(iii) For projects described in para-
1
graph (4)(C), an amount not to exceed a 
2
total of $1,558,400,000 as follows: 
3
‘‘(I) For each of fiscal years 
4
2024 and 2025, $151,200,000. 
5
‘‘(II) For each of fiscal years 
6
2026 through 2030, $251,200,000. 
7
‘‘(iv) For projects described in para-
8
graph (4)(D), an amount not to exceed 
9
$15,400,000 for each of fiscal years 2022 
10
through 2031. 
11
‘‘(C) 
ADDITIONAL
NIH
INNOVATION 
12
PROJECTS.—In addition to funding NIH Inno-
13
vation Projects pursuant to subparagraph (B), 
14
of the total amounts made available under sub-
15
paragraph (A), a total amount not to exceed 
16
the following shall be made available for the fol-
17
lowing categories of NIH Innovation Projects: 
18
‘‘(i) To support research related to 
19
combating antimicrobial resistance and an-
20
tibiotic resistant bacteria, including re-
21
search into new treatments, diagnostics, 
22
and vaccines, research, in consultation with 
23
the Centers for Disease Control and Pre-
24
vention, into stewardship, and the develop-
25
04:12 Apr 27, 2021
H3
152 
•HR 3 IH
ment of strategies, in coordination with the 
1
Biomedical Advanced Research and Devel-
2
opment Authority under section 319L of 
3
the Public Health Service Act, to support 
4
commercialization of new antibiotics, not 
5
to exceed a total of $1,144,500,000, as fol-
6
lows: 
7
‘‘(I) For each of fiscal years 
8
2022 through 2025, $100,000,000. 
9
‘‘(II) For each of fiscal years 
10
2026 and 2027, $120,000,000. 
11
‘‘(III) For each of fiscal years 
12
2028 through 2030, $125,000,000. 
13
‘‘(IV) For fiscal year 2031, 
14
$129,500,000. 
15
‘‘(ii) To support research and re-
16
search activities related to rare diseases or 
17
conditions, including studies or analyses 
18
that help to better understand the natural 
19
history of a rare disease or condition and 
20
translational studies related to rare dis-
21
eases or conditions, not to exceed a total of 
22
$530,600,000, as follows: 
23
‘‘(I) 
For 
fiscal 
year 
2022, 
24
$40,000,000. 
25
04:12 Apr 27, 2021
H3
153 
•HR 3 IH
‘‘(II) 
For 
fiscal 
year 
2023, 
1
$45,000,000. 
2
‘‘(III) For fiscal year 2024, 
3
$48,000,000. 
4
‘‘(IV) For each of fiscal years 
5
2025 and 2026, $52,400,000. 
6
‘‘(V) 
For 
fiscal 
year 
2027, 
7
$55,800,000. 
8
‘‘(VI) For fiscal year 2028, 
9
$56,000,000. 
10
‘‘(VII) For fiscal year 2029, 
11
$57,000,000. 
12
‘‘(VIII) For each of fiscal years 
13
2030 and 2031, $62,000,000.’’. 
14
(2) CONFORMING AMENDMENTS.—Section 1001 
15
of the 21st Century Cures Act (Public Law 114– 
16
255) is amended— 
17
(A) in subsection (a), by striking ‘‘sub-
18
section (b)(4)’’ and inserting ‘‘subsections 
19
(b)(4) and (b)(5)’’; 
20
(B) in subsection (b)(1), by striking ‘‘para-
21
graph (4)’’ and inserting ‘‘paragraphs (4) and 
22
(5)’’; 
23
04:12 Apr 27, 2021
H3
154 
•HR 3 IH
(C) in subsection (c)(2)(A)(ii), by inserting 
1
‘‘or pursuant to subsection (b)(5)’’ after ‘‘sub-
2
section (b)(3)’’; and 
3
(D) in subsection (d), by inserting ‘‘or pur-
4
suant to subsection (b)(5)’’ after ‘‘subsection 
5
(b)(3)’’. 
6
(b) WORKPLAN.—Section 1001(c)(1) of the 21st 
7
Century Cures Act (Public Law 114–255) is amended by 
8
adding at the end the following: 
9
‘‘(D) UPDATES.—The Director of NIH 
10
shall, after seeking recommendations in accord-
11
ance with the process described in subpara-
12
graph (C), update the work plan submitted 
13
under this subsection for each of fiscal years 
14
2022 through 2031 to reflect the amendments 
15
made to this section by the Elijah E. Cum-
16
mings Lower Drug Costs Now Act.’’. 
17
(c) ANNUAL REPORTS.—Section 1001(c)(2)(A) of the 
18
21st Century Cures Act (Public Law 114–255) is amend-
19
ed by striking ‘‘2027’’ and inserting ‘‘2031’’. 
20
(d) SUNSET.—Section 1001(e) of the 21st Century 
21
Cures Act (Public Law 114–255) is amended by striking 
22
‘‘September 30, 2026’’ and inserting ‘‘September 30, 
23
2031’’. 
24
04:12 Apr 27, 2021
H3
155 
•HR 3 IH
SEC. 502. NIH CLINICAL TRIAL. 
1
Part A of title IV of the Public Health Service Act 
2
(42 U.S.C. 281 et seq.) is amended by adding at the end 
3
the following: 
4
‘‘SEC. 404O. CLINICAL TRIAL ACCELERATION PILOT INITIA-
5
TIVE. 
6
‘‘(a) ESTABLISHMENT
OF PILOT PROGRAM.—The 
7
Secretary, acting through the Director of the National In-
8
stitutes of Health, shall, not later than 2 years after the 
9
date of enactment of this Act, establish and implement 
10
a pilot program to award multi-year contracts to eligible 
11
entities to support phase II clinical trials and phase III 
12
clinical trials— 
13
‘‘(1) to promote innovation in treatments and 
14
technologies supporting the advanced research and 
15
development and production of high need cures; and 
16
‘‘(2) to provide support for the development of 
17
medical products and therapies. 
18
‘‘(b) ELIGIBLE ENTITIES.—To be eligible to receive 
19
assistance under the pilot program established under sub-
20
section (a), an entity shall— 
21
‘‘(1) be seeking to market a medical product or 
22
therapy that is the subject of clinical trial or trials 
23
to be supported using such assistance; 
24
‘‘(2) be a public or private entity, which may 
25
include a private or public research institution, a 
26
04:12 Apr 27, 2021
H3
156 
•HR 3 IH
contract research organization, an institution of 
1
higher education (as defined in section 101 of the 
2
Higher Education Act of 1965 (20 U.S.C. 1001)), a 
3
medical center, a biotechnology company, or an aca-
4
demic research institution; and 
5
‘‘(3) comply with requirements of the Federal 
6
Food, Drug, and Cosmetic Act and section 351 of 
7
this Act, as applicable, at all stages of development, 
8
manufacturing, review, approval, and safety surveil-
9
lance of a medical product. 
10
‘‘(c) DUTIES.—The Secretary, acting through the Di-
11
rector of National Institutes of Health, shall— 
12
‘‘(1) in establishing the pilot program under 
13
subsection (a), consult with— 
14
‘‘(A) the Director of the National Center 
15
for Advancing Translational Sciences and the 
16
other national research institutes in considering 
17
their requests for new or expanded clinical trial 
18
support efforts; and 
19
‘‘(B) the Commissioner of Food and Drugs 
20
and any other head of a Federal agency as the 
21
Secretary determines to be appropriate to en-
22
sure coordination and efficiently advance clin-
23
ical trial activities; 
24
04:12 Apr 27, 2021
H3
157 
•HR 3 IH
‘‘(2) in implementing the pilot program under 
1
subsection (a), consider consulting with patients and 
2
patient advocates; and 
3
‘‘(3) in awarding contracts under the pilot pro-
4
gram under subsection (a), consider— 
5
‘‘(A) the expected health impacts of the 
6
clinical trial or trials to be supported under the 
7
contract; and 
8
‘‘(B) the degree to which the medical prod-
9
uct or therapy that is the subject of such clin-
10
ical trial or trials is a high need cure. 
11
‘‘(d) EXCLUSION.—A contract may not be awarded 
12
under the pilot program under subsection (a) if the drug 
13
that is the subject of the clinical trial or trials to be sup-
14
ported under the contract is a drug designated under sec-
15
tion 526 of the Federal Food, Drug, and Cosmetic Act 
16
as a drug for a rare disease or condition. 
17
‘‘(e) NIH CLINICAL
TRIAL
ACCELERATOR
AC-
18
COUNT.— 
19
‘‘(1) ESTABLISHMENT.—There is established in 
20
the Treasury an account, to be known as the ‘NIH 
21
Clinical Trial Accelerator Account’ (referred to in 
22
this section as the ‘Account’), for purposes of car-
23
rying out this section. 
24
04:12 Apr 27, 2021
H3
158 
•HR 3 IH
‘‘(2) TRANSFER
OF
DIRECT
SPENDING
SAV-
1
INGS.—There shall be transferred to the Account 
2
from 
the 
general 
fund 
of 
the 
Treasury, 
3
$400,000,000 for each of fiscal years 2022 through 
4
2026, to be available until expended without further 
5
appropriation. 
6
‘‘(3) WORK PLAN.—Not later than 180 days 
7
after the date of enactment of this Act, the Sec-
8
retary shall submit to the Committee on Energy and 
9
Commerce of the House of Representatives and the 
10
Committee on Health, Education, Labor, and Pen-
11
sions of the Senate a work plan that includes the 
12
proposed implementation of this section and the pro-
13
posed allocation of funds in the Account. 
14
‘‘(f) REPORTS TO CONGRESS.—Not later than Octo-
15
ber 1 of each fiscal year, the Secretary shall submit to 
16
the Committee on Energy and Commerce of the House 
17
of Representatives and the Committee on Health, Edu-
18
cation, Labor, and Pensions of the Senate a report on— 
19
‘‘(1) the implementation of this section; 
20
‘‘(2) any available results on phase II clinical 
21
trials and phase III clinical trials supported under 
22
this section during such fiscal year; and 
23
‘‘(3) the extent to which Federal funds are obli-
24
gated to support such clinical trials, including the 
25
04:12 Apr 27, 2021
H3
159 
•HR 3 IH
specific amount of such support and awards pursu-
1
ant to an allocation from the Account under sub-
2
section (e). 
3
‘‘(g) DEFINITIONS.—In this section: 
4
‘‘(1) PHASE
II
CLINICAL
TRIAL.—The term 
5
‘phase II clinical trial’ means a phase II clinical in-
6
vestigation, as described in section 312.21 of title 
7
21, Code of Federal Regulations (or any successor 
8
regulations). 
9
‘‘(2) PHASE III CLINICAL TRIALS.—The term 
10
‘phase III clinical trial’ means a phase III clinical 
11
investigation, as described in section 312.21 of title 
12
21, Code of Federal Regulations (or any successor 
13
regulations). 
14
‘‘(3) HIGH NEED CURE.—The term ‘high need 
15
cure’ has the meaning given such term in section 
16
480(a)(3).’’. 
17
SEC. 503. INNOVATION NETWORK. 
18
Part A of title IV of the Public Health Service Act 
19
(42 U.S.C. 281 et seq.), as amended by section 502, is 
20
further amended by adding at the end the following: 
21
‘‘SEC. 404P. INNOVATION NETWORK. 
22
‘‘(a) FUNDS.—The Director of NIH shall award 
23
grants or contracts to eligible entities to develop, expand, 
24
and enhance the commercialization of biomedical products. 
25
04:12 Apr 27, 2021
H3
160 
•HR 3 IH
‘‘(b) ELIGIBLE ENTITY.—In this section, the term 
1
‘eligible entity’ means an entity receiving funding under— 
2
‘‘(1) the Small Business Innovation Research 
3
program of the National Institutes of Health; or 
4
‘‘(2) the Small Business Technology Transfer 
5
program of the National Institutes of Health. 
6
‘‘(c) USE OF FUNDS.—An eligible entity shall use the 
7
funds received through such grant or contract to sup-
8
port— 
9
‘‘(1) the Commercialization Readiness Pilot 
10
program of the National Institutes of Health; 
11
‘‘(2) the Innovation Corps program of the Na-
12
tional Institutes of Health; 
13
‘‘(3) the Commercialization Accelerator pro-
14
gram of the National Institutes of Health; 
15
‘‘(4) the Commercialization Assistance program 
16
of the National Institutes of Health; and 
17
‘‘(5) such other programs and activities as the 
18
Director of NIH determines to be appropriate, to 
19
support the commercialization stage of research, 
20
later stage research and development, technology 
21
transfer, and commercialization technical assistance. 
22
‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—There 
23
are authorized to be appropriated to carry out this section 
24
04:12 Apr 27, 2021
H3
161 
•HR 3 IH
$100,000,000 for each of fiscal years 2022 through 2026, 
1
to be available until expended.’’. 
2
Subtitle B—Investing in Safety and 
3
Innovation 
4
SEC. 511. FOOD AND DRUG ADMINISTRATION. 
5
(a) FDA INNOVATION ACCOUNT.— 
6
(1) IN GENERAL.—Section 1002(b) of the 21st 
7
Century Cures Act (Public Law 114–255) is amend-
8
ed— 
9
(A) in paragraph (1), by striking ‘‘para-
10
graph (4)’’ and inserting ‘‘paragraphs (4) and 
11
(5)’’; and 
12
(B) by adding at the end the following new 
13
paragraph: 
14
‘‘(5) SUPPLEMENTAL
FUNDING
AND
ADDI-
15
TIONAL ACTIVITIES.— 
16
‘‘(A) IN
GENERAL.—In addition to the 
17
funds made available under paragraph (2), 
18
there are authorized to be appropriated, and 
19
are hereby appropriated, to the Account, out of 
20
any monies in the Treasury not otherwise ap-
21
propriated, to be available until expended with-
22
out further appropriation, the following: 
23
‘‘(i) 
For 
fiscal 
year 
2022, 
24
$417,500,000. 
25
04:12 Apr 27, 2021
H3
162 
•HR 3 IH
‘‘(ii) For each of fiscal years 2023 
1
and 2024, $157,500,000. 
2
‘‘(iii) For each of fiscal years 2025 
3
through 2027, $152,500,000. 
4
‘‘(iv) For each of fiscal years 2028 
5
through 2031, $202,500,000. 
6
‘‘(B) SUPPLEMENTAL FUNDING FOR CER-
7
TAIN ACTIVITIES.—Of the total amounts made 
8
available under subparagraph (A) for each of 
9
fiscal years 2028 through 2031, a total amount 
10
not to exceed $50,000,000 for each such fiscal 
11
year, shall be made available for the activities 
12
under subtitles A through F (including the 
13
amendments made by such subtitles) of title III 
14
of this Act and section 1014 (relating to Inter-
15
center Institutes) of the Federal Food, Drug, 
16
and Cosmetic Act. 
17
‘‘(C) ADDITIONAL
FDA
ACTIVITIES.—In 
18
addition to funding activities pursuant to sub-
19
paragraph (B), of the total amounts made 
20
available under subparagraph (A), a total 
21
amount not to exceed the following shall be 
22
made available for the following categories of 
23
activities: 
24
04:12 Apr 27, 2021
H3
163 
•HR 3 IH
‘‘(i) For modernization of the tech-
1
nical infrastructure of the Food and Drug 
2
Administration, including enhancements 
3
such as interoperability across the agency, 
4
and additional capabilities to develop an 
5
advanced information technology infra-
6
structure to support the agency’s regu-
7
latory mission: 
8
‘‘(I) 
For 
fiscal 
year 
2022, 
9
$180,000,000. 
10
‘‘(II) For each of fiscal years 
11
2023 through 2031, $60,000,000. 
12
‘‘(ii) For support for continuous man-
13
ufacturing of drugs and biological prod-
14
ucts, including complex biological products 
15
such as regenerative medicine therapies, 
16
through grants to institutions of higher 
17
education and nonprofit organizations and 
18
other appropriate mechanisms, for each of 
19
fiscal 
years 
2022 
through 
2031, 
20
$20,000,000. 
21
‘‘(iii) For support for the Commis-
22
sioner of Food and Drugs to engage ex-
23
perts, such as through the formation and 
24
operation of public-private partnerships or 
25
04:12 Apr 27, 2021
H3
164 
•HR 3 IH
other appropriate collaborative efforts, to 
1
advance the development and delivery of 
2
individualized human gene therapy prod-
3
ucts: 
4
‘‘(I) 
For 
fiscal 
year 
2022, 
5
$50,000,000. 
6
‘‘(II) For each of fiscal years 
7
2023 through 2031, $10,000,000. 
8
‘‘(iv) For support for inspections, en-
9
forcement, and quality surveillance activi-
10
ties across the Food and Drug Administra-
11
tion, including foreign and domestic in-
12
spections across products, for each of fiscal 
13
years 2022 through 2031, $20,000,000. 
14
‘‘(v) For support for activities of the 
15
Food and Drug Administration related to 
16
customs and border protection to provide 
17
improvements to technologies, inspection 
18
capacity, and sites of import (including 
19
international mail facilities) in which the 
20
Food and Drug Administration operates, 
21
for each of fiscal years 2022 through 
22
2031, $10,000,000. 
23
‘‘(vi) To further advance the develop-
24
ment of a coordinated postmarket surveil-
25
04:12 Apr 27, 2021
H3
165 
•HR 3 IH
lance system for all medical products, in-
1
cluding drugs, biological products, and de-
2
vices, linked to electronic health records in 
3
furtherance of the Food and Drug Admin-
4
istration’s postmarket surveillance capabili-
5
ties: 
6
‘‘(I) 
For 
fiscal 
year 
2022, 
7
$112,500,000. 
8
‘‘(II) For each of fiscal years 
9
2023 through 2031, $12,500,000. 
10
‘‘(vii) For support for Food and Drug 
11
Administration activities to keep pace with 
12
the projected product development of re-
13
generative therapies, including cellular and 
14
somatic cell gene therapy products: 
15
‘‘(I) For each of fiscal years 
16
2022 through 2024, $10,000,000. 
17
‘‘(II) For each of fiscal years 
18
2025 through 2031, $5,000,000. 
19
‘‘(viii) For carrying out section 714A 
20
of the Federal Food, Drug, and Cosmetic 
21
Act (21 U.S.C. 379d–3a; relating to hiring 
22
authority for scientific, technical, and pro-
23
fessional personnel), for each of fiscal 
24
years 2022 through 2031, $2,500,000. 
25
04:12 Apr 27, 2021
H3
166 
•HR 3 IH
‘‘(ix) For the Food and Drug Admin-
1
istration to support improvements to the 
2
technological infrastructure for reporting 
3
and analysis of adverse events associated 
4
with the use of drugs and biological prod-
5
ucts, for each of fiscal years 2022 through 
6
2031, $12,500,000.’’. 
7
(2) CONFORMING AMENDMENTS.—Section 1002 
8
of the 21st Century Cures Act (Public Law 114– 
9
255) is amended— 
10
(A) in subsection (a), by inserting before 
11
the period at the end the following: ‘‘or pursu-
12
ant to subparagraph (A) of subsection (b)(5) to 
13
carry out the activities described in subpara-
14
graphs (B) and (C) of such subsection’’; and 
15
(B) in subsection (d)— 
16
(i) by inserting ‘‘or pursuant to sub-
17
paragraph (A) of subsection (b)(5)’’ after 
18
‘‘subsection (b)(3)’’; and 
19
(ii) by striking ‘‘subsection (b)(4)’’ 
20
and inserting ‘‘subsections (b)(4) and 
21
(b)(5)’’. 
22
(b) ANNUAL REPORT.—Section 1002(c)(2)(A) of the 
23
21st Century Cures Act (Public Law 114–255) is amend-
24
04:12 Apr 27, 2021
H3
167 
•HR 3 IH
ed, in the matter preceding clause (i), by striking ‘‘2026’’ 
1
and inserting ‘‘2032’’. 
2
(c) SUNSET.—Section 1002(e) of the 21st Century 
3
Cures Act (Public Law 114–255) is amended by striking 
4
‘‘September 30, 2025’’ and inserting ‘‘September 30, 
5
2030’’. 
6
SEC. 512. STUDY ON HIGH-RISK, HIGH-REWARD DRUGS. 
7
(a) IN GENERAL.—Not later than 180 days after the 
8
date of enactment of this Act, the Secretary of Health and 
9
Human Services shall conduct a study to identify— 
10
(1) diseases or conditions that lack a treatment 
11
approved by the Food and Drug Administration and 
12
instances in which development of a treatment for 
13
such diseases or conditions could fill an unmet med-
14
ical need for the treatment of a serious or life- 
15
threatening disease or condition or a rare disease or 
16
condition; and 
17
(2) appropriate incentives that would lead to 
18
the development, approval, and marketing of such 
19
treatments. 
20
(b) REPORT TO CONGRESS; RECOMMENDATIONS.— 
21
Not later than one year after the date of enactment of 
22
this Act, the Secretary shall submit to the Congress a re-
23
port that includes— 
24
04:12 Apr 27, 2021
H3
168 
•HR 3 IH
(1) findings from the study under subsection 
1
(a); and 
2
(2) recommendations regarding legislation nec-
3
essary to create appropriate incentives identified 
4
pursuant to subsection (a)(2). 
5
Subtitle C—Overdose Epidemic 
6
Response 
7
SEC. 521. OVERDOSE EPIDEMIC RESPONSE FUND. 
8
(a) IN GENERAL.—The Secretary of Health and 
9
Human Services (referred to in this section as the ‘‘Sec-
10
retary’’) shall use any funds made available pursuant to 
11
subsection (b) to carry out the programs and activities de-
12
scribed in subsection (c) to address the overdose and sub-
13
stance use disorder epidemic. Such funds shall be in addi-
14
tion to any funds which are otherwise available to carry 
15
out such programs and activities. 
16
(b) OPIOID EPIDEMIC RESPONSE FUND.— 
17
(1) ESTABLISHMENT OF ACCOUNT.—There is 
18
established in the Treasury an account, to be known 
19
as the Opioid Epidemic Response Fund (referred to 
20
in this section as the ‘‘Fund’’), for purposes of fund-
21
ing the programs and activities described in sub-
22
section (c). 
23
(2) FUNDING.—There is authorized to be ap-
24
propriated, and there is appropriated, to the Fund, 
25
04:12 Apr 27, 2021
H3
169 
•HR 3 IH
out of any monies in the Treasury not otherwise ap-
1
propriated $2,000,000,000 for each of fiscal years 
2
2022 through 2026. 
3
(3) AVAILABILITY.—Amounts made available by 
4
paragraph (2) shall be made available to the agen-
5
cies specified in subsection (c) in accordance with 
6
such subsection. Amounts made available to an 
7
agency pursuant to the preceding sentence for a fis-
8
cal year shall remain available until expended. 
9
(c) PROGRAMS
AND
ACTIVITIES.—Of the total 
10
amount in the Fund for each of fiscal years 2022 through 
11
2026, such amount shall be allocated as follows: 
12
(1) SAMHSA.—For the Substance Abuse and 
13
Mental Health Services Administration to carry out 
14
programs and activities pursuant to section 522, 
15
$1,500,000,000 for each of fiscal years 2022 
16
through 2026. 
17
(2) CDC.—For the Centers for Disease Control 
18
and Prevention to carry out programs and activities 
19
pursuant to section 523, $120,000,000 for each of 
20
fiscal years 2022 through 2026. 
21
(3) FDA.—For the Food and Drug Adminis-
22
tration to carry out programs and activities pursu-
23
ant to section 524, $10,000,000 for each of fiscal 
24
years 2022 through 2026. 
25
04:12 Apr 27, 2021
H3
170 
•HR 3 IH
(4) NIH.—For the National Institutes of 
1
Health to carry out programs and activities pursu-
2
ant to section 525, $240,000,000 for each of fiscal 
3
years 2022 through 2026. 
4
(5) HRSA.—For the Health Resources and 
5
Services Administration to carry out programs and 
6
activities pursuant to section 526, $90,000,000 for 
7
each of fiscal years 2022 through 2026. 
8
(6) ACF.—For the Administration for Children 
9
and Families to carry out programs and activities 
10
pursuant to section 527, $40,000,000 for each of 
11
fiscal years 2022 through 2026. 
12
(d) ACCOUNTABILITY AND OVERSIGHT.— 
13
(1) WORK PLAN.— 
14
(A) IN
GENERAL.—Not later than 180 
15
days after the date of enactment of this Act, 
16
the Secretary of Health and Human Services 
17
shall submit to the Committee on Health, Edu-
18
cation, Labor, and Pensions and the Committee 
19
on Appropriations of the Senate and the Com-
20
mittee on Energy and Commerce, the Com-
21
mittee on Appropriations, and the Committee 
22
on Education and Labor of the House of Rep-
23
resentatives, a work plan including the proposed 
24
allocation of funds made available pursuant to 
25
04:12 Apr 27, 2021
H3
171 
•HR 3 IH
subsection (b) for each of fiscal years 2022 
1
through 2026 and the contents described in 
2
subparagraph (B). 
3
(B) CONTENTS.—The work plan submitted 
4
under subparagraph (A) shall include— 
5
(i) the amount of money to be obli-
6
gated or expended out of the Fund in each 
7
fiscal year for each program and activity 
8
described in subsection (c); and 
9
(ii) a description and justification of 
10
each such program and activity. 
11
(2) ANNUAL REPORTS.—Not later than October 
12
1 of each of fiscal years 2023 through 2027, the 
13
Secretary of Health and Human Services shall sub-
14
mit to the Committee on Health, Education, Labor, 
15
and Pensions and the Committee on Appropriations 
16
of the Senate and the Committee on Energy and 
17
Commerce, the Committee on Appropriations, and 
18
the Committee on Education and Labor of the 
19
House of Representatives, a report including— 
20
(A) the amount of money obligated or ex-
21
pended out of the Fund in the prior fiscal year 
22
for each program and activity described in sub-
23
section (c); 
24
04:12 Apr 27, 2021
H3
172 
•HR 3 IH
(B) a description of all programs and ac-
1
tivities using funds made available pursuant to 
2
subsection (b); and 
3
(C) how the programs and activities are re-
4
sponding to the opioid and substance use dis-
5
order epidemic. 
6
(e) LIMITATIONS.—Notwithstanding any authority in 
7
this subtitle or any appropriations Act, any funds made 
8
available pursuant to subsection (b) may not be used for 
9
any purpose other than the programs and activities de-
10
scribed in subsection (c). 
11
SEC. 522. SUBSTANCE ABUSE AND MENTAL HEALTH SERV-
12
ICES ADMINISTRATION. 
13
(a) IN GENERAL.—The entirety of the funds made 
14
available pursuant to section 521(c)(1) shall be for the As-
15
sistant Secretary for Mental Health and Substance Use 
16
to continue to award the State Opioid Response Grants 
17
funded by the heading ‘‘Substance Abuse And Mental 
18
Health Services Administration—Substance Abuse Treat-
19
ment’’ in title II of the Departments of Labor, Health and 
20
Human Services, and Education, and Related Agencies 
21
Appropriations Act, 2018 (Public Law 115–141). Subject 
22
to subsections (b) and (c), such grants shall be awarded 
23
in the same manner and subject to the same conditions 
24
as were applicable to such grants for fiscal year 2018. 
25
04:12 Apr 27, 2021
H3
173 
•HR 3 IH
(b) REQUIREMENT
THAT
TREATMENT
BE
EVI-
1
DENCE-BASED.—As a condition on receipt of a grant pur-
2
suant to subsection (a), a grantee shall agree that— 
3
(1) treatments, practices, or interventions fund-
4
ed through the grant will be evidence-based; and 
5
(2) such treatments, practices, and interven-
6
tions will include medication-assisted treatment for 
7
individuals diagnosed with opioid use disorder, using 
8
drugs only if the drugs have been approved or li-
9
censed by the Food and Drug Administration under 
10
section 505 of the Federal Food, Drug, and Cos-
11
metic Act (21 U.S.C. 355) or section 351 of the 
12
Public Health Service Act (42 U.S.C. 262). 
13
(c) RESERVATIONS.—Of the amount made available 
14
pursuant to section 521(c)(1) for a fiscal year— 
15
(1) not less than $75,000,000 shall be reserved 
16
to make grants under subsection (a) to Indian 
17
Tribes or Tribal organizations; and 
18
(2) not less than $50,000,000 shall be reserved 
19
to make grants under subsection (a) to political sub-
20
divisions of States, such as counties, cities, or towns. 
21
SEC. 523. CENTERS FOR DISEASE CONTROL AND PREVEN-
22
TION. 
23
(a) ADDRESSING OPIOID USE DISORDER.—The en-
24
tirety of the funds made available pursuant to section 
25
04:12 Apr 27, 2021
H3
174 
•HR 3 IH
521(c)(2) shall be for the Director of the Centers for Dis-
1
ease Control and Prevention, pursuant to applicable au-
2
thorities in the Public Health Service Act (42 U.S.C. 201 
3
et seq.), to continue and expand programs of the Centers 
4
for Disease Control and Prevention to address opioid and 
5
substance use disorder, including by— 
6
(1) improving the timeliness and quality of data 
7
on the opioid use disorder epidemic, including im-
8
provement of— 
9
(A) data on fatal and nonfatal overdoses; 
10
(B) syndromic surveillance; 
11
(C) data on long-term sequelae (including 
12
neonatal abstinence syndrome); and 
13
(D) cause of death reporting related to 
14
substance abuse or opioid overdose; 
15
(2) expanding and strengthening evidence-based 
16
prevention and education strategies; 
17
(3) supporting responsible prescribing practices, 
18
including through development and dissemination of 
19
prescriber guidelines; 
20
(4) improving access to and use of effective pre-
21
vention, treatment, and recovery support, including 
22
through grants and the provision of technical assist-
23
ance to States and localities; 
24
04:12 Apr 27, 2021
H3
175 
•HR 3 IH
(5) strengthening partnerships with first re-
1
sponders, including to protect their safety; 
2
(6) considering the needs of vulnerable popu-
3
lations; 
4
(7) addressing infectious diseases linked to the 
5
opioid crisis; 
6
(8) strengthening prescription drug monitoring 
7
programs; and 
8
(9) providing financial and technical assistance 
9
to State and local health department efforts to treat 
10
and prevent substance use disorder. 
11
(b) LIMITATION.—Of the funds made available pur-
12
suant to section 521(c)(2) for carrying out this section, 
13
not more than 20 percent may be used for intramural pur-
14
poses. 
15
SEC. 524. FOOD AND DRUG ADMINISTRATION. 
16
The entirety of the funds made available pursuant to 
17
section 521(c)(3) shall be for the Commissioner of Food 
18
and Drugs, pursuant to applicable authorities in the Pub-
19
lic Health Service Act (42 U.S.C. 201 et seq.) or the Fed-
20
eral Food, Drug, and Cosmetic Act (21 U.S.C. 301 et 
21
seq.) and other applicable law, to support widespread inno-
22
vation in non-opioid and non-addictive medical products 
23
for pain treatment, access to opioid addiction treatments, 
24
appropriate use of approved opioids, and efforts to reduce 
25
04:12 Apr 27, 2021
H3
176 
•HR 3 IH
illicit importation of opioids. Such support may include the 
1
following: 
2
(1) Facilitating the development of non-opioid 
3
and non-addictive pain treatments. 
4
(2) Advancing guidance documents for sponsors 
5
of non-opioid pain products. 
6
(3) Developing evidence to inform the potential 
7
for nonprescription overdose therapies. 
8
(4) Examining expanded labeling indications for 
9
medication-assisted treatment. 
10
(5) Conducting public education and outreach, 
11
including public workshops or public meetings, re-
12
garding the benefits of medication-assisted treat-
13
ment, including all drugs approved by the Food and 
14
Drug Administration, and device treatment options 
15
approved or cleared by the Food and Drug Adminis-
16
tration. 
17
(6) Exploring the expansion and possible man-
18
datory nature of prescriber education regarding pain 
19
management and appropriate opioid prescribing 
20
through authorities under section 505–1 of the Fed-
21
eral Food, Drug, and Cosmetic Act (21 U.S.C. 355– 
22
1). 
23
04:12 Apr 27, 2021
H3
177 
•HR 3 IH
(7) Examining options to limit the duration of 
1
opioid prescriptions for acute pain, including 
2
through packaging options. 
3
(8) Increasing staff and infrastructure capacity 
4
to inspect and analyze packages at international 
5
mail facilities and pursue criminal investigations. 
6
SEC. 525. NATIONAL INSTITUTES OF HEALTH. 
7
The entirety of the funds made available pursuant to 
8
section 521(c)(4) shall be for the Director of the National 
9
Institutes of Health, pursuant to applicable authorities in 
10
the Public Health Service Act (42 U.S.C. 201 et seq.), 
11
to carry out activities related to— 
12
(1) accelerating research for addressing the 
13
opioid use disorder epidemic, including developing 
14
non-opioid medications and interventions, including 
15
non-addictive medications, to manage pain, as well 
16
as developing medications and interventions to treat 
17
and to prevent substance use disorders; 
18
(2) conducting and supporting research on 
19
which treatments (in terms of pain management as 
20
well as treating and preventing substance use dis-
21
orders) are optimal for which patients; and 
22
(3) conducting and supporting research on cre-
23
ating longer-lasting or faster-acting antidotes for 
24
04:12 Apr 27, 2021
H3
178 
•HR 3 IH
opioid overdose, particularly in response to the prev-
1
alence of fentanyl and carfentanyl overdoses. 
2
SEC. 526. HEALTH RESOURCES AND SERVICES ADMINIS-
3
TRATION. 
4
The entirety of the funds made available pursuant to 
5
section 521(c)(5) shall be for the Administrator of the 
6
Health Resources and Services Administration, pursuant 
7
to applicable authorities in titles III, VII, and VIII of the 
8
Public Health Service Act (42 U.S.C. 241 et seq.), to 
9
carry out activities that increase the availability and ca-
10
pacity of the behavioral health workforce. Such activities 
11
shall include providing loan repayment assistance for sub-
12
stance use disorder treatment providers. 
13
SEC. 527. ADMINISTRATION FOR CHILDREN AND FAMILIES. 
14
Of the funds made available pursuant to section 
15
521(c)(6) for each of fiscal years 2022 through 2026, 
16
$40,000,000 for each such fiscal year shall be for the Sec-
17
retary of Health and Human Services to carry out title 
18
I of the Child Abuse Prevention and Treatment Act (42 
19
U.S.C. 5101 et seq.). 
20
Æ 
04:12 Apr 27, 2021
H3
